



US 20110104186A1

(19) **United States**(12) **Patent Application Publication**
Valiante et al.(10) **Pub. No.: US 2011/0104186 A1**(43) **Pub. Date: May 5, 2011**(54) **SMALL MOLECULE
IMMUNOPOTENTIATORS AND ASSAYS FOR
THEIR DETECTION**No. 60/612,070, filed on Sep. 21, 2004, provisional
application No. 60/614,963, filed on Sep. 30, 2004.**Publication Classification**(76) Inventors: **Nicholas Valiante**, Fremont, CA
(US); **Feng Xu**, Emeryville, CA
(US); **Johanna Jansen**, San
Francisco, CA (US); **Susan
Kaufman**, Lafayette, CA (US)(51) **Int. Cl.**
A61K 39/00 (2006.01)
C40B 30/04 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/496 (2006.01)
A61K 31/56 (2006.01)
A61P 31/14 (2006.01)
A61P 35/00 (2006.01)
A61P 37/08 (2006.01)
A61P 11/06 (2006.01)(21) Appl. No.: **11/630,550**(22) PCT Filed: **Jun. 24, 2005**(86) PCT No.: **PCT/US05/22520**

§ 371 (c)(1),

(2), (4) Date: **Jan. 5, 2009**(52) **U.S. Cl. 424/184.1; 506/9; 514/338; 514/252.14;
514/180****Related U.S. Application Data**(60) Provisional application No. 60/582,654, filed on Jun.
24, 2004, provisional application No. 60/590,459,
filed on Jul. 22, 2004, provisional application No.
60/599,717, filed on Aug. 5, 2004, provisional appli-
cation No. 60/599,592, filed on Aug. 5, 2004, provi-
sional application No. 60/600,850, filed on Aug. 11,
2004, provisional application No. 60/603,001, filed on
Aug. 19, 2004, provisional application No. 60/603,
867, filed on Aug. 23, 2004, provisional application(57) **ABSTRACT**

The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.

SMALL MOLECULE IMMUNOPOTENTIATORS AND ASSAYS FOR THEIR DETECTION

FIELD OF THE INVENTION

[0001] In one embodiment, this invention relates generally to compounds capable of stimulating or modulating an immune response in a subject. More particularly the invention pertains to novel combinations of antigens with small molecules to be used in vaccine therapies. The compounds in one embodiment can be used as adjuvants for prophylactic and therapeutic vaccines for infectious diseases and cancer. In another embodiment they can be used as immunotherapeutics for cancer, infectious diseases and/or allergy/asthma either alone or in combination with existing therapies. In a further embodiment, the invention pertains generally to methods of identifying small molecule immunomodulators, and, more particularly, to high throughput assays for detection of immunopotentiators and immunosuppressants by measurement of immunological markers, such as cytokines, chemokines, and/or growth factors.

BACKGROUND OF THE INVENTION

[0002] Immune response to certain antigens that are otherwise weakly antigenic can be enhanced through the use of vaccine adjuvants. Such adjuvants potentiate the immune response to specific antigens and are therefore the subject of considerable interest and study within the medical community.

[0003] Research has permitted development of vaccines possessing antigenic epitopes that were previously impossible to produce. For example, currently available vaccine candidates include synthetic peptides mimicking streptococcal, gonococcal, and malarial antigens. These purified antigens are generally weak antigens, however, that require adjuvants in order to evoke protective immunity. However, conventional vaccine adjuvants possess a number of drawbacks that limit their overall use and effectiveness.

Again, this is fine for vaccines but not other uses.


[0004] Substances that stimulate immune cells in vitro exhibit similar immuno-stimulatory effects in vivo. These compounds, such as recombinant cytokines, pathogen products (e.g. toxins, lipids, proteins/peptides, carbohydrates and nucleic acids) and other mammalian-derived immunostimulatory molecules (e.g. heat shock proteins, complement, immune complexes and proteoglycans) all induce a measurable pro-inflammatory response both in vitro and in vivo.

[0005] Historically, the classic adjuvants have been Freund's complete or incomplete (i.e., without mycobacteria) adjuvants. Edmund Coley described the potential of Coley's toxin for cancer immuno-therapy. Other materials, such as mineral oil and aluminum hydroxide, have also been used as adjuvants, but they invariably suffer from disadvantages. For example, mineral oil is known to produce tissue irritation and to be potentially oncogenic. Alum, the only approved adjuvant in the United States, can induce granulomas at the inoculation site and does not effectively induce cell-mediated immunity. Moreover, many of the adjuvants currently available have limited utility because they contain components, which are not metabolizable in humans. Additionally, most adjuvants are difficult to prepare in that they may require time

consuming procedures and the use, in some cases, of elaborate and expensive equipment to formulate a vaccine and adjuvant system.

[0006] Immunological adjuvants are described in "Current Status of Immunological Adjuvants", Ann. Rev. Immunol., 1986, 4, pp. 369-388, and "Recent Advances in Vaccine Adjuvants and Delivery Systems" by Derek T O'Hagan and Nicholas M. Valiente. See also U.S. Pat. Nos. 4,806,352; 5,026,543; and 5,026,546 for disclosures of various vaccine adjuvants appearing in the patent literature.

[0007] Compounds are described in issued U.S. Pat. Nos. 4,547,511 and 4,738,971 with the general structure (a):




a

for the treatment of disorders responsive to agents that enhance cell-mediated immunity. An essential component of the molecule as described in the cited patents is the amide substituent as shown in structure (a). The invention did not contemplate combinations with antigens.

[0008] Immunostimulatory oligonucleotides and polynucleotides are described in PCT WO 98/55495 and PCT WO 98/16247. U.S. Patent Application No. 2002/0164341 describes adjuvants including an unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. U.S. Patent Application No. 2002/0197269 describes compositions comprising an antigen, an antigenic CpG-ODN and a polycationic polymer.

[0009] Additionally, issued U.S. Pat. Nos. 4,689,338, 5,389,640, 5,268,376, 4,929,624, 5,266,575, 5,352,784, 5,494,916, 5,482,936, 5,346,905, 5,395,937, 5,238,944, 5,525,612, WO99/29693 and U.S. Ser. No. 09/361,544 disclose compounds of the general structure (b):



b

for the use as "immune response modifiers."

[0010] There has been an effort to find new immune modulators for use as adjuvants for vaccines and immunotherapies that would overcome the drawbacks and deficiencies of conventional immune modulators. In particular, an adjuvant formulation that elicits potent cell-mediated and humoral immune responses to a wide range of antigens in humans and domestic animals, but lacking the side effects of conventional adjuvants and other immune modulators, would be highly desirable. This need could be met by small molecule immune

potentiators (SMIPs) because the small molecule platform provides diverse compounds for the selective manipulation of the immune responses.

[0011] Furthermore, it would be desirable to provide novel compounds with a varied capacity to alter levels and/or profiles of cytokine production in human immune cells. Compounds with structural disparities will often times elicit a desired response through a different mechanism of action, or with greater specificity to a target, such as a dendritic cell, modulating potency and lowering side effects when administered to a patient.

[0012] The immunosuppressive effect of cytostatic substances has rendered them useful in the therapy of autoimmune diseases such as multiple sclerosis, psoriasis and certain rheumatic diseases. Even here their beneficial effect has to be weighed against the serious side effects that necessitate too low dosages and/or interruption of the treatment.

[0013] To date immune suppressants have also been of great interest due to their ability to decrease immune responses in surgical operations and transplants, when a full-blown immune attack or rejection of a transplant organ could prove fatal.

[0014] It is one object of the present invention to provide a combination of active substances that results in a significantly improved cytostatic or cytotoxic effect as compared to conventional cytostatics given alone, e.g. vincristin, methotrexate, cisplatin etc. Thereby, chemotherapies may be offered that combine increasing efficiency with a large reduction of side effects and therapeutic doses. Thus, the therapeutic efficiency of known cytostatic drugs is increased. Also, certain cell lines that are insensitive to chemotherapeutic treatment may become susceptible to chemotherapy by applying the combination of active substances.

[0015] Therapeutics that could serve to augment natural host defenses against viral and bacterial infections, or against tumor induction and progression, with reduced cytotoxicity would be very beneficial. The present invention provides such therapeutic agents, and further provides other related advantages.

[0016] The small molecule platform provides diverse compounds for the selective manipulation of the immune response, necessary for increasing the therapeutic index of a drug. Compounds with structural disparities will often times elicit a desired response through a different mechanism of action, or with greater specificity to a target, such as a dendritic cell, modulating potency and lowering side effects when administered to a patient.

[0017] It would therefore be beneficial to provide an assay for rapidly screening large quantities of small molecule compounds, which may have immunomodulatory activity. It is an object of the instant invention to provide a high throughput screen for detecting small molecules capable of modulating an immune response. It is also an object of the invention to provide methods of producing large libraries of compounds, through solid support resins, capable of being screened in the high throughput assays of the invention.

[0018] All of the aforementioned documents are incorporated by reference as if fully set forth herein.

BRIEF DESCRIPTION OF THE TABLES

[0019] Table 1 lists in vitro inhibitory activity of TNF- α for 1H-imidazoquinolines

[0020] Table 2 identifies potent SMIS compounds and analogs thereof, which have been shown to be SMIPs.

[0021] Table 3 lists SMIS analogs, which are SMIPs.

[0022] Table 4 lists preferred SMIS compounds and their corresponding references, which are capable of modulating an immune response in a patient and being modified to elicit an immune response in a patient.

[0023] Table 5 lists chemokine species which may serve as immunological markers for identification of immunomodulation.

[0024] Table 6 lists interleukin species which may serve as immunological markers for identification of immunomodulation.

SUMMARY OF THE INVENTION

[0025] The instant invention provides novel immune potentiators, immunogenic compositions, novel compounds and pharmaceutical compositions, and novel methods of administering a vaccine, by administering small molecule immune potentiators in combination with antigens. The invention further provides compositions, novel compounds and pharmaceutical compositions, for use in the treatment of cancer, infectious diseases, allergies, and asthma.

[0026] The SMIP compounds used in the methods and compositions of the invention are inexpensive to produce and easy to administer. They have potential for finer specificity compared to existing immunostimulants, thus providing improved efficacy and safety profiles.

[0027] As adjuvants, the SMIP compounds are combined with numerous antigens and delivery systems to form a final vaccine product.

[0028] As immuno-therapeutics, the SMIP compounds are used alone or in combination with other therapies (e.g. antivirals, anti-bacterials, other immune modulators or in therapeutic vaccine antigens) for treatment of chronic infections such as HIV, HCV, HBV, HSV, and *H. pylori*, as well as medicaments for the reduction of tumor growth.

[0029] As immunotherapeutics, the SMIP compounds also may be used for the treatment of cancer either alone or in combination with other anti-cancer therapies (e.g. chemotherapeutic agents, mAbs or other immune potentiators). In addition, certain SMIPs with the capacity to induce Type 1 cytokines (e.g. IL-12, TNF or IFN's) could be useful for the treatment of allergies or asthma due to their capacity to steer the immune response towards more benign sequelae. The SMIP compounds may be used for example for the treatment of BCG, cholera, plague, typhoid, hepatitis B infection, influenza, inactivated polio, rabies, measles, mumps, rubella, oral polio, yellow fever, tetanus, diphtheria, hemophilus influenzae b, meningococcus infection, and pneumococcus infection. The SMIP compounds may be used in an anti cell proliferative effective amount for the treatment of cancer. The SMIP compounds may also be used in anti-Th2/Type2 cytokine amount for the deviation of allergic/asthmatic immune responses.

[0030] In another embodiment methods of treating cancer are provided wherein known anticancer agents are combined with SMIP compounds to reduce tumor growth in a subject. A number of suitable anticancer agents are contemplated for use in the methods of the present invention and are described more thoroughly in the detailed description.

[0031] In accordance with the present invention, there is provided a method of inhibiting tumor cell growth in a subject, which method comprises administering to said subject an effective dose of a combination containing at least a SMIP and a MAb, wherein said combination is more effective to

inhibit such cell growth than when said MAb is administered individually. Further provided are methods of treating cancer with said combination comprising an additional SMIP compound or MAb, as well as methods of administration to a subject in need thereof.

[0032] Additional embodiments, methods and compositions contemplated to be useful in the instant invention are disclosed in U.S. Ser. No. 10/814,480, 10/762,873, and 10/748,071 which are incorporated by reference as if set forth fully herein.

[0033] In a further embodiment, the invention provides a high throughput assay for identifying small molecule immunomodulators, said assay comprising:

[0034] a) contacting a plurality of test compounds with cells to form one or more test solution(s);

[0035] b) incubating said test solution for at least 30 minutes;

[0036] c) measuring for an increased level of one or more immunological markers in said test solution;

wherein immunomodulation by one or more test compounds present in said plurality of test compounds causes an increase in the amount of said immunological markers in said test solution.

[0037] Another embodiment of the invention provides a high throughput assay for identifying small molecule immunomodulators, said assay comprising:

[0038] a) contacting a plurality of test compounds with cells to form one or more test solution(s);

[0039] b) adding a known immunopotentiating agent to said test solution and to a control solution devoid of said test compounds;

[0040] c) incubating said test solution and said control solution for at least 1 hour;

[0041] d) measuring levels of one or more immunological markers in said test solution and said control solution;

[0042] e) comparing said levels of one or more immunological markers in said test solution with corresponding levels of one or more immunological markers in said control solution to detect a difference in the levels of one or more immunological markers between said test solution and said control solution;

wherein a decrease in the level of one or more of the immunological markers in the test solution indicates immunosuppression by one or more of the test compounds and an increase in the level of one or more of the immunological markers in the test solution indicates immunopotentiality by one or more of the test compounds.

[0043] Another embodiment of the invention provides a high throughput assay for identifying a small molecule immunomodulator, said method comprising:

[0044] a) providing a mixture of test compounds divided into an archive portion and a screening portion from a combinatorial library, wherein (i) said mixture comprises a plurality of resin support beads having test compounds attached thereto, and (ii) each said bead has only one discrete test compound at a concentration greater than 1 nmol attached thereto;

[0045] b) contacting said screening portion with cells;

[0046] c) measuring for increased levels of immunological markers in said screening portion, wherein immunomodulation by one or more test compounds present in said screening portion causes an increase in the amount of said immunological markers;

[0047] d) individually distributing beads from the archive portion in step (a) into a plurality of reaction vessels such that each vessel contains a single bead;

[0048] e) cleaving the test compounds from the beads and separating said beads from the cleaved test compounds, thereby providing discrete samples of individual test compounds;

[0049] f) screening each cleaved test compound for identification of a small molecule immunomodulator;

[0050] g) performing a mass spectrometric analysis on said small molecule immunomodulator; and

[0051] h) deriving the chemical identity of said small molecule immunomodulator from said reserved portion using said mass spectrometric analysis.

[0052] In another embodiment of the invention, a method is provided for screening components of a combinatorial library for immunological activity, and then performing a nonsynthetic deconvolution to identify and characterize specific components from the library.


[0053] Further embodiments of the invention include those described in the detailed description.

DETAILED DESCRIPTION

[0054] Applicants have discovered compounds capable of stimulating cytokine activity in cells and immunotherapeutics and/or vaccine adjuvants in combination with an antigen (s), that will provide effective treatments for disorders described herein and those apparent to one skilled in the art.

[0055] For each of the following embodiments, a method of eliciting an immune response in a patient can be replaced with: use of a SMIP in the manufacture of a medicament for eliciting an immune response in a patient. In other embodiments the SMIPs are used in the manufacture of a medicament for treating an infectious disease, autoimmune disease, allergies, or cancer. In other embodiments the SMIPs are used in the manufacture of a medicament for use as an adjuvant. SMIPs of the present invention include those described in formula I-L.

[0056] One embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (I):



[0057] wherein,

[0058] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and

unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and


[0059] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0060] R_e is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

[0061] n is 1, 2, or 3.

[0062] In a more particular embodiment of formula I, R_a at position 1 is H. In a more particular embodiment of formula I, R_c at position 2 is substituted or unsubstituted alkyl. In a more particular embodiment of formula I, R_b is H. In a more particular embodiment of formula I wherein R_a at position 3 is H. In a more particular embodiment of formula I, R_e is substituted or unsubstituted alkyl.

[0063] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (II):



II

[0064] wherein,

[0065] a dotted line represents an optional placement of an additional bond;

[0066] R_6 is H, substituted alkyl or unsubstituted alkyl; R_7 is $=O$; and the dotted line is absent; or

[0067] R_6 is absent; R_7 is selected from the group consisting of H, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, and substituted and unsubstituted carbocyclylalkyl; and the dotted line represents the placement of an additional bond;

[0068] X is $=N-$ or $=C(R_8)-$, wherein R_8 is selected from the group consisting of H, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, and substituted and unsubstituted carbocyclylalkyl;


[0069] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0070] n is 1, 2, or 3.

[0071] In another embodiment, if R_7 is $=O$ and R_8 is a heterocyclyl, it is not a substituted benzimidazole. In a more particular embodiment of formula II, Examples 42, 43, and 44 are excluded.

[0072] In a more particular embodiment of formula II, R_b is H, halogen, or unsubstituted alkoxy. In a more particular embodiment of formula II, R_6 is H; R_7 is $=O$, and the dotted


line is absent. In a more particular embodiment still, R_6 is H; R_7 is $=O$, the dotted line is absent; X is CR_8 and R_8 is further defined as a structure of formula (R_{8a}):



[0073] wherein, R_9 and R_{10} are independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl.

[0074] In a more particular embodiment of formula II, R_6 is absent, R_7 is selected from the group consisting of H, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkenyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, and substituted and unsubstituted carbocyclylalkyl; and the dotted line is present. In a more particular embodiment thereof, R_7 is selected from the group consisting of substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, and substituted and unsubstituted heterocyclylalkyl. In a still more particular embodiment of formula said aryl group of R_7 is more particularly defined as a fused arylaryl or unfused arylaryl and said heteroaryl group of R_7 is more particularly defined as a fused heteroarylaryl, fused heteroarylheteroaryl, unfused heteroarylaryl, or unfused heteroarylheteroaryl. In a more particular embodiment X is N and R_b at position 5 is a substituted arylamino group.

[0075] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (III):



III


[0076] wherein,

[0077] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0078] n is independently 1, 2, or 3; and

[0079] p is 1 or 2.

[0080] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (IV):



IV

[0081] wherein,

[0082] R_{11} is selected from the group consisting of hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted arylamino, substituted and unsubstituted heteroarylamino, substituted and unsubstituted heterocyclylamino, and substituted and unsubstituted carbocyclylamino;

[0083] R_{12} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted


alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

[0084] R_{13} is selected from the group consisting of H, hydroxyl, alkoxy, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl; or

[0085] R_{12} and R_{13} are bound together to form a substituted or unsubstituted heterocyclyl group; and

[0086] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0087] In a more particular embodiment of formula IV, R_{12} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl; R_{13} is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl; and R_{11} is further defined as structure of formula (R_{11a}):

 R_{11a}

[0088] wherein,


[0089] R_{14} and R_{15} are independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy,

substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or

[0090] R_{14} and R_{15} are taken together to form a substituted or unsubstituted heteroaryl group.

[0091] In a more particular embodiment of formula R_{11a} , R_{14} and R_{15} are taken together to form a substituted heteroaryl group such that R_{11a} is a DNA base. In a more particular embodiment said DNA base is adenine. In a more particular embodiment of formula R_{11a} , R_{14} is aminocarbonyl. In a more particular embodiment of formula R_{11a} , R_{15} is hydroxy.

[0092] In a more particular embodiment of formula IV, R_{12} and R_{13} are bound together to form a heterocyclyl group as shown in Figure (IV_a):


 IV_a

[0093] wherein,

[0094] R_{12a} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

[0095] R_{13a} is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl.

[0096] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (V):



V

[0097] wherein,

[0098] R_{16} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0099] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0100] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0101] n is 1, 2, or 3.

[0102] In a more particular embodiment of formula V, Example 57 is excluded.

[0103] In a more particular embodiment of formula V, n is 1 and R_b is trifluoromethyl.

[0104] In a more particular embodiment of formula V, n is 1 and R_b is cyano. In a more particular embodiment of formula V, R_{16} is further defined as a structure of formula R_{16a} :




R_{16a}

[0105] wherein,

[0106] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0107] R_{17} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0108] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (VI):



VI

[0109] wherein,

[0110] Y_1 and Y_2 are independently N or CR_b ;

[0111] R_{18} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and

unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0112] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0113] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalalkyl, substituted and unsubstituted carbocyclalalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalalkenyl, and substituted and unsubstituted carbocyclalalkenyl; and

[0114] n is 1, 2, or 3.

[0115] In a more particular embodiment of formula VI, Examples 2-11 and 59 are excluded.


[0116] In a more particular embodiment of formula VI, at least one of Y_1 and Y_2 is N.

[0117] In a more particular embodiment of formula VI, Y₁ and Y₂ are both N.

[0118] In a more particular embodiment of formula VI, R_{18} is selected from the group consisting of substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted carbocyclyl, and substituted and unsubstituted heterocyclyl.

[0119] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a steroid SMIP to a patient in need thereof.

In a more particular embodiment, said steroid SMIP is more particularly defined as a structure of formula (VII):



[0120] wherein,

[0121] a dotted line represents an optional placement of an additional bond with the proviso that two contiguous bonds are not double bonds;

[0122] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroarvl;

[0123] R₁₉ is connected by a single bond and is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkylthiol, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0124] R₂₀ is selected from the group consisting of H, hydroxy, cyano nitro, carboxylic acid, halogen, amino, substituted and unsubstituted alkyl, substituted and unsubstituted alkylthiol, substituted and unsubstituted alylamino, substituted and unsubstituted alkylcarbonyl, and substituted and unsubstituted alkoxy; or

[0125] R₁₉ is =O and R₂₉ is absent;

[0126] R₂₁ is connected by a single bond and is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substi-

tuted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or

[0127] R₂₁ is =O;

[0128] G is O— and R_g is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl; or


[0129] G is O= and R₈ is absent; and

[0130] R₂₃ is H or substituted or unsubstituted alkyl; or

[0131] a double bond connects position 8 and 9 and R₂₃ is absent.

[0132] In another embodiment, R_a at position 3 is not hydroxy. In a more particular embodiment of formula VII, Example 62 is excluded.

[0133] In a more particular embodiment said steroid SMIP is defined as a structure of formula (VIII):



VIII

[0134] wherein,

[0135] a dotted line represents an optional placement of an additional bond with the proviso that two contiguous bonds are not double bonds;

[0136] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0137] R₁₅ is connected by a single bond and is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkythiol, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl,

substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0138] R₂₀ is selected from the group consisting of H, hydroxy, cyano nitro, carboxylic acid, halogen, amino, substituted and unsubstituted alkyl, substituted and unsubstituted alkylthiol, substituted and unsubstituted alkylamino, substituted and unsubstituted alkylcarbonyl, and substituted and unsubstituted alkoxy; or

[0139] R₁₉ is =O and R₂₀ is absent;

[0140] R₂₃ is connected by a single bond and is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or

[0141] R₂₁ is =O;

[0142] G is O— and R₈ is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl; or


[0143] G is O= and R₂₂ is absent; and

[0144] R₂₃ is H or substituted or unsubstituted alkyl; or

[0145] a double bond connects position 8 and 9 and R₂₃ is absent.

[0146] In another embodiment, R_a at position 3 is not hydroxy. In a more particular embodiment of formula VIII, Example 62 is excluded.

[0147] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (IX):




IX

- [0148] wherein,
- [0149] a dotted line represents an optional placement of an additional bond with the proviso that two contiguous bonds are not double bonds;
- [0150] Z is CR_b or N;
- [0151] R₂₄ is selected from the group consisting of H, substituted and unsubstituted alkyl, aryl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted alkyl-amino-alkyl;
- [0152] R₂₅ is O= or bound by a single bond and selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl;
- [0153] R₂₆ is absent or selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl;
- [0154] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl, with the proviso that R_a at position 3 is not hydroxy;
- [0155] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substi-

tuted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

- [0156] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0157] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XI):



IX

- [0158] wherein,

[0159] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0160] R_b is independently selected from the group consisting of H, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and


[0161] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0162] In a more particular embodiment of formula XI, R_b at position 1 is a nitrogen-containing heterocyclyl group selected from the group consisting of piperazine, morpholine, homomorpholine, piperidine, and pyrrolidine.

[0163] In a more particular embodiment of formula XI, R_b at position 2 is selected from the group consisting of substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, and substituted and unsubstituted heterocyclyl-

lalkyl. In a preferred embodiment thereof said aryl group is more particularly defined as a fused arylaryl or unfused arylaryl and said heteroaryl group is more particularly defined as a fused heteroarylaryl, fused heteroarylheteroaryl, unfused heteroarylaryl, or unfused heteroarylheteroaryl.

[0164] Another embodiment of the invention provides a method of eliciting an immune response comprising administering a macrocycle SMIP to a patient in need thereof. In a more particular embodiment said macrocycle SMIP is an analog of cyclosporine. In a more particular embodiment, said analog of cyclosporine has a structure of formula (XII):



XII


[0165] wherein,

[0166] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0167] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0168] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or the stereoisomers thereof.

[0169] In a more particular embodiment said macrocycle SMIP has a structure of formula (XIII):



XIII

[0170] wherein,

[0171] a dotted line represents an optional placement of an additional bond;

[0172] A is selected from the group consisting of substituted C_1 - C_{16} alkyl, unsubstituted C_1 - C_{16} alkyl, substituted C_1 - C_{16} alkenyl, unsubstituted C_1 - C_{16} alkenyl, substituted C_1 - C_{16} alkoxy, or unsubstituted C_1 - C_{16} alkoxy;

[0173] D is absent, thereby forming a covalent bond or selected from the group consisting of $-\text{CH}(\text{alkoxy})-$, $-\text{CH}(\text{alkoxyalkyl})-$, $-\text{CH}(\text{alkylamino})-$, $-\text{CH}(\text{aminoalkyl})-$, $-\text{CH}(\text{alkylaminoalkyl})-$, $-\text{C}(=\text{O})-$, $-\text{CH}(\text{alkyl})-$, and $-\text{CH}_2-$;

[0174] R_1 is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0175] R_2 is selected from the group consisting of H, halogen, hydroxy, $=\text{O}$, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;

[0176] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and


[0177] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl; and

[0178] p is 1 or 2;

[0179] or the stereoisomers thereof.

[0180] In a more particular embodiment of formula XIII, R_2 is substituted carbocyclalkenyl.

[0181] In a more particular embodiment of formula XIII, A is further defined as a structure of group A_1 :



[0182] wherein,

[0183] a dotted line represents an optional placement of an additional bond;


[0184] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0185] R_3 is $=O$ or bound by a single bond and selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted

and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl groups.

[0186] In a more particular embodiment of formula A_1 , R_1 is substituted carbocyclalkenyl, R_3 is $=O$ and D is $-CH$ (alkoxy)-.

[0187] In a more particular embodiment of formula XIII, A is further defined as a structure of group A_2 :



[0188] wherein,


[0189] a dotted line represents an optional placement of an additional bond;

[0190] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0191] R_4 is $=O$ or bound by a single bond and selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl groups.

[0192] In a more particular embodiment of formula A_2 , R_1 is substituted carbocyclalkenyl, R_4 is $=O$ and D is $-CH$ (alkoxy)-.

[0193] The method as in any of formula's XIII, A_1 , or A_2 , R_1 is further defined as a substituent of formula (R_{1a}):



[0194] wherein,

[0195] a dotted line represents an optional placement of an additional bond;


[0196] R_5 is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted

carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, substituted and unsubstituted carbocyclylalkenyl;

[0197] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted allylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0198] n is 1, 2, or 3.

[0199] In a more particular embodiment said macrocycle SMIP has a structure of formula (XIV):



XIV

[0200] wherein,

[0201] a dotted line represents an optional placement of an additional bond;

[0202] R_8 is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0203] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted

alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0204] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0205] n is 1, 2, or 3; and


[0206] p is 1 or 2;

[0207] or the stereoisomers thereof.

[0208] In a more particular embodiment of formula XIV, R_b is H.

[0209] In a more particular embodiment of formula XIV, R_c is methoxy.

[0210] In a more particular embodiment said macrocycle SMIP has a structure of formula (XV):



XV

[0211] wherein,

[0212] a dotted line represents an optional placement of an additional bond;

[0213] E_1 is $-\text{N}-$, $-(R_a)\text{C}-$, $-(R_c)\text{N}-$, or $-(R_c)\text{CH}-$;

[0214] E_2 is absent forming a covalent bond, $-\text{O}-$ or $-\text{CHR}_e-$;

[0215] R_{27} is $\text{O}=\text{C}$ or bound by a single bond selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0216] R_{28} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0217] R_{29} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or

[0218] R_{28} and R_{29} are bound together by an oxygen atom, forming an epoxide;

[0219] R_{30} is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0220] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0221] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;


[0222] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0223] n is 1, 2, or 3;

[0224] or the stereoisomers thereof.

[0225] In a more particular embodiment of formula XV, E_1 is $—N=$, E_2 is $—O=$, and R_{27} is $O=$.

[0226] In a more particular embodiment said macrocycle SMIP has a structure of formula (XVI):



[0227] wherein,

[0228] a dotted line represents an optional placement of an additional bond;

[0229] T_1 is $—CH(R_c)—$, $—O—$, or $—N(R_c)—$;

[0230] R_{30} , R_{31} , and R_{32} are independently $O=$, or selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0231] R_{33} is selected from the group consisting of H, halogen, amino, hydroxy substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0232] R_{34} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or

[0233] R_{33} and R_{34} are bound together forming a substituted carbocycle unsubstituted carbocycle, substituted heterocycle or unsubstituted heterocycle;

[0234] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0235] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or the stereoisomers thereof.

R_{33a}


[0237] wherein,

[0238] T₂ is —CH(R_c)—, —O—, or —N(R_c)—;

[0239] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0240] n is 1, 2, or 3.

[0241] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XVII):



XVII

[0242] wherein,

[0243] a dotted line represents an optional placement of an additional bond with the proviso that two contiguous bonds are not double bonds;

[0244] W₁, W₂, and W₃ are independently —CH(R_a)— or —N(R_c)—;

[0245] W₄ is —O—, —CH(R_a)— or —C(R_a)=;

[0246] W₅ is —O—, —CH(R_a)— or =C(R_a)—, with the proviso that both W₄ and W₅ are not —O—;

[0247] W₆ is —CH(R_a)—, =C(R_a)—, or NR_c;

[0248] W₇ is —O— or —CH(R_a)—;

[0249] R₃₅, R₃₆, R₃₈ and R₃₉ are independently O= or selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0250] R₃₇ is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0251] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0252] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0253] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0254] In a more particular embodiment of formula XVII, W_1 , W_2 , and W_3 are NH; W_7 is $-\text{CH}(\text{R}_a)-$; and R_{37} is aminocarbonylamino.

[0255] In a more particular embodiment of XVII, wherein W_1 , W_2 , and W_3 are $-\text{CH}(\text{R}_a)-$; W_4 is $-\text{CH}(\text{R}_a)-$ or $-\text{C}(\text{R}_a)=$; W_5 is $-\text{CH}(\text{R}_a)-$ or $=\text{C}(\text{R}_a)-$; W_6 is $=\text{C}(\text{R}_a)-$; W_7 is $-\text{O}-$; and R_{37} is H.

[0256] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XVIII):



XVIII

[0257] wherein,

[0258] R_{40} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0259] R_{41} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or


[0260] R_{40} and R_{41} are bound together forming a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl group;

[0261] R_{42} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0262] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0263] In a more particular embodiment of formula XVIII R_{40} and R_{41} are bound together forming an optionally substituted benzyl group. In a more particular embodiment of formula XVIII, wherein R_{40} and R_{41} are bound together forming an optionally substituted benzyl group, R_{42} is unsubstituted alkyl.

[0264] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XIX):



XIX

[0265] D_1 is $-\text{N}=$ or $-\text{C}(\text{R}_{46})=$;

[0266] D_2 and D_3 are independently selected from the group consisting of a covalent bond, $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, and $-\text{NR}_d-$;

[0267] R_{43} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted aralkylsulfonyle, substituted and unsubstituted heteroaralkylsulfonyle, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0268] R_{44} and R_{45} are independently selected from the group consisting of H, halogen, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl groups;

[0269] R_{46} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, $-\text{CH}=\text{N}-\text{N}-\text{CO}-\text{R}_a$, $-\text{CH}_2\text{CHR}_a\text{COR}_b$, substi-

tuted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0270] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0271] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0272] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0273] n is 1, 2, or 3;


[0274] with the proviso that if R_{43} is amino, alkylamino, carbonylamino, or alkylcarbonylamino, then both D_2 and D_3 are covalent bonds.

[0275] In a more particular embodiment of formula XIX, D_1 is CR_{46} , wherein R_{46} is $—CH=N—N—CO—R_a$ or

$—CH_2CHR_aCOR_b$. In a more particular embodiment of formula XIX, wherein D_1 is CR_{46} , wherein R_{46} is $—CH=N—N—CO—R_a$ or $—CH_2CHR_aCOR_b$, R_{43} is H.

[0276] In a more particular embodiment of formula XIX, R_{43} is substituted or unsubstituted heteroaralkylsulfonyle.

[0277] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP, of formula (XX):



XX

[0278] wherein,

[0279] a dotted line represents an optional placement of an additional bond;

[0280] Q_1 is $—N(R_d)—$ or $—CH(R_b)—$;

[0281] Q_2 is $—N(R_c)—$, $=N—$, or $=C(R_b)—$;

[0282] R_{47} is absent, $=NR_c$, or $—CH(R_b)—$;

[0283] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0284] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0285] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and

unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl; and

[0286] n is 1, 2, or 3.


[0287] In another embodiment, if n is 2 then R_b at positions 2 and 3 are not methoxy. In a more particular embodiment of formula XX, Examples 22 and 23 are excluded.

[0288] In a more particular embodiment of formula XX, Q_1 is $-\text{N}(R_d)-$, Q_2 is $-$, $\text{C}(R_b)=$ and R_{47} is $=\text{NR}_c$.

[0289] In a more particular embodiment of formula XX, Q_1 is $-\text{CH}(R_b)-$, Q_2 is $-\text{N}(R_c)-$, and R_{47} is $-\text{CH}(R_b)-$. In a more particular embodiment of formula XX wherein Q_1 is $-\text{CH}(R_b)-$, Q_2 is $-\text{N}(R_c)-$, and R_{47} is $-\text{CH}(R_b)-$, of Q_2 is substituted or unsubstituted heteroaryl.

[0290] In a more particular embodiment of formula XX, R_{47} is absent and Q_1 is $-\text{N}(R_d)-$ and Q_2 is $=\text{N}-$.

[0291] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXI):



[0292] wherein,

[0293] a dotted line represents an optional placement of an additional bond with the proviso that two contiguous bonds are not double bonds;

[0294] R_{48} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocycl, substituted and unsubstituted heterocycl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;


[0295] R_{49} is $=\text{CH}_2$, $=\text{O}$ or bound by a single bond and selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substi-

tuted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocycl, substituted and unsubstituted heterocycl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;

[0296] R_{50} and R_{51} are independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocycl, and substituted and unsubstituted heteroaryl; and

[0297] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocycl, substituted and unsubstituted heterocycl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl.


[0298] In a more particular embodiment of formula XXI, R_{48}



is:

[0299] In a more particular embodiment of formula XXI, positions 1 and 3 are in an R configuration.

[0300] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SNIP of formula (XXII):




[0301] wherein,

[0302] R₅₈ is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0303] R₅₉ is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted aminocarbonylalkyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl.


[0304] In a more particular embodiment of formula XXII, R₅₈ is unsubstituted alkyl such as propyl.

[0305] In a more particular embodiment of formula XXII, R₅₈ is substituted aminocarbonylalkyl, such as:



[0306] Further embodiments of the invention include a SMIP of structure XXI or XXII or the more particular embodiments thereof, wherein upon administration of said SMIP, cannabinoid receptors are inhibited in said patient.

[0307] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXII):



[0308] wherein,

[0309] a dotted line represents an optional placement of an additional bond;


[0310] R₅₂ is bound by a double bond and selected from the group consisting of =O, substituted and unsubstituted alkenyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, substituted and unsubstituted carbocyclalkenyl, substituted and unsubstituted imine, or bound by a single bond and selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted aminocarbonylalkyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl groups;

[0311] R₅₃ is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl groups;

[0312] R_8 is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0313] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or the stereoisomers thereof.

[0314] In a more particular embodiment of formula XXIII, R_{52} is a substituted carbocyclylalkenyl as shown in figure R_{52a} :

 R_{52a}

[0315] wherein,

[0316] a dotted line represents an optional placement of an additional bond;

[0317] R_{54} is $=CH_2$, $=O$, or bound by a single bond and selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substi-


tuted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, substituted and unsubstituted carbocyclylalkenyl; and

[0318] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0319] In a more particular embodiment of formula R_{52a} , R_{54} is $=CH_2$ and R_a at positions 6 and 7 is hydroxy.

[0320] In a more particular embodiment of formula XXIII, R_{53} is selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, and substituted and unsubstituted alkoxyalkyl.

[0321] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXIII):



XXIV

[0322] wherein,

[0323] a dotted line represents an optional placement of an additional bond, with the proviso that R_{57} is absent if R_{56} is bound by a double bond;

[0324] V_1 is CR_b or NR_d ;

[0325] R_{55} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, substituted and unsubstituted carbocyclylalkenyl; and

[0326] R_{56} is $=O$ and R_{57} is absent; or

[0327] R_{56} is bound to position 3 by a single bond and selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted

and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0328] R_{57} is bound to position 3 by a single bond and selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, and substituted and unsubstituted carbonyl;


[0329] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0330] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0331] In a more particular embodiment of formula XXIV, V_1 is N-alkyl-amino or N-alkyl-heterocyclyl. In a more particular embodiment of formula XXIV, wherein V_1 is N-alkyl-amino or N-alkyl-heterocyclyl, R_{56} and R_{57} are indepen-

dently substituted or unsubstituted alkyl and bound to position 3 by a single bond. In a more particular embodiment thereof, R_{56} is $=O$, R_{57} is absent and V_1 is CR_b , R_b being preferably alkenyl.

[0332] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXV):



XXV

[0333] wherein,

[0334] R_{60} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0335] R_{61} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and


[0336] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl,

substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0337] In a more particular embodiment of formula XXV, R_b is heteroarylsulfonyl.

[0338] In a more particular embodiment of formula XXV, R_{60} is an aryl or aralkyl group wherein said aryl group alone or appended to an alkyl group is more particularly defined as an unfused arylaryl group. In preferred embodiments of any of the embodiments formula XXV; XXV where R_b is heteroarylsulfonyl; or XXV where R_{60} is an optionally substituted aryl or aralkyl group wherein said aryl group alone or appended to an alkyl group is more particularly defined as an unfused arylaryl group,

[0339] R_{61} is amino, substituted alkylamino, or unsubstituted alkylamino. Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXVI):



XXVI

[0340] wherein,

[0341] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0342] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0343] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted

alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0344] In a more particular embodiment of formula XXVI, R_b is a substituted benzyl group.

[0345] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXVII):



XXVII

[0346] wherein,

[0347] a dotted line represents an optional placement of an additional bond;

[0348] R_{62} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted arylcarbonyloxy, substituted and unsubstituted heteroarylcarbonyloxy, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0349] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted


tuted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0350] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0351] In a more particular embodiment of formula XXVII, R_{62} is substituted or unsubstituted heteroarylcarbonyloxy.

[0352] In a more particular embodiment of formula XXVII, the dotted line represents the placement of an additional bond.

[0353] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXVIII):



XXVIII

[0354] wherein,

[0355] U_1 is $-\text{CH}(11.0- \text{ or } -\text{O}-$;

[0356] R_{63} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0357] R_{64} is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, substituted and unsubstituted carbocyclylalkenyl; or

[0358] R_{63} and R_{64} are taken together to form an optionally substituted heterocyclyl group;


[0359] R_{65} is selected from the group consisting of H, halogen, amino, hydroxy, sulfonyl, $-\text{O}-\text{PO}_3$, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and =substituted heteroaryl;

[0360] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0361] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0362] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0363] In a more particular embodiment of formula XXVIII, R_{63} and R_{64} are taken together to form an optionally substituted heterocyclyl group of formula R_{63a} :

 R_{63a}

[0364] wherein,

[0365] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0366] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or


bonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl.

[0367] In a more particular embodiment of formula XXVIII, wherein R_{63} and R_{64} are taken together to form an optionally substituted heterocyclyl group of formula R_{63a} , U_1 is $-\text{CH}_2-$ and R_b of formula R_{63a} is alkylamino.

[0368] In a more particular embodiment of formula XXVIII, R_b at position 4 is para-methoxybenzyl.

[0369] In a more particular embodiment of formula XXVIII, R_{65} is $-\text{O}-\text{PO}_3$.

[0370] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXIX):



XXIX

[0371] wherein,

[0372] a dotted line represents an optional placement of an additional bond;

[0373] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0374] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and

unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;


[0375] R_e is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

[0376] n is 1, 2, or 3.

[0377] In a more particular embodiment of formula XXIX, R_b at positions 1, 3, and 4 is hydroxy.

[0378] In a more particular embodiment of formula XXIX, the dotted line represents the placement of an additional bond and R_b at position 5 is amino.

[0379] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXX):



XXX

[0380] wherein,

[0381] R_{66} and R_{67} are independently H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted aminosulfonyl, substituted and unsubstituted alkylaminosulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted aryloxy, substituted and unsubstituted heteroaryloxy, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl; and

[0382] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted


alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0383] In a more particular embodiment of formula XXX, R_{67} is substituted aminosulfonyl, unsubstituted aminosulfonyl, substituted alkylaminosulfonyl, or unsubstituted aminosulfonyl.

[0384] In a more particular embodiment of formula XXX, R_{66} is substituted aryloxy, unsubstituted aryloxy, substituted heteroaryloxy, or unsubstituted heteroaryloxy.

[0385] In a more particular embodiment of formula XXX, R_b at position 3 is substituted or unsubstituted carbonylamino.

[0386] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXI)



[0387] wherein,

[0388] R_{68} and R_{69} are independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0389] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0390] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy,

substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0391] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and


[0392] n is 1, 2, or 3.

[0393] In a more particular embodiment of formula XXXI, R_{68} is a substituted or unsubstituted aryl group.

[0394] In a more particular embodiment of formula XXXI, R_{69} is optionally substituted 4H-pyran-4-one.

[0395] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXII):

XXXII




[0396] wherein,

[0397] R_{70} is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkylamino, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0398] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0399] In a more particular embodiment of formula XXXII, R_{70} is further defined as R_{70a} :

 R_{70a} 


[0400] wherein,

[0401] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted


and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0402] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0403] In a more particular embodiment R_{70a} is defined as:



[0404] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXIII):



[0405] wherein,

[0406] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0407] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and


[0408] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0409] In a more particular embodiment of formula XXXIII, R_b at positions 1 and 2 are independently selected from the group consisting of substituted or unsubstituted aralkyl and heteroaralkyl.

[0410] In a more particular embodiment of Formula XXXIV, R_a is trimethoxyphenyl.

[0411] Another embodiment of the invention provides a method of treating a patient comprising administering a terpene SMIP to a patient in need thereof, wherein upon administration an immune response is elicited in said patient.

[0412] In a more particular embodiment said terpene SMIP is a structure of formula (XXXIV):



[0413] wherein,


[0414] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0415] R_{71} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0416] In a more particular embodiment of formula XXXIV, R_{71} is a substituted or unsubstituted aryl group more particularly defined as a substituted or unsubstituted unfused arylaryl group.

[0417] In a more particular embodiment of formula XXXIV, wherein R_{71} is a substituted or unsubstituted unfused

arylaryl group, said substituted or unsubstituted arylaryl group is defined as R_{71a} :

 R_{71a}


[0418] wherein,

[0419] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0420] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroalkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0421] n is independently 1, 2, or 3.

[0422] In a more particular embodiment, said terpene SMIP is a structure of formula (XXXV):



XXXV

[0423] wherein,


[0424] R_{74} is selected from the group consisting substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl;

[0425] R_{75} and R_{76} are independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; or

[0426] R_{75} and R_{76} are bound together to form an epoxide; and,

[0427] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0428] In a more particular embodiment of formula XXXV, R_{74} is further defined as a structure of formula R_{74a} :


 R_{74a}

[0429] wherein,

[0430] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0431] R_e is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl.

[0432] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXVI):



XXXVI

[0433] wherein,


[0434] R_{72} is selected from the group consisting of H, halogen, amino, hydroxy, sulfonyl, $-\text{O}-\text{PO}_3$, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0435] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0436] In a more particular embodiment of formula XXXVI, R_c is H.

[0437] In a more particular embodiment of formula XXXVI, R_{72} is $-\text{O}-\text{PO}_3$.

[0438] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXVII):



XXXVII

[0439] wherein,

[0440] T_1 and T_2 are independently O, S, CHR_c , or NR_c ;

[0441] R_{72} and R_{73} are independently selected from the group consisting of H, halogen, amino, hydroxy, sulfonyl, $-\text{PO}_3$, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0442] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkyamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0443] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0444] n is 1, 2, or 3; or

[0445] the pharmaceutically acceptable salts thereof.

[0446] In a more particular embodiment of formula XXXVII, Examples 2, 6, 9, 11, 20, and 21 are excluded.


[0447] Furthermore, R_b of formula XXXVII may be H and said pharmaceutically acceptable salt may be sodium.

[0448] In a more particular embodiment of formula XXXVII, T_1 and T_2 are both S. Furthermore, R_b may be H and said pharmaceutically acceptable salt may be sodium.

[0449] In a more particular embodiment of formula XXXVII, R_{72} and R_{73} are $-\text{PO}_3$. Furthermore, R_1 may be H and said pharmaceutically acceptable salt may be sodium.

[0450] Another embodiment of the invention provides a method of treating; a patient comprising administering a ruthenium complex SMIP to a patient in need thereof, wherein upon administration an immune response is elicited in said patient. In a more particular embodiment said ruthenium complex SMIP consists of at least 2 nitrogen-containing heteroaryl groups, such as imidazole. In an even more particular embodiment, said ruthenium complex SMIP consists of 6 nitrogen-containing heteroaryl groups, such as imidazole.

[0451] In a more particular embodiment, said ruthenium complex SMIP is a structure of formula (XXXVIII):




XXXVIII

[0452] wherein,

[0453] NH_{aryl} is a substituted or unsubstituted nitrogen containing heteroaryl group.

[0454] In a more particular embodiment of formula XXXVIII, said nitrogen containing heteroaryl group is selected from the group consisting of acridine, carbazole, β -carboline, cinnoline, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, oxazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, and thiazole.

[0455] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XXXIX):



XXXIX

[0456] wherein,

[0457] R_{77} is selected from the group consisting of H, halo, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substi-


tuted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkylamino, substituted and unsubstituted heteroaralkylamino, substituted and unsubstituted heterocyclalkylamino, substituted and unsubstituted carbocyclalkylamino, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;

[0458] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0459] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0460] In a more particular embodiment of formula XXXIX, R₇₇ is selected from the group consisting of substituted and unsubstituted aralkylamino and substituted and unsubstituted heteroaralkylamino.

[0461] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XL):



[0462] wherein,

[0463] R₇₈ is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxycarbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted substituted and unsubstituted

tuted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted heteroaralkoxy, substituted and unsubstituted aralkoxy, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;


[0464] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and

[0465] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0466] n is 1, 2, or 3.

[0467] In a more particular embodiment of formula XL, R₇₈ is substituted or unsubstituted aralkoxy.

[0468] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLI):



[0469] wherein,

[0470] R₈₀ is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroarvl:

[0471] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0472] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl;


[0473] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0474] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl; and

[0475] n is 1, 2, or 3.

[0476] In a more particular embodiment of formula XLI, R_{80} is undecanyl.

[0477] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLII):



XLII


[0478] wherein,

[0479] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclalkyl, substituted and unsubstituted carbocyclalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclalkenyl, and substituted and unsubstituted carbocyclalkenyl; and

[0480] n is 1, 2, or 3.

[0481] In a more particular embodiment of formula XIII, R_b at position 1 is a substituted alkyl group further defined as carbonylalkyl or -alkyl-COOH.

[0482] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLIII):



XLIII

[0483] wherein,

[0484] X_1 is selected from the group consisting of $-\text{CO}-$, $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, sulfonyl, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbonylalkyl, carbonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, sulfonamide, imine, and thiourea;

[0485] R_{81} is selected from the group consisting of H, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted carbocyclyl, and substituted and unsubstituted heteroaryl;

[0486] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0487] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano,

carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;


[0488] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0489] R_e is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

[0490] p is 1 or 2.

[0491] In a more particular embodiment of formula XLIII, X_1 is substituted or unsubstituted alkenyl. In a more particular embodiment of formula XLIII, wherein X_1 is substituted or unsubstituted alkenyl, R_{81} is substituted or unsubstituted aryl. In a preferred embodiment thereof, R_{81} is an aryl substituted with a sulfonyl or alkylsulfonyl group.

[0492] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLIV):



XLIV

[0493] wherein,

[0494] X_2 is selected from the group consisting of $-\text{CO}-$, $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, sulfonyl, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbonylalkyl, carbonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted allylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, sub-

stituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, sulfonamide, imine, and thiourea;

[0495] R_{82} is selected from the group consisting of H, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted carbocyclyl, and substituted and unsubstituted heteroaryl;


[0496] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0497] R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0498] p is 1 or 2.

[0499] In a more particular embodiment of formula XLIV, X_2 is a substituted alkenyl that is further defined as an optionally substituted -alkenyl-carbonyl-oxy-. In a more particular embodiment thereof, R_{82} is a substituted or unsubstituted heterocyclyl, such as morpholine.

[0500] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLV):



XLV

[0501] wherein,

[0502] R_{83} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted car-

bonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted carbocycylamino, substituted and unsubstituted heterocycylamino, substituted and unsubstituted arylamino, substituted and unsubstituted heteroarylamino, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocycylalkyl, substituted and unsubstituted carbocycylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocycylalkenyl, and substituted and unsubstituted carbocycylalkenyl;

[0503] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocycylalkyl, substituted and unsubstituted carbocycylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocycylalkenyl, and substituted and unsubstituted carbocycylalkenyl;

[0504] R_c is independently selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl; and


[0505] n is 1, 2, or 3.

[0506] In another embodiment of the invention, if both R_e groups and R_b are all H, then R_{83} is not an alkyl group substituted with a piperiziny group. In another embodiment of formula XLV, Example 15 is excluded.

[0507] In a more particular embodiment of formula XLV, R_b at position 3 may be substituted or unsubstituted carbocyclyl.

[0508] In a more particular embodiment of formula XLV, R_{83} is substituted or unsubstituted carbocycylamino. Furthermore, R_b at position 3 may be substituted or unsubstituted carbocyclyl.

[0509] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLVI):



XLVI

[0510] wherein,

[0511] X_3 is a substituted or unsubstituted alkyl group;

[0512] X_4 is a covalent bond or selected from the group consisting of $-\text{CO}-$, $-\text{O}-\text{CO}-\text{N}(\text{R}_a)-$, $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, sulfonyl, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbonylalkyl, carbonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted carbonyloxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, sulfonamide, imine, and thiourea;

[0513] R_{84} is selected from the group consisting of H, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl groups;

[0514] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0515] R_b is independently selected from the group consisting of H, halogen, hydroxy; amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocycylalkyl, substituted and unsubstituted carbocycylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocycylalkenyl, and substituted and unsubstituted carbocycylalkenyl; and

[0516] n is 1, 2, or 3.

[0517] In a more particular embodiment of formula XLVI, X_3 is ethyl and X_4 is $—O—CO—NH—$.

[0518] In a more particular embodiment of formula XLVI, R_b is H. Furthermore, X_3 may be ethyl and X_4 , $—O—CO—NH—$.

[0519] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLVII):



XLVII

[0520] wherein,

[0521] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0522] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0523] n is 1, 2, or 3.

[0524] In a more particular embodiment of formula XLVII, R_b at position 2 is substituted or unsubstituted alkylcarbonylamino.

[0525] In a more particular embodiment of formula XLVII, R_a is H.

[0526] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLVIII):



XLVIII

[0527] wherein,


[0528] R_{84} , R_{85} , and R_{86} are independently selected from the group consisting of substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl groups; and

[0529] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl.

[0530] In a more particular embodiment of formula XLVIII, R_{84} , R_{85} , and R_{86} are independently substituted or unsubstituted aryl.

[0531] In a more particular embodiment of formula XLVIII, R_{84} , R_{85} , and R_{86} are independently substituted or unsubstituted phenyl.

[0532] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (XLIX):



XLIX

[0533] wherein,

[0534] R_a is independently selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0535] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0536] R_c is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and

unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;

[0537] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0538] R_e is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl;

[0539] n is 1, 2, or 3; and


[0540] p is 1 or 2.

[0541] In a more particular embodiment of formula XLIX, R_d is substituted or unsubstituted carbocyclylalkyl.

[0542] In a more particular embodiment of formula XLIX, R_a at position 1 is substituted or unsubstituted alkyl.

[0543] In a more particular embodiment of formula XLIX, R_a at position 2 is substituted or unsubstituted alkoxy.

[0544] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (L):



[0545] wherein,

[0546] R_{87} is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

[0547] R_a is selected from the group consisting of H, halogen, amino, hydroxy, substituted and unsubstituted alkyl, substituted and unsubstituted alkoxy, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted heteroaryl;


[0548] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0549] n is 1, 2, or 3.

[0550] In a more particular embodiment of formula L, R_b is H.

[0551] In a more particular embodiment of formula L, R_{87} is a substituted aryl or heteroaryl group. Furthermore, R_b may be H. In a more particular embodiment of formula L, wherein R_{87} is a substituted aryl or heteroaryl group, said aryl or heteroaryl group of R_{87} may be substituted with a malonate. Furthermore, R_b may be H.

[0552] Another embodiment of the invention provides a method of eliciting an immune response in a patient comprising administering a SMIP of formula (LI):



LI

[0553] wherein,

[0554] R_b is independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted

tuted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; and

[0555] R_d is selected from the group consisting of H, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkoxy carbonyl, substituted and unsubstituted carbonyl, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

[0556] In a more particular embodiment of formula LI, R_d is substituted or unsubstituted carbonyl.

[0557] In a more particular embodiment of formula LI, R_d is methylcarbonyl.

[0558] In one embodiment of the invention compounds of Table 3 (Examples 2-67) are excluded from any one of the embodiments disclosed herein. In another embodiment of the invention any of the compounds disclosed in U.S. application Ser. No. 10/814,480 are excluded, from any one of the embodiments disclosed herein. Preferably specific embodiments for which the aforementioned disclaimers apply are those of Formula I-LI.

[0559] Another embodiment of the invention provides a method of identifying a SMIP comprising:

[0560] a. identifying a core scaffold of a SMIS;

[0561] b. altering or adding at least one variable substituent of said core scaffold of said SMIS with a substituent selected from the group consisting of substituted or unsubstituted alkyl, alkoxy, alkenyl, alkynyl, amino, alkylamino, dialkylamino, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, carbonyl, carbonyloxy, sulfonyl, carbonylamino, aminocarbonyl, guanidiny, and alkoxy carbonyl, to form a SMIS analog;

[0562] c. contacting said SMIS analog with cells to form a reaction solution;

[0563] d. monitoring said reaction solution for an immune response to said SMIS analog; and

[0564] e. identifying said immune response to said SMIS analog by detecting increased levels of cytokines or TNF- α , wherein a SMIS analog capable of eliciting cytokine or TNF- α production is a SMIP.

[0565] In a more particular embodiment, said cells are human peripheral blood mononuclear cells. In another embodiment said cells are human monocyte-derived cells, specifically THP-1. In another embodiment said cells are mouse monocyte-derived cell, such as, Raw 264.7. In another more particular embodiment said reaction solution is incubated at about 37° C.

[0566] In another more particular embodiment said reaction solution is incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours.

[0567] In another more particular embodiment, wherein said cells are human peripheral blood mononuclear cells; and said reaction solution is incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours, said reaction solution is incubated at about 37° C.

[0568] In another more particular embodiment said step of detecting increased levels of cytokines or TNF- α is done by using a primary plate bound antibody for capture followed by a secondary biotinylated anti-TNF antibody. In a more particular embodiment said secondary biotinylated anti-TNF antibody is detected using streptavidin-Europium. In a more particular embodiment thereof, increased levels of cytokines or TNF- α in said reaction solution are identified by an increased europium count. In a still more particular embodiment said increased europium count is identified by time resolved fluorescence.

[0569] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said SMIP is co-administered with another agent, such as a vaccine.

[0570] Other embodiments provide the use of a SMIP of formula I-L and another agent for simultaneous separate or sequential administration. In a more particular embodiment the other agent is an antigen. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0571] Other embodiments provide a pharmaceutical preparation or system, comprising (a) a first pharmaceutical agent, which comprises a SMIP of formula I-L; and (b) a second pharmaceutical agent, wherein said first and second agents are either in admixture or are separate compositions. In a more particular embodiment the second agent is an antigen. More specifically, the agents are for simultaneous separate or sequential administration. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0572] A kit comprising (a) a first pharmaceutical agent, which comprises a SMIP of formula I-L; and (b) a second pharmaceutical agent. In a more particular embodiment the second agent is an antigen. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0573] Another embodiment provides the use of a SMIP of formula I-L and another agent in the manufacture of a combination medicament. In a more particular embodiment the other agent is an antigen. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0574] Another embodiment provides the use of a SMIP of formula I-L in the manufacture of a medicament, wherein the medicament is co-administered with another agent. In a more

particular embodiment the second agent is an antigen. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0575] Another embodiment provides the use of an antigen in the manufacture of a medicament, wherein the medicament is co-administered with a SMIP of formula I-L.

[0576] The two agents are preferably administered within 4 hours of each other.

[0577] Another embodiment provides the use of a SMIP of formula I-L in the manufacture of a medicament, wherein the medicament is for administration to a patient who has been pre-treated with another agent. In a more particular embodiment the second agent is an antigen. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0578] Another embodiment provides the use of an antigen in the manufacture of a medicament, wherein the medicament is for administration to a patient who has been pre-treated with a SMIP of formula I-L. The pre-treatment may be recent (e.g. within the 24 hours preceding administration of said medicament), intermediate (e.g. more than 24 hours previous, but no longer than 4 weeks), more distant (e.g. at least 4 weeks previous), or very distant (e.g. at least 6 months previous), with these time periods referring to the most recent pre treatment dose. The patient may be refractory to treatment by the pharmaceutical agent that was administered in the pre-treatment. In another more particular embodiment the use is for eliciting an immune response in a patient. In another embodiment the use is for treating an infectious disease, autoimmune disease, allergies, or cancer. In another embodiment the use is as an adjuvant.

[0579] Another embodiment provides, the use of a SMIP of formula I-L in the manufacture of a medicament, wherein the medicament is for administration to a patient who has a tumor or infection that is resistant to treatment with another agent.

[0580] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said SMIP is administered in a dose capable of increasing TNF- α levels.

[0581] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said SMIP modulates activity of at least one target selected from the group consisting of glucocorticoid receptors, DNA alkylation, calcineurin, INK, p38 kinase, cyclin kinase cascade, PDE IV, IMPDH, DHOD, Ick, and thymidylate synthase.

[0582] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said immune response involves production of cytokines.

[0583] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said immune response involves increased production of TNF- α .

[0584] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein the patient is suffering from a viral infection, such as HCV. In a preferred embodiment said SMIP is co-administered with another agent, such as a vaccine.

[0585] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said patient is suffering from increased cellular proliferation or cancer. In a preferred embodiment said SMIP is co-administered with another agent, such as a vaccine.

[0586] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said patient is suffering from allergic diseases. In a preferred embodiment said SMIP is co-administered with another agent, such as a vaccine.

[0587] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said patient is suffering from asthma. In a preferred embodiment said SMIP is co-administered with another agent, such as a vaccine.

[0588] Further embodiments of the invention include a SMIP of structure I-L or the more particular embodiments thereof, wherein said SMIP, present at a concentration less than 20 μ M, induces production of TNF- α .

[0589] Candidate small molecule immuno-potentiators can be identified in vitro. Compounds are screened in vitro for their ability to activate immune cells. One marker of such activation is the induction of cytokine production, for example TNF- α production. Apoptosis inducing small molecules may be identified having this activity. These small molecule immuno-potentiators have potential utility as adjuvants and immuno-therapeutics.

[0590] Another embodiment of the invention provides a method of identifying a SMIP comprising:

[0591] a) contacting a compound with cells to form a cell culture;

[0592] b) incubating said cell culture for at least 1 hour;

[0593] c) monitoring for increased TNF- α levels in said cell culture;

[0594] d) identifying said SMIP by the increased TNF- α levels in said cell culture.

[0595] In a more particular embodiment, said cells are human peripheral blood mononuclear cells. In another more particular embodiment said cell culture is incubated at about 37° C.

[0596] In another more particular embodiment said cell culture is incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours.

[0597] In another more particular embodiment, wherein said cells are human peripheral blood mononuclear cells; and said cell culture is incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours, said cell culture is incubated at about 37° C.

[0598] In another more particular embodiment said step of monitoring for increased TNF- α levels in said cell culture is done by using a primary plate bound antibody for capture followed by a secondary biotinylated anti-TNF antibody. In a more particular embodiment said secondary biotinylated anti-TNF antibody is detected using streptavidin-Europium. In a more particular embodiment thereof, increased TNF- α levels in said cell culture are identified by an increased europium count. In a still more particular embodiment said increased europium count is identified by time resolved fluorescence.

[0599] Another embodiment of the invention provides a method of identifying a potency of a SMIP comprising:

- [0600] a) contacting a compound, and separately LPS, with cells to form a compound cell culture and an LPS cell culture;
- [0601] b) incubating said compound cell culture and said LPS cell culture for at least 1 hour;
- [0602] c) monitoring for increased TNF- α levels in said compound cell culture and said LPS cell culture;
- [0603] d) comparing the increased TNF- α levels in said compound cell culture with the increased TNF- α levels in said LPS cell culture;
- [0604] e) identifying the potency of said SMIP by the increase in TNF- α levels in said compound cell culture with respect to the increased TNF- α levels in said LPS cell culture.

[0605] In a more particular embodiment said cells are human peripheral blood mononuclear cells. In another more particular embodiment said compound cell culture and said LPS cell culture are incubated at about 37° C.

[0606] In another more particular embodiment said compound cell culture and said LPS cell culture are incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours.

[0607] In another more particular embodiment, wherein said cells are human peripheral blood mononuclear cells; and said compound cell culture and said LPS cell culture are incubated for at least about 2 hours, or at least about 5 hours, or at least about 10 hours, or at least about 15 hours, or at least about 18 hours, or about 18 hours, said cell culture is incubated at about 37° C.

[0608] In another more particular embodiment said step of monitoring for increased TNF- α levels in said compound cell culture and said LPS cell culture is done by using a primary plate bound antibody for capture followed by a secondary biotinylated anti-TNF antibody. In a more particular embodiment said secondary biotinylated anti-TNF antibody is detected using streptavidin-Europium. In a more particular embodiment thereof increased TNF- α levels in said compound cell culture and said LPS cell culture are identified by an increased europium count. In still a more particular embodiment said increased europium count is identified by time resolved fluorescence.

[0609] One embodiment of the invention provides a high throughput assay for identifying small molecule immunomodulators, said assay comprising:

- [0610] a) contacting a plurality of test compounds with cells to form one or more test solution(s);
- [0611] b) incubating said test solution for at least 30 minutes;
- [0612] c) measuring for an increased level of one or more immunological markers in said test solution;

wherein immunomodulation by one or more test compounds present in said plurality of test compounds causes an increase in the amount of said immunological markers in said test solution.

[0613] In a more particular embodiment, said small molecule immunomodulators are SMIPs and said immunomodulation is immunopotential. A more particular embodiment provides the high throughput assay further comprising the step of comparing said amount of immunological markers in said test solution with an unstimulated solution, devoid of any

test compounds. More particularly, said unstimulated solution is run in parallel with said test solution.

[0614] In a more particular embodiment, the high throughput assay further comprises the step of comparing said amount of immunological markers in said test solution with a stimulated solution containing a known immunopotentiating agent. Further still, said stimulated solution is run in parallel with said test solution. In another more particular embodiment, said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3.

[0615] In another more particular embodiment said immunological markers are cytokines. In another more particular embodiment said immunological markers are chemokines. In another more particular embodiment said immunological markers are growth factors. In another more particular embodiment said immunological markers are both cytokines and chemokines. In another more particular embodiment said immunological markers are both cytokines and growth factors. In another more particular embodiment said immunological markers are both chemokines and growth factors. In another more particular embodiment said immunological markers are cytokines, chemokines and growth factors.

[0616] In another more particular embodiment said immunological marker is TGF-beta, said small molecule immunomodulators are SMIS, and said immunomodulation is immunosuppression.

[0617] In another embodiment of the high throughput assay, an initial step of providing said plurality of test compounds bound to one or more support resins is provided. In a more particular embodiment said plurality of test compounds are cleaved from their support resins before the step of contacting them with cells. In another more particular embodiment said support resins are beads and said beads are distributed such that a single bead is distributed in separate wells of a multi-well plate. In another more particular embodiment each bead contains between 20 and 100 test compounds. In another more particular embodiment, the high throughput screen further comprises the step of comparing said amount of immunological markers in said test solution with a stimulated solution containing a known immunopotentiating agent. In another more particular embodiment said stimulated solution is run in parallel with said test solution. In another more particular embodiment said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3. In another more particular embodiment the high throughput assay further provides the step of comparing said amount of immunological markers in said test solution with an unstimulated solution, devoid of any test compounds. In another more particular embodiment said unstimulated solution is run in parallel with said test solution. In another more particular embodiment said immunological markers are cytokines. In another more particular embodiment said immunological markers are chemokines. In another more particular embodiment said immunological markers are growth factors. In another more particular embodiment said immunological markers are both cytokines and chemokines. In another more particular embodiment said immunological markers are both cytokines and growth factors. In another more particular embodiment said immunological markers are both chemokines and growth factors. In another more particular embodiment said immunological markers are cytokines, chemokines and growth factors.

[0618] In another a more particular embodiment said test solution is incubated for at least 1 hour, or 2 hours, or 3 hours, or 4 hours, or 5 hours, or 6 hours, or 10 hours, or 15 hours, or 18 hours.

[0619] In another a more particular embodiment said test compounds have a molecular weight of less than 700 g/mol.

[0620] In another a more particular embodiment said immunological markers are detected by fluorescent dyes bound to capture antibodies.

[0621] In another a more particular embodiment said cytokines are selected from the group consisting of IL 1-26, TNF-alpha, TNF-beta, IFN-alpha, IFN-beta and IFN-gamma.

[0622] In another a more particular embodiment said cytokines are selected from the group consisting of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-13.

[0623] In another a more particular embodiment said chemokines are selected from the group consisting of CXCL 1-16, XCL 1-2, CX₃CL 1, and CCL 1-28.

[0624] In another a more particular embodiment said growth factors are selected from the group consisting of GM-CSF, G-CSF and M-CSF.

[0625] In another a more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that one species of test compound is distributed per well.

[0626] In another more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that more than one species of test compound is distributed per well. Alternatively, said plurality of test compounds are added to one or more vessels such that more than one species of test compound exists in each vessel.

[0627] In another a more particular embodiment identification of said small molecule immunomodulator is performed by successively screening an incrementally smaller subset of said plurality of test compounds contained within wells showing immunomodulatory activity until the small molecule immunomodulator is isolated.

[0628] In another a more particular embodiment said plurality of test compounds refers to at least 20 distinct test compound species.

[0629] In another a more particular embodiment said cells are human PBM cells or mu-splenocytes.

[0630] Another embodiment of the invention provides a high throughput assay for identifying small molecule immunomodulators, said assay comprising:

[0631] a) contacting a plurality of test compounds with cells to form one or more test solution(s);

[0632] b) adding a known immunopotentiating agent to said test solution and to a control solution devoid of said test compounds;

[0633] c) incubating said test solution and said control solution for at least 1 hour;

[0634] d) measuring levels of one or more immunological markers in said test solution and said control solution;

[0635] e) comparing said levels of one or more immunological markers in said test solution with corresponding levels of one or more immunological markers in said control solution to detect a difference in the levels of one or more immunological markers between said test solution and said control solution;

wherein a decrease in the level of one or more of the immunological markers in the test solution indicates immunosuppression by one or more of the test compounds and an

increase in the level of one or more of the immunological markers in the test solution indicates immunopotentialiation by one or more of the test compounds.

[0636] In another more particular embodiment said immunopotentiating agent is added in a sub-optimal concentration, such that said immunological markers are only partially stimulated.

[0637] Another embodiment provides the high throughput screen further comprising the step of comparing said amount of immunological markers in said test solution with an unstimulated solution, devoid of any test compounds or immunopotentiating agents. Further still, said unstimulated solution is run in parallel with said test solution. In another embodiment said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3.

[0638] In another embodiment, said immunological markers are cytokines. In another more particular embodiment said immunological markers are chemokines. In another more particular embodiment said immunological markers are growth factors. In another more particular embodiment said immunological markers are both cytokines and chemokines. In another more particular embodiment said immunological markers are both cytokines and growth factors. In another more particular embodiment said immunological markers are both chemokines and growth factors. In another more particular embodiment said immunological markers are cytokines, chemokines and growth factors.

[0639] In another a more particular embodiment said test solution is incubated for at least 1 hour, or 2 hours, or 3 hours, or 4 hours, or 5 hours, or 6 hours, or 10 hours, or 15 hours, or 18 hours.

[0640] In another a more particular embodiment said test compounds have a molecular weight of less than 700 g/mol.

[0641] In another a more particular embodiment said immunological markers are detected by fluorescent dyes bound to capture antibodies.

[0642] In another a more particular embodiment said cytokines are selected from the group consisting of IL 1-26, TNF-alpha, TNF-beta, IFN-alpha, IFN-beta and IFN-gamma.

[0643] In another a more particular embodiment said cytokines are selected from the group consisting of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-13.

[0644] In another a more particular embodiment said chemokines are selected from the group consisting of CXCL 1-16, XCL 1-2, CX₃CL 1, and CCL 1-28.

[0645] In another a more particular embodiment said growth factors are selected from the group consisting of GM-CSF, G-CSF and M-CSF.

[0646] In another a more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that one species of test compound is distributed per well.

[0647] In another more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that more than one species of test compound is distributed per well. Alternatively, said plurality of test compounds are added to one or more vessels such that more than one species of test compound exists in each vessel.

[0648] In another a more particular embodiment identification of said small molecule immunomodulator is performed by successively screening an incrementally smaller subset of

said plurality of test compounds contained within wells showing immunomodulatory activity until the small molecule immunomodulator is isolated.

[0649] In another a more particular embodiment said plurality of test compounds refers to at least 20 distinct test compound species.

[0650] In another a more particular embodiment said cells are human PBM cells or mu-splenocytes.

[0651] In another embodiment of the high throughput assay, an initial step of providing said plurality of test compounds bound to one or more support resin(s) is provided. In a more particular embodiment said plurality of test compounds are cleaved from their support resins before the step of contacting them with cells. In another more particular embodiment said support resins are beads and said beads are distributed such that a single bead is distributed in each well. In another more particular embodiment each bead contains between 20 and 100 test compounds. In another more particular embodiment, the high throughput screen further comprises the step of comparing said amount of immunological markers in said test solution with a stimulated solution containing a known immunopotentiating agent. In another more particular embodiment said stimulated solution is run in parallel with said test solution. In another more particular embodiment said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3. In another more particular embodiment the high throughput assay further provides the step of comparing said amount of immunological markers in said test solution with an unstimulated solution, devoid of any test compounds. In another more particular embodiment said unstimulated solution is run in parallel with said test solution. In another more particular embodiment said immunological markers are cytokines. In another more particular embodiment said immunological markers are chemokines. In another more particular embodiment said immunological markers are growth factors. In another more particular embodiment said immunological markers are both cytokines and chemokines. In another more particular embodiment said immunological markers are both cytokines and growth factors. In another more particular embodiment said immunological markers are both chemokines and growth factors. In another more particular embodiment said immunological markers are cytokines, chemokines and growth factors.

[0652] Another embodiment of the invention provides a high throughput assay for identifying a small molecule immunomodulator, said method comprising:

[0653] a) providing a mixture of test compounds divided into an archive portion and a screening portion from a combinatorial library, wherein (i) said mixture comprises a plurality of resin support beads having test compounds attached thereto, and (ii) each said bead has only one discrete test compound at a concentration greater than 1 nmol attached thereto;

[0654] b) contacting said screening portion with cells;

[0655] c) measuring for increased levels of immunological markers in said screening portion, wherein immunomodulation by one or more test compounds present in said screening portion causes an increase in the amount of said immunological markers;

[0656] d) individually distributing beads from the archive portion in step (a) into a plurality of reaction vessels such that each vessel contains a single bead;

[0657] e) cleaving the test compounds from the beads and separating said beads from the cleaved test compounds, thereby providing discrete samples of individual test compounds;

[0658] f) screening each cleaved test compound for identification of a small molecule immunomodulator;

[0659] g) performing a mass spectrometric analysis on said small molecule immunomodulator; and

[0660] h) deriving the chemical identity of said small molecule immunomodulator from said reserved portion using said mass spectrometric analysis.

[0661] In another a more particular embodiment said screening portion is incubated for at least 2 hours.

[0662] In a more particular embodiment said small molecule immunomodulator is a SMIP and said immunomodulation is immunopotential. In another embodiment, the high throughput assay, further comprising the step of comparing said amount of immunological markers in said screening portion with an unstimulated solution, devoid of any test compounds. In another more particular embodiment said unstimulated solution is run in parallel with said screening portion.

[0663] Another embodiment provides the high throughput assay, further comprising the step of comparing said amount of immunological markers in said screening portion with a stimulated solution containing a known immunopotentiating agent. In a more particular embodiment said stimulated solution is run in parallel with said screening portion. In a more particular embodiment said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3.

[0664] In a more particular embodiment said immunological markers are cytokines. In another a more particular embodiment said immunological markers are chemokines. In another a more particular embodiment said immunological markers are growth factors. In another a more particular embodiment said immunological markers are both cytokines and chemokines. In another a more particular embodiment said immunological markers are both cytokines and growth factors. In another a more particular embodiment said immunological markers are both chemokines and growth factors. In another a more particular embodiment said immunological markers are cytokines, chemokines and growth factors.

[0665] In another a more particular embodiment said immunological marker is TGF-beta, said small molecule immunomodulators are SMIS, and said immunomodulation is immunosuppression.

[0666] In another a more particular embodiment said cells are human PBM cells or mu-splenocytes.

[0667] In another a more particular embodiment said test solution is incubated for at least 1 hour, or 2 hours, or 3 hours, or 4 hours, or 5 hours, or 6 hours, or 10 hours, or 15 hours, or 18 hours.

[0668] In another a more particular embodiment said test compounds have a molecular weight of less than 700 g/mol.

[0669] In another a more particular embodiment said immunological markers are detected by fluorescent dyes bound to capture antibodies.

[0670] In another a more particular embodiment said cytokines are selected from the group consisting of IL 1-26, TNF-alpha, TNF-beta, IFN-alpha, IFN-beta and IFN-gamma.

[0671] In another a more particular embodiment said cytokines are selected from the group consisting of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-13.

[0672] In another a more particular embodiment said cytokines are selected from the group consisting of CXCL 1-16, XCL 1-2, CX₃CL 1, and CCL 1-28.

[0673] In another a more particular embodiment said growth factors are selected from the group consisting of GM-CSF, G-CSF and M-CSF.

[0674] In another a more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that one species of test compound is distributed per well.

[0675] In another more particular embodiment said plurality of test compounds are distributed in a multi-well plate such that more than one species of test compound is distributed per well. Alternatively, said plurality of test compounds are added to one or more vessels such that more than one species of test compound is distributed per vessel.

[0676] In another a more particular embodiment identification of said small molecule immunomodulator is performed by successively screening an incrementally smaller subset of said plurality of test compounds contained within wells showing immunomodulatory activity until the small molecule immunomodulator is isolated.

[0677] In another a more particular embodiment said plurality of test compounds refers to at least 20 distinct test compound species.

[0678] It should be understood that the organic compounds described herein may exhibit the phenomenon of tautomerism. It should be understood that the invention encompasses any tautomeric form of the drawn structure. The compounds comprise asymmetrically substituted carbon atoms. Such asymmetrically substituted carbon atoms can result in the compounds comprising mixtures of stereoisomers at a particular asymmetrically substituted carbon atom or a single stereoisomer. As a result, racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds are included in the present invention. The terms "S" and "R" configuration, are as defined by the IUPAC 1974 *Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem.* (1976) 45, 13-30. The terms α and β are employed for ring positions of cyclic compounds. The α -side of the reference plane is that side on which the preferred substituent lies at the lowered numbered position. Those substituents lying on the opposite side of the reference plane are assigned β descriptor. It should be noted that this usage differs from that for cyclic stereocenters, in which " α " means "below the plane" and denotes absolute configuration. The terms α and β configuration, are as defined by the *Chemical Abstracts Index Guide-Appendix IV* (1987) paragraph 203.

[0679] The SMIP compounds can be used with or without an antigen in therapeutic applications, for example to treat cancer or infectious diseases. The SMIP compounds also may be used in combination with other therapeutic agents, such as anti-virals and monoclonal antibodies in different therapeutic applications.

[0680] One preferred embodiment of the method of inducing an immunostimulatory effect in a patient is directed to administering an immunogenic composition comprising a vaccine in an amount effective to stimulate an immune response such as a cell-mediated immune response and, as a vaccine adjuvant, a SMIP compound, in an amount effective to potentiate the immune response such as the cell-mediated immune response to the vaccine.

[0681] It is contemplated that a vast number of disorders can be treated with the SMIP compounds and compositions of the present invention. Preferred methods of the invention include SMIP compounds as single agents or in combination with (an)other agent(s), to treat diseases including bacterial diseases, mycotic diseases, viral diseases, malignant tumors, hyperlipemias, and ischemic heart diseases; for example, digestive diseases, circulatory organs' diseases, urinary/genital organs' diseases, immune diseases, cranial nerve diseases, eye diseases, skin diseases, and diseases of nose, ear and throat.

[0682] Examples of such diseases susceptible to the SMIP compounds and combinations are bacterial diseases such as bacterial corneal ulcer, bacterial conjunctivitis, bacterial food poisoning, septic shock, endotoxin shock, bacterial endocarditis, bacterial meningitis, bacterial pneumonia, bacterial aneurysm, and bacterial cerebral aneurysm; viral diseases such as fungal meningitis, fungal corneal ulcer, fungal skin diseases, candidiasis, and tinea; viral diseases such as viral gastroenterocolitis, viral hepatitis, viral bronchitis, viral colon inflammatory, viral myocarditis, viral meningitis, viral enterocolitis, viral encephalitis, viral pneumonia, and AIDS; massive malignant tumors such as renal cell carcinoma, mycosis fungoides, and chronic granuloma; blood malignant tumors such as colonic cancer, rectal cancer, carcinoma of the colon and rectum, gastric cancer, thyroid carcinoma, cancer of the tongue, bladder carcinoma, cilium carcinoma, hepatoma, prostatic cancer, carcinoma uteri, cancer of pharynx, lung cancer, breast cancer, malignant melanoma, Kaposi's sarcoma, brain tumor, neuroblastoma, ovarian tumor, testicular tumor, pancreatic tumor, renal cancer, hypemephroma, hemangioendothelioma, adult T-cell leukemia (ATL), chronic myelogenous leukemia (CML), and malignant lymphoma; autoimmune-, allergic- and viral-diseases such as active chronic hepatitis, atrophic gastritis, autoimmune hemolytic anemia, Basedow disease, Behcet's syndrome, Crohn's disease, CRST syndrome, cold agglutinin hemolytic anemia, idiopathic ulcerative colitis, Goodpasture's syndrome, hyperthyroidism, chronic thyroiditis, inflammation of pulmonary alveoli, glomerulonephritis, idiopathic thrombocytopenic purpura, juvenile diabetes mellitus, insulin dependent diabetes mellitus, leukopenia, multi sclerosis, myasthenia gravis, paroxysmal cold hemoglobinuria, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, rheumatic fever, rheumatoid arthritis, Sjögren's syndrome, sympathetic ophthalmia, progressive systemic sclerosis, Wegener granulomatosis, asthma, atopic dermatitis, bronchial asthma, graft-versus-host disease, allergic rhinitis, pollinosis and allergy for bee's toxic; hepatic diseases such as alcoholic hepatitis, toxic hepatitis, viral cirrhosis, alcoholic cirrhosis, toxic cirrhosis, biliary cirrhosis, fatty liver, hepatic tumor, and hepatic vascular disorder; gallbladder/biliary-tract diseases such as cholangitis, cholecystitis, primary clerosing cholangitis, gallbladder tumor, and cancer of the bile duct; pancreatic diseases such as acute insufficiency, pancreatic tumor, and pancreatic cysts; circulatory organs' diseases such as ischemia, ischemic heart disease, cerebral ischemia, basilar artery migraine, abnormal vasculature at the brain base, cerebral apoplexy, aneurysm of the brain base, arteriosclerosis, vascular endothelial disorder, noninsulin-dependent diabetes mellitus, occlusion of the mesenteric vessel, and superior mesenteric artery syndrome; nerve diseases such as Parkinson's disease, spinal atrophy, amyotrophic lateral sclerosis, Alzheimer's disease, dementia,

cerebrovascular dementia, AIDS dementia, and Meningitis; digestive diseases such as peptic ulcer, peptic esophagus ulcer, intestinal polyp, intestinal adhesion, intestinal rigidity, and gastric ulcer; sleep disturbances caused by the incidence of mental diseases, central nervous system depressants, habitual alcohols, and the disorder of respiratory system; and other diseases induced by side effects accompanied by the administration of hypnotics.

[0683] Agents combined with the SMIP compounds, contemplated to be useful in treating the aforementioned diseases include those well known in the art, such as, anesthetics, hypnotic sedatives, anti-anxieties, antiepileptics, antipyretic antiphlogistics, stimulants, wake amines, anti-parkinson drugs, agents for psychoneuroses, agents for central nervous system, skeletal muscle relaxants, agents for autonomic nervous system, antispastic agents, cytotoxic agents, monoclonal antibodies, drugs for eye, drugs for nose and ear, anti-vertiginous drugs, cardiotonics, antiarrhythmic drugs, diuretics, pressure reduction drugs, vasoconstrictors, coronary vaso-dilators, peripheral vasodilating drugs, hyperlipemia drugs, breath stimulants, antitussive and expectorant drugs, bronchodilators, drugs for allergy, antidiarrheal drugs, drugs for intestinal disorders, peptic ulcer drugs, stomachic digestants, antacids, cholagogues, pituitary hormone drugs, salivary gland hormones, thyroid hormone drugs, anti-thyroid drugs, anabolic steroids, corticosteroids, androgen drugs, estrogen drugs, corpus luteum hormone drugs, mixed hormones, urinary/genital organ drugs, anus drugs, surgical sterilizations/antiseptics, wound protectives, externals for purulent diseases, analgesics, antipruritics, astringents, antiphlogistics, externals for parasite skin diseases, skin-softening drugs, caustics, dental/oral drugs, vitamins, inorganic preparations, supplemental liquids, hemostatics, anticoagulation drugs, drugs for liver diseases, antidotes, habitual intoxication drugs, drugs for treatment of gout, enzyme preparations, diabetic drugs, antioncotics, antihistaminics, drugs for stimulation treatment, antibiotics, chemotherapeutics, biological preparations, anthelmintics, anti-Protozoas, drugs for preparations, X-ray contrast media, and diagnostic drugs.

[0684] Further methods of the invention are provided wherein compositions described herein are used for the treatment of cancer and reduction of tumor growth. In one aspect a SMIP compound of the invention is combined with a known MAb for the treatment of cancer. In a presently preferred aspect of this embodiment of the present invention, an antibody and a SMIP compound are administered. It may be particularly preferred that said antibody, individually, has an inhibiting effect upon tumor cell growth and that the SMIP compound induces the production of cytokines.

[0685] In accordance with another embodiment of the present invention, there is provided a therapeutic composition for inhibiting tumor cell growth in a subject, which composition comprises an effective amount of a combination of at least a SMIP compound and a MAb and a pharmaceutically acceptable carrier, wherein said combination is more effective to inhibit growth of certain mammalian tumor cells than are either of the agents when administered individually.

[0686] In another embodiment methods of treating cancer are provided wherein known anticancer agents are combined with SMIP compounds to reduce tumor growth in a subject. A number of suitable anticancer agents are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration

of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., ribozymes); polypeptides (e.g., enzymes); drugs; biological mimetics; 25 alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides; biological response modifiers (e.g. interferons [e.g. IFN- α , etc.] and interleukins [e.g. IL-2, etc.], etc.); adoptive immunotherapy agents; hematopoietic growth factors; agents that induce tumor cell differentiation (e.g. all-trans-retinoic acid, etc.); gene 30 therapy reagents; antisense therapy reagents and nucleotides; tumor vaccines; and inhibitors of angiogenesis, and the like. Numerous other examples of chemotherapeutic compounds and anticancer therapies suitable for coadministration with the disclosed SMIP compounds are known to those skilled in the art.

[0687] In preferred embodiments, anticancer agents comprise agents that induce or stimulate apoptosis. Agents that induce apoptosis include, but are not limited to, radiation (e.g., W); kinase inhibitors (e.g., Epidermal Growth Factor Receptor [EGFR] kinase; inhibitor, Vascular Growth Factor Receptor [VGFR] kinase inhibitor, Fibroblast Growth 5 Factor Receptor [FGFR] kinase inhibitor, Platelet-derived Growth Factor Receptor [PGFR] I kinase inhibitor, and Bcr-Abl kinase inhibitors such as STI-571, Gleevec, and Glivec); antisense molecules; antibodies [e.g., Herceptin and Rituxan]; anti-estrogens [e.g., raloxifene and tamoxifen]; anti-androgens [e.g., flutamide, bicalutamide, finasteride, aminoglutethamide, ketoconazole, and corticosteroids]; cyclooxygenase 2 (COX-2) inhibitors [e.g., Celecoxib, meloxicam, NS-398, and non-steroidal

antiinflammatory drugs I (NSAIDs)]; and cancer chemotherapeutic drugs [e.g.,

irinotecan (Camptosar), CPT-11, fludarabine (Fludara), dacarbazine (DTIC), dexamethasone, mitoxantrone, Mylotarg, VP-; 16, cisplatin, 5-FU, Doxorubicin, Taxotere or taxol]; cellular signaling molecules; ceramides and cytokines; and staurosporine, and the like.

[0688] In another embodiment methods of treating allergies are provided comprising administering a SMIP compound alone or in combination with at one other agent known to be effective against allergies, wherein said combination is more effective in treating an allergic condition than the known agent(s) are without the addition of said SMIP compound. In a more preferred embodiment the known agent is antihistamine and/or leukotriene inhibitor. In another preferred embodiment, the allergic condition is asthma. In another preferred embodiment, the allergic condition is selected from the group consisting of allergic rhinitis, dermatosis, and urticaria. In an even more preferred embodiment the combination is administered to a subject enterally, parenterally, intranasally, subcutaneously, or intraarterially.

[0689] In another embodiment, the present invention provides methods of screening a SMIP compound and a test compound comprising: providing a SMIP compound; a test compound; a first group of cells; and contacting the first group of cells with the SMIP compound and the test compound; and observing the effects of contacting the first group of cells with the SMIP compound and the test compound. In some of these embodiments, the present invention further provides the additional step of comparing the effects observed in the first cells against a second group of the cells contacted with the SMIP compound alone, or with the test compound alone. Effects that may be observed include, but are not limited to, changes

in cell proliferation, changes in TNF alpha levels, changes in infected viral content of a cell, changes in bacterial infection levels in a cell, changes in histamine levels of a cell, changes in apoptotic stats, and changes in the expression of Bcl-2 family proteins, and the like.

[0690] In another embodiment methods of manufacturing compounds and compositions described herein are provided and contemplated to fall within the scope of the invention.

[0691] Qualitative and quantitative measurement of the immune response of a compound or composition can be implemented using methods known in the art, such as measuring antigen specific antibody production, activation of specific populations of lymphocytes such as CD4⁺, CD8⁺ T cells or NK cells, and/or production of cytokines such as IFN, IL-2, IL-4 or IL-12. Methods for measuring specific antibody responses include enzyme-linked immunosorbent assay (ELISA) as known in the art. Measurement of numbers of specific types of lymphocytes such as CD4⁺ T cells can be achieved, for example, with fluorescence-activated cell sorting (FACS). Cytotoxicity assays can be performed, e.g., as described in Raz et al., (1994) Proc. Natl. Acad. Sci. USA 91:9519-9523. Serum concentrations of cytokines can be measured, for example, by ELISA. Such assays are described, e.g., in Selected Methods in Cellular Immunology (1980) Mishell and Shiigi, eds., W.H. Freeman and Co.

[0692] In one embodiment, a compound or composition, such as a SMIP compound, is considered effective to elicit an immune response if a concentration of 20 μ M (or alternatively 100 or 200 μ M, or 300 μ M) of the SMIP compound causes the production of TNF- α in an in vitro cell based assay of human peripheral blood mononuclear cells, wherein the concentration of the human peripheral blood mononuclear cells is about 500,000/mL, and wherein the cells are exposed to the compound for about 18-24 hours, e.g., about 24 hours.

[0693] The above method of stimulating a local immune response for example in selected cells or tissues of a patient includes the stimulation of a local immune response wherein the selected cells or tissues are infected or cancerous. In one embodiment the selected cells or tissues are infected with a fungus or bacterium. In another embodiment the selected tissues are inflamed with an allergen, for example in an asthmatic condition. In another embodiment the selected cells are infected with a virus or bacteria. In still a more particular embodiment the infectious agent is HCV, HIV, HBV, HSV, *H. pylori*, HSV Type 1 or 2, or Human Papilloma Virus.

[0694] The methods and compounds disclosed herein can be used generally for the treatment of asthma by steering the immune response away from Type 2 cytokine secretion and effector mechanisms (e.g. IgE production and/or mast cell/basophil activation).

[0695] The immunogenic compositions of the invention can contain further pharmaceutically acceptable ingredients, excipients, carriers, and the like well known to those skilled in the art.

[0696] The vaccine composition may include an additional adjuvant. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without specific immunostimulating agents such as muramyl peptides or bacterial cell wall components), such as, for example (a) MF59TM (WO90/14837), containing 5% squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron

particles using a microfluidizer, (b) SAF, containing 5% squalene, 0.5% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DetoxTM); (3) saponin adjuvants, such as QS21 or StimulonTM (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMs may be devoid of additional detergent e.g. WO00/07621; (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/144636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (6) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL), optionally in the substantial absence of alum when used with pneumococcal saccharides e.g. WO00/56358; and RC529 (7) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions e.g. EP-A-0835318; (8) oligonucleotides comprising CpG motifs, i.e. containing at least one CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (9) a polyoxyethylene ether or a polyoxyethylene ester e.g. WO99/52549; (10) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (WO0121207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152); (11) a saponin and an immunostimulatory oligonucleotide (e.g. a CpG oligonucleotide) (WO00/62800); (12) an immunostimulant and a particle of metal salt e.g. WO00/23105; (13) a saponin and an oil-in-water emulsion e.g. WO99/11241; (14) a saponin (e.g. QS21)+3dMPL+IL-12 (optionally+a sterol) e.g. WO98/57659; (14) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. In one particular embodiment, Alum (especially aluminium phosphate and/or hydroxide) and MF59 are preferred for use with saccharide antigens.

[0697] The invention is also directed to administering the immunogenic composition. The vaccine is administered in an amount effective to stimulate an immune response. The amount that constitutes an effective amount depends, inter alia, on the particular vaccine used, the particular adjuvant compound being administered and the amount thereof, the immune response that is to be enhanced (humoral or cell mediated), the state of the immune system (e.g., suppressed, compromised, stimulated), and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the vaccine. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.

[0698] The immunogenic compositions of the invention can be administered to animals, e.g., mammals human and non-human, including, for example, pocket pets, fowl, and the like according to conventional methods well known to those skilled in the art (e.g., orally, subcutaneously, nasally, topically).

[0699] Suitable vaccines include, but are not limited to, any material that raises either humoral or cell mediated immune response, or both. Suitable vaccines include live viral and bacterial antigens and inactivated viral, tumor-derived, protozoal, organism-derived, fungal, and bacterial antigens, toxoids, toxins, polysaccharides, proteins, glycoproteins, peptides, and the like. Conventional vaccines, such as those used in connection with BCG (live bacteria), cholera, plague, and typhoid (killed bacteria), hepatitis B, influenza, inactivated polio, and rabies (inactivated virus), measles, mumps, rubella, oral polio, and yellow fever (live virus), tetanus and diphtheria (toxoids), *hemophilus influenzae* b, meningococcal, and pneumococcal (bacterial polysaccharides) also can be used. Any antigen known in the art or disclosed herein may be used.

[0700] Furthermore, it is contemplated that certain currently experimental vaccines, especially materials such as recombinant proteins, glycoproteins, and peptides that do not raise a strong immune response, will also find use in connection with the SMIP compound. Exemplary experimental sub-unit antigens include those related to viral disease such as adenovirus, AIDS, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, hepatitis A, hepatitis B, hepatitis C, HSV-1, HSV-2, hog cholera, influenza A, influenza B, Japanese encephalitis, measles, parainfluenza, rabies, respiratory syncytial virus, rotavirus, wart, and yellow fever.

[0701] Specific antigens for use with the invention include, but are not limited to, those listed below. The number(s) in parenthesis indicate representative resources of the antigen. The resource list follows the antigen list and each resource is incorporated by reference in its entirety.

[0702] Specific antigens include: a protein antigen from *N. meningitides* serogroup B (1-7); an outer-membrane vesicle (OMV) preparation from *N. meningitides* serogroup B. (8, 9, 10, 11); a saccharide antigen from *N. meningitides* serogroup A, C W135 and/or Y, such as the oligosaccharide (12) from serogroup C (13); a saccharide antigen from *Streptococcus pneumoniae* (14, 15, 16); an antigen from *N. gonorrhoeae* (1, 2, 3); an antigen from *Chlamydia pneumoniae* (17, 18, 19, 20, 21, 22, 23); an antigen from *Chlamydia trachomatis* (24); an antigen from hepatitis A virus, such as inactivated virus (25, 26); an antigen from hepatitis B virus, such as the surface and/or core antigens (e.g. 26, 27); an antigen from hepatitis C virus (28); an antigen from *Bordetella pertussis*, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B. pertussis*, optionally also combination with pertactin and/or agglutinogens 2 and 3 (29, 30); a diphtheria antigen, such as a diphtheria toxoid (31:chapter 3) e.g. the CRM₁₉₇ mutant (32); a tetanus antigen, such as a tetanus toxoid (31:chapter 4); a protein antigen from *Helicobacter pylori* such as CagA (33), VacA (33), NAP (34), HopX (5), HopY (35) and/or urease; a saccharide antigen from *Haemophilus influenzae* B (13); an antigen from *Porphyromonas gingivalis* (36); polio antigen(s) (37, 38) such as IPV or OPV; rabies antigen(s) (39) such lyophilized inactivated virus (40, RabAvert™); measles, mumps and/or rubella antigens (31: chapters 9, 10, & 11); influenza antigen(s) (31:chapter 19), such as the haemagglutinin and/or neuraminidase surface proteins; an antigen from *Moraxella catarrhalis* (41); an antigen from *Streptococcus agalactiae* (group B streptococcus) (42, 43); an antigen from *Streptococcus pyogenes* (group A streptococcus) (43, 44, 45); and an antigen from *Staphylococcus aureus* (46).

[0703] The composition may comprise one or more of the above antigens.

[0704] Where a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance antigenicity (47-56). Preferred carrier proteins are bacterial toxine or toxoids, such as diphtheria or tetanus toxoids. The CRM₁₉₇ diphtheria toxoid is particularly preferred. Other suitable carrier proteins include the *N. meningitides* outer membrane protein (57), synthetic peptides (58, 59), heat shock proteins (60), pertussis proteins (61, 62), protein D from *H. influenzae* (63), toxin A or B from *C. difficile* (64) etc. Where a mixture comprises capsular saccharides from both serogroups A and C, it is preferred that the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (e.g. 2:1, 3:1, 4:4, 5:1, 10:1 or higher). Saccharides from different serogroups of *N. meningitides* may be conjugated to the same or different carrier proteins.

[0705] Any suitable conjugation reaction can be used, with any suitable linker where necessary. Toxic protein antigens may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means (30)). Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigens and pertussis antigens. Similar, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similar, where pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.

[0706] The pharmaceutical compositions containing the compounds described herein can include additives such as excipients. Suitable pharmaceutically acceptable excipients include processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-β-cyclodextrin, polyvinylpyrrolidone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof. Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences," Mack Pub. Co., New Jersey (1991), incorporated herein by reference.

[0707] Pharmaceutical compositions containing the compounds of the invention may be in any form suitable for the intended method of administration, including, for example, a solution, a suspension, or an emulsion. Liquid carriers are typically used in preparing solutions, suspensions, and emulsions. Liquid carriers contemplated for use in the practice of the present invention include, for example, water, saline, pharmaceutically acceptable organic solvent(s), pharmaceutically acceptable oils or fats, and the like, as well as mixtures of two or more thereof. The liquid carrier may contain other suitable pharmaceutically acceptable additives such as solubilizers, emulsifiers, nutrients, buffers, preservatives, suspending agents, thickening agents, viscosity regulators, stabilizers, and the like. Suitable organic solvents include, for example, monohydric alcohols, such as ethanol, and polyhydric alcohols, such as glycols. Suitable oils include, for example, soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, and the like. For parenteral administration, the carrier can also be an oily ester such as ethyl oleate, isopropyl myristate, and the like. Compositions of the present invention may also be in the form of microparticles, microcapsules, and the like, as well as combinations of any two or more thereof.

[0708] The compounds and combinations of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., *Methods in Cell Biology*, Volume XIV, Academic Press, New York, N.W., p. 33 et seq (1976).

[0709] Other additives include immunostimulatory agents known in the art. Immunostimulatory oligonucleotides and polynucleotides are described in PCT WO 98/55495 and PCT WO 98/16247. U.S. Patent Application No. 2002/0164341 describes adjuvants including an unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. U.S. Patent Application No. 2002/0197269 describes compositions comprising an antigen, an antigenic CpG-ODN and a polycationic polymer. Other immunostimulatory additives described in the art may be used, for example, as described in U.S. Pat. No. 5,026,546; U.S. Pat. No. 4,806,352; and U.S. Pat. No. 5,026,543. Additionally, SMIP compounds as described in U.S. Ser. No. 60/458,888, which is incorporated herein by reference, are contemplated as effective co-administration agents or combination with the compositions of the instant invention. The SMIPs may serve as vaccine adjuvants as well.

[0710] A controlled release delivery system may be used, such as a diffusion controlled matrix system or an erodible system, as described for example in: Lee, "Diffusion-Controlled Matrix Systems", pp. 155-198 and Ron and Langer, "Erodible Systems", pp. 199-224, in "Treatise on Controlled Drug Delivery", A. Kydonieus Ed., Marcel Dekker, Inc., New York 1992. The matrix may be, for example, a biodegradable material that can degrade spontaneously in situ and in vivo for, example, by hydrolysis or enzymatic cleavage, e.g., by proteases. The delivery system may be, for example, a naturally occurring or synthetic polymer or copolymer, for example in the form of a hydrogel. Exemplary polymers with cleavable linkages include polyesters, polyorthoesters, polyanhydrides, polysaccharides, poly(phosphoesters), polyamides, polyurethanes, poly(imidocarbonates) and poly(phosphazenes).

[0711] The compounds of the invention may be administered enterally, orally, parenterally, sublingually, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. For example, suitable modes of administration include oral, subcutaneous, transdermal, transmucosal, iontophoretic, intravenous, intramuscular, intraperitoneal, intranasal, subdermal, rectal, and the like. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.

[0712] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wet-

ting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0713] Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

[0714] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

[0715] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.

[0716] Effective amounts of the compounds of the invention generally include any amount sufficient to detectably treat the disorders described herein.

[0717] Successful treatment of a subject in accordance with the invention may result in the inducement of a reduction or alleviation of symptoms in a subject afflicted with a medical or biological disorder to, for example, halt the further progression of the disorder, or the prevention of the disorder.

[0718] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The therapeutically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician.

[0719] The compounds can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,

methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of formula (I), or separately by reacting carboxylic acid moieties with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutical acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary amine. Pharmaceutical acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

[0720] Other additives include immunostimulatory agents known in the art. Immunostimulatory oligonucleotides and polynucleotides are described in PCT WO 98/55495 and PCT WO 98/16247. U.S. Patent Application No. 2002/0164341 describes adjuvants including an unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. U.S. Patent Application No. 2002/0197269 describes compositions comprising an antigen, an antigenic CpG-ODN and a polycationic polymer. Other immunostimulatory additives described in the art may be used, for example, as described in U.S. Pat. No. 5,026,546; U.S. Pat. No. 4,806,352; and U.S. Pat. No. 5,026,543.

[0721] It is contemplated that the invention encompasses all possible combinations of the embodiments described herein.

DEFINITIONS

As used above and elsewhere herein the following terms and abbreviations have the meanings defined below

- [0722] ATP: Adenosine triphosphate
- [0723] BCG *Mycobacterium bovis* bacillus Calmette-Guerin
- [0724] BSA: Bovine Serum Albumin
- [0725] FHA Filamentous haemagglutinin
- [0726] GCMS Gas Chromatography/Mass Spectroscopy
- [0727] *H. Pylori* *Helicobacter Pylori*
- [0728] HAV Hepatitis A Virus
- [0729] HBV Hepatitis B Virus
- [0730] HCV Hepatitis C Virus
- [0731] HIV Human Immunodeficiency Virus
- [0732] HPLC High Performance Liquid Chromatography
- [0733] HSV Herpes Simplex Virus
- [0734] IC₅₀ value: The concentration of an inhibitor that causes a 50% reduction in a measured activity.
- [0735] IFN Interferon
- [0736] IL Interleukin
- [0737] IMS Immunomagnetic separation
- [0738] IPV Inactivated polio virus
- [0739] LCMS Liquid Chromatography/Mass Spectroscopy
- [0740] LPS Lipopolysaccharide
- [0741] Men A *Neisseria Meningitidis* Type A
- [0742] Men C *Neisseria Meningitidis* Type C
- [0743] Men B *Neisseria Meningitidis* Type B
- [0744] Men W *Neisseria Meningitidis* Type W
- [0745] Men Y *Neisseria Meningitidis* Type Y
- [0746] MeOH: Methanol
- [0747] NANB Non-A, non-B hepatitis
- [0748] NMR Nuclear magnetic resonance
- [0749] OMV Outer membrane vesicle
- [0750] PBMC Peripheral blood mononuclear cells
- [0751] PT Pertussis holotoxin
- [0752] Rt Room temperature (25° C.)
- [0753] SMIP Small Molecule Immune Potentiator
- [0754] SMIS Small Molecule Immune Suppressant (or Small Molecule Immunosuppressant)
- [0755] TLC Thin-layer chromatography
- [0756] TNF- α Tumour necrosis factor- α
- [0757] The methods of the invention are useful in treating "allergic diseases," that is accomplished in the same way as other immunotherapeutic methods described herein.
- [0758] An "allergen" refers to a substance (antigen) that can induce an allergic or asthmatic response in a susceptible subject. The list of allergens is enormous and can include pollens, insect venoms, animal dander, dust, fungal spores, and drugs (e.g. penicillin).
- [0759] "Asthma" refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.
- [0760] The term "leukotriene inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the action or activity of leukotrienes, such as, but not limited to, 5-lipoxygenase ("5-LO") inhibitors, 5-lipoxygenase activating protein ("FLAP") antagonists, and leukotriene D4 ("LTD4") antagonists.
- [0761] "Immune-stimulation" or "immune potentiation" refers to activation of the immune system, including humoral or cellular activation, for example, activation of a cell, such as a killer (T or NK) or dendritic cell of the immune system, for example, causing the increase in cytokine production from a dendritic cell leading to an overall enhancement of host defense (immune response).
- [0762] An "immunogenic composition" refers to a composition capable of modulating the production of cytokines in a subject thereby effecting immune potentiation in the subject.
- [0763] An "immune-stimulatory effective amount" is an amount effective for activation of the immune system, for

example, causing the increase in cytokine production from a dendritic cell leading to an overall enhancement of host defense (immune response).

[0764] “Enhancing the immune response to an antigen” by a compound refers to enhancement of the immune response in comparison to that in the absence of the compound. An enhanced immune-response eliciting composition is a composition generally comprising an antigen and a small molecule immune potentiator compound that elicits an immune response greater than a composition comprising an antigen and not containing one or more small molecule immune potentiator compounds. In this embodiment, the compound acts as an adjuvant, for example for use in vaccine compositions and methods.

[0765] The term “small molecule immunomodulator” or “small molecule immuno-modulatory composition” refers to small molecule compounds below about MW 800 g/mol, capable of stimulating or suppressing an immune response in a patient.

[0766] “Modulating” refers to inducing or suppressing.

[0767] “Immune suppression” or “immunosuppression” refers to deactivation of the immune system, for example, preventing or lessening cytokine production from a dendritic cell leading to an overall attenuation of host defense (immune response).

[0768] Reference to a “sub-optimal concentration,” indicates a less than maximum effect of an agent on a system due to a decreased quantity of the agent in the system, whereby an increased amount of the agent or addition of another agent capable of stimulating a response would lead to further production of immunological markers, such as cytokines, chemokines, and/or growth factors.

[0769] Reference to a “sub-optimal concentration, such that said immunological markers are only partially stimulated” indicates a concentration of an agent that renders an immunological response less than the maximum, whereby an increased amount of the agent or addition of another agent capable of stimulating a response would lead to further production of immunological markers, such as cytokines, chemokines, and/or growth factors.

[0770] Reference to a “compound” is meant to indicate a small molecule, unless otherwise specified, wherein a small molecule has a molecular weight less than 800 g/mol and preferably less than 700 g/mol.

[0771] A “test compound” has the same meaning as compound, wherein the compound is being tested for activity, such as immunomodulation, immunosuppression, or immunopotential.

[0772] The term “plurality of compounds” refers to more than one compound. More preferably it refers to at least ten compounds, or even more preferably, 20-100 compounds.

[0773] A “high throughput assay” is meant to indicate an assay capable of identifying a certain attribute, specifically immunosuppression and/or immunopotential, in a number of compounds simultaneously.

[0774] A “capture antibody” is an antibody that is able to bind a particular immunological marker, such as a particular chemokine, cytokine, or growth factor. The capture antibodies are labeled, preferably with fluorescent dyes, such that they can be recognized and quantified. See Luminex Technologies, U.S. Pat. No. 6,268,222 B1.

[0775] Reference to “wells” or “a well,” as will be apparent to one skilled in the art, is meant to indicate a vessel for holding a reaction mixture for an assay, more specifically, a

vessel for holding a test solution, control solution, stimulated solution, or unstimulated solution, as further described herein.

[0776] An “unstimulated solution” refers to a reaction mixture in which no agent capable of modulating an immune response was added.

[0777] A “stimulated solution” refers to a reaction mixture in which a known immune stimulant or immunopotentiating agent was added.

[0778] An “immunopotentiating agent” includes, among others, LPS, CpG, resiquimod (or R848), an adjuvant or SMIP disclosed in any reference cited herein, Poly I:C (dsRNA), Pam3-Cys, MPL, and stimulatory antibodies, specifically anti-CD3.

[0779] Reference to “immunological markers” indicates substances produced as a result of immunomodulation. If not otherwise specified, immunological markers could be present as a result of immunopotential or immunosuppression. Preferred immunological markers include cytokines, chemokines and growth factors.

[0780] Preferred “cytokines” include IL 1-30 (as described in Table 6) as well as TNF-alpha, TNF-beta, IFN-alpha (family), IFN-beta and IFN-gamma.

[0781] Reference to “IL 1-30” indicates interleukin cytokines selected from the group consisting of IL1A, IL1B, IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, IL1F10, IL1R1, IL1R2, IL1RAP, IL1RAPL1, IL1RAPL2, IL1IL1RL2, IL1RN, IL2, IL2RA, IL2RB, IL2RG, IL3, IL3RA, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6RL1, IL6ST, IL6ST2, IL6STP, IL7, IL7R, IL8, IL8RA, IL8RB, IL5RBP, IL9, IL9R, IL9RP1, IL9RP2, IL9RP3, IL9RP4, IL10, IL10RA, IL10RB, IL11, IL11RA, IL11RB, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL13RA2, IL14, IL15, IL15RA, IL15RB, IL16, IL17, IL17B, IL17C, IL17D, IL17E, IL17F, IL17R, IL17RB, IL17RC, IL17RD, IL17RE, IL18, IL18BP, IL18R1, IL18RAP, IL19, IL20, IL20RA, IL20RB, IL21, IL21R, IL22, IL22RA1, IL22RA2, IL23A, IL24, IL26, IL28A, IL28B, IL28RA, IL29, and IL30. More preferred interleukins include IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-13. The accession ID numbers for each of IL 1-30 are listed in Table 6.

[0782] Reference to “chemokines” indicates: CXC chemokines including CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, and CXCL16; C chemokines including XCL1, and XCL2; CX₃C chemokines including CX₃CL1; and CC chemokines including CCL1, CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, and CCL28 for which greater description is given in Table 5.

[0783] “Growth factors” that may serve as immunological markers include, among others, GM-CSF, G-CSF, M-CSF, VEGF, EGF, HGF, and FGF.

[0784] The term “providing” as it pertains to compounds bound to support resins, encompasses synthesizing and/or purchasing.

[0785] The terms “solid phase,” “resin support bead,” and “bead,” intend any solid support or substrate on which screening and/or the reaction steps of chemical syntheses involving a sequence of reaction steps can be carried out. Thus, the term

includes particulate substrates such as polystyrene resins which have traditionally been employed in standard Fmoc chemical syntheses.

[0786] The term “library” or “combinatorial library” includes, inter alia, a collection of sublibraries each containing 2-500 components or compounds, and more preferably about 10-100 components or compounds. The components or compounds of such sublibraries are diverse synthesized molecules which have been prepared using standard combinatorial chemistries (see, e.g., Furka et al., *Int. J. Peptide Protein Res.* 37:487-493 (1991); and Lam et al., *Nature* 354:82-84 (1991)).

[0787] The term “effective amount” is an amount necessary or sufficient to realize a desired biological effect. For example, an effective amount of a compound to treat an infectious disorder may be an amount necessary to cause an antigen specific immune response upon exposure to an infectious agent. The effective amount may vary, depending, for example, upon the condition treated, weight of the subject and severity of the disease. One of skill in the art can readily determine the effective amount empirically without undue experimentation.

[0788] As used herein “an effective amount for treatment” refers to an amount sufficient to palliate, ameliorate, stabilize, reverse, slow or delay progression of a condition such as a disease state.

[0789] A “subject” or “patient” is meant to describe a human or vertebrate animal including a dog, cat, pocket pet, marmoset, horse, cow, pig, sheep goat, elephant, giraffe, chicken, lion, monkey, owl, rat, squirrel, slender loris, and mouse.

[0790] A “pocket pet” refers to a group of vertebrate animals capable of fitting into a commodious coat pocket such as, for example, hamsters, chinchillas, ferrets, rats, guinea pigs, gerbils, rabbits and sugar gliders.

[0791] As used herein, the term “pharmaceutically acceptable ester” refers to esters, which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Representative examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

[0792] The compounds of the present invention can be used in the form of salts as in “pharmaceutically acceptable salts” derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucuheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, sulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dim-

ethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

[0793] The term “pharmaceutically acceptable prodrugs” as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “prodrug” refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, *Pro-drugs as Novel Delivery Systems*, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. Prodrugs as described in U.S. Pat. No. 6,284,772 for example may be used.

[0794] The term “incubating” refers to maintaining a system under specific conditions in order to promote a particular reaction.

[0795] The term “preparing” in reference to a solution or combination of elements includes mixing, adding, or combining the elements in any order as well as procuring the solution or combination of elements in its final form.

[0796] The term “SMIP” refers to small molecule immunopotentiating compounds, including small molecule compounds below about MW 800 g/mol, capable of stimulating or modulating a pro-inflammatory response in a patient. In an embodiment, the SMIP compounds are able to stimulate human peripheral blood mononuclear cells to produce cytokines, chemokines, and/or growth factors.

[0797] The term “SMIS” refers to small molecule immunosuppressant compounds, including small molecule compounds below about MW 800 g/mol, capable of suppressing or modulating an immune response in a patient. In an embodiment, the SMIS compounds are able to inhibit human peripheral blood mononuclear cell's ability to produce cytokines, chemokines, and/or growth factors. In another embodiment, the SMIS compounds are able to stimulate TGF-beta, thereby suppressing an immune response. In some embodiments, compounds of interest in the instant invention are analogs thereof, or “SMIS analogs,” which are meant to describe a derivative of a compound known generally in the art to suppress the immune system. Preferred examples include compounds and analogs thereof described in the following US patents, US patent application publications, and PCT publications, which are hereby incorporated by reference as if set forth fully herein: U.S. Pat. No. 4,810,692, U.S. Pat. No. 4,617,315, U.S. Pat. No. 4,988,680, U.S. Pat. No. 5,087,619, U.S. Pat. No. 5,001,124, U.S. Pat. No. 4,987,139, U.S. Pat. No. 5,023,264, U.S. Pat. No. 5,023,263, U.S. Pat. No. 4,975,372, U.S. Pat. No. 4,981,792, U.S. Pat. No. 5,064,835, U.S. Pat. No. 5,120,842, U.S. Pat. No. 5,120,727, U.S. Pat. No. 5,120,725, U.S. Pat. No. 5,118,678, U.S. Pat. No. 5,118,677, U.S. Pat. No. 5,130,307, U.S. Pat. No. 5,100,883, U.S. Pat. No. 5,102,876, U.S. Pat. No. 5,093,338, U.S. Pat. No. 5,143,918, U.S. Pat. No. 5,091,389, U.S. Pat. No. 5,120,726, U.S.

Pat. No. 5,233,036, U.S. Pat. No. 5,227,467, U.S. Pat. No. 5,221,740, U.S. Pat. No. 5,247,076, U.S. Pat. No. 5,208,241, U.S. Pat. No. 5,262,423, U.S. Pat. No. 5,260,300, U.S. Pat. No. 5,258,389, U.S. Pat. No. 5,247,119, U.S. Pat. No. 5,376,663, U.S. Pat. No. 5,373,014, U.S. Pat. No. 5,371,225, U.S. Pat. No. 5,362,735, U.S. Pat. No. 5,360,794, U.S. Pat. No. 5,352,783, U.S. Pat. No. 5,310,903, U.S. Pat. No. 5,302,584, U.S. Pat. No. 5,444,072, U.S. Pat. No. 5,387,680, U.S. Pat. No. 5,389,639, U.S. Pat. No. 6,121,257, U.S. Pat. No. 6,071,947, U.S. Pat. No. 6,150,373, U.S. Pat. No. 6,051,590, U.S. Pat. No. 6,015,809, U.S. Pat. No. 5,252,732, U.S. Pat. No. 5,874,411, U.S. Pat. No. 5,877,184, U.S. Pat. No. 5,252,732, U.S. Pat. No. 5,247,076, U.S. Pat. No. 5,344,925, U.S. Pat. No. 5,777,105, U.S. Pat. No. 5,739,169, U.S. Pat. No. 5,696,156, U.S. Pat. No. 5,679,705, U.S. Pat. No. 5,631,282, U.S. Pat. No. 5,561,228, U.S. Pat. No. 5,563,145, U.S. Pat. No. 5,525,610, U.S. Pat. No. 5,523,408, U.S. Pat. No. 5,512,687, U.S. Pat. No. 5,463,048, U.S. Pat. No. 5,451,604, U.S. Pat. No. 5,461,054, U.S. Pat. No. 5,302,584, U.S. Pat. No. 5,162,334, U.S. Pat. No. 5,284,877, U.S. Pat. No. 5,284,840, U.S. Pat. No. 5,256,790, U.S. Pat. No. 5,252,579, U.S. Pat. No. 5,262,533, US 2002016460, US 2002061905, U.S. Pat. No. 6,440,991, U.S. Pat. No. 6,399,626, U.S. Pat. No. 6,399,773, U.S. Pat. No. 6,331,547, U.S. Pat. No. 6,110,922, U.S. Pat. No. 5,759,550, U.S. Pat. No. 5,192,773, U.S. Pat. No. 5,194,447, U.S. Pat. No. 5,189,042, U.S. Pat. No. 5,162,333, U.S. Pat. No. 5,162,334, U.S. Pat. No. 5,149,701, U.S. Pat. No. 5,147,877, U.S. Pat. No. 4,885,276, U.S. Pat. No. 4,314,061, U.S. Pat. No. 4,895,872, U.S. Pat. No. 4,847,299, U.S. Pat. No. 4,525,299, U.S. Pat. No. 5,679,640, U.S. Pat. No. 5,385,910, U.S. Pat. No. 5,385,908, U.S. Pat. No. 5,385,909, U.S. Pat. No. 5,378,836, U.S. Pat. No. 5,362,718, U.S. Pat. No. 5,470,878, U.S. Pat. No. 5,346,912, U.S. Pat. No. 5,359,073, U.S. Pat. No. 6,100,259, U.S. Pat. No. 5,550,214, U.S. Pat. No. 5,455,230, U.S. Pat. No. 6,136,817, U.S. Pat. No. 5,385,910, U.S. Pat. No. 5,730,979, U.S. Pat. No. 5,817,311, U.S. Pat. No. 5,189,039, U.S. Pat. No. 5,171,864, U.S. Pat. No. 5,169,963, U.S. Pat. No. 5,183,906, U.S. Pat. No. 5,006,520, U.S. Pat. No. 5,091,381, U.S. Pat. No. 5,905,090, U.S. Pat. No. 5,665,772, U.S. Pat. No. 5,260,323, U.S. Pat. No. 5,091,381, U.S. Pat. No. 4,675,382, U.S. Pat. No. 5,321,009, U.S. Pat. No. 5,776,943, U.S. Pat. No. 5,286,730, U.S. Pat. No. 5,387,589, U.S. Pat. No. 5,496,832, U.S. Pat. No. 4,829,061, U.S. Pat. No. 4,963,557, U.S. Pat. No. 4,648,996, U.S. Pat. No. 4,351,841, U.S. Pat. No. 4,284,786, U.S. Pat. No. 4,965,276, U.S. Pat. No. 5,268,382, U.S. Pat. No. 5,459,163, U.S. Pat. No. 5,504,084, U.S. Pat. No. 5,494,911, U.S. Pat. No. 5,532,259, U.S. Pat. No. 5,700,823, U.S. Pat. No. 5,700,822, U.S. Pat. No. 5,610,173, U.S. Pat. No. 4,968,702, U.S. Pat. No. 5,639,455, U.S. Pat. No. 5,466,697, U.S. Pat. No. 5,366,986, U.S. Pat. No. 5,173,499, U.S. Pat. No. 5,391,730, U.S. Pat. No. 4,968,702, U.S. Pat. No. 4,910,211, U.S. Pat. No. 4,968,702, U.S. Pat. No. 4,603,137, U.S. Pat. No. 4,347,315, U.S. Pat. No. 5,051,441, U.S. Pat. No. 4,894,374, U.S. Pat. No. 5,470,831, U.S. Pat. No. 6,034,096, U.S. Pat. No. 5,356,897, U.S. Pat. No. 5,478,827, U.S. Pat. No. 5,624,931, U.S. Pat. No. 5,219,864, U.S. Pat. No. 4,894,374, U.S. Pat. No. 5,530,101, U.S. Pat. No. 4,753,935, U.S. Pat. No. 4,786,637, U.S. Pat. No. 4,894,366, U.S. Pat. No. 4,929,611, U.S. Pat. No. 4,956,352, U.S. Pat. No. 5,110,811, U.S. Pat. No. 5,254,562, U.S. Pat. No. 5,266,692, U.S. Pat. No. 4,916,138, U.S. Pat. No. 4,940,797, U.S. Pat. No. 5,087,703, U.S. Pat. No. 5,011,943, U.S. Pat. No. 5,194,372, U.S. Pat. No. 5,196,437, WO 8707276, WO 8805784, WO 8809183, WO 8908658,

WO 9110650, WO 9102736, WO 9101982, WO 9200314, WO 9014359, WO 9200313, WO 9113899, WO 9113889, WO 9211275, WO 9205189, WO 9205179, WO 9138901, WO 9203441, WO 9200980, WO 9200314, WO 9316083, WO 9311130, WO 9312125, WO 9310122, WO 9310796, WO 9305059, WO 9305058, WO 9318050, WO 9318049, WO 9318048, WO 9318042, WO 9501355, WO 9429295, WO 9322286, WO 9425468, WO 9424095, WO 9420488, WO 9418208, WO 9418206, WO 9409010, WO 9522537, WO 9522536, WO 9408943, WO 9516691, WO 9515328, WO 9517381, WO 9514023, WO 9408943, WO 9506045, WO 9509857, WO 9504060, WO 9504738, WO 0058318, WO 0053190, WO 0058314, WO 0039129, WO 0034228, WO 0034248, WO 0032604, WO 9840380, WO 0024744, WO 0012514, WO 0009510, WO 0002879, WO 9955689, WO 9965909, WO 9965908, WO 9965450, WO 9947707, WO 9938829, WO 9940069, WO 9941239, WO 9509857, WO 9305058, WO 9931087, WO 9931060, WO 9929695, WO 9931066, WO 9931063, WO 9931064, WO 9925703, WO 9912890, WO 9920267, WO 9920274, WO 9915530, WO 9305058, WO 9305059, WO 9708182, WO 9828301, WO 9818780, WO 9816532, WO 9816531, WO 9816518, WO 9806719, WO 9809972, WO 9739999, WO 9748696, WO 9748695, WO 9744351, WO 9744052, WO 9317699, WO 9740028, WO 9606068, WO 9720814, WO 9716438, WO 9716437, WO 9716182, WO 9716068, WO 9714410, WO 9712888, WO 9712887, WO 9711080, WO 9711092, WO 9709298, WO 9640688, WO 9641807, WO 9631529, WO 9304679, WO 9630381, WO 9625936, WO 9624579, WO 9617845, WO 9615131, WO 9611200, WO 9613510, WO 9535299, WO 9535120, WO 9534568, WO 9534565, WO 9522538, WO 9515947, WO 9522534, WO 9522537, WO 9220688, WO 9402485, WO 9402137, WO 9402136, WO 9404540, WO 0270472, WO 0253543, WO 0257216, WO 0257237, WO 0251397, WO 0125238, WO 0119829, WO 0230938, WO 0228867, WO 0228866, WO 0218395, WO 0206268, WO 0025780, WO 0200661, WO 0190110, WO 0034296, WO 0033887, WO 0059880, WO 0039081, WO 0107401, WO 0105768, WO 0105750, WO 0076953, WO 9426265, WO 9305058, WO 9222294, WO 9307871, WO 9221313, WO 9305046, WO 9220688, WO 9218496, WO 9010631, WO 9007523, WO 9007520, WO 9002727, WO 9824762, WO 9809946, WO 9743434, WO 9809970, WO 9804521, WO 9732847, WO 9741148, WO 9739018, WO 9723453, WO 9709325, WO 9702285, WO 9702820, WO 9709315, WO 9428910, WO 9422863, WO 9412500, WO 0062778, WO 0056331, WO 9831227, WO 0040562, WO 0025786, WO 9615105, WO 9617874, WO 9616967, WO 9611199, WO 9611198, WO 9603419, WO 9531463, WO 9531463, WO 9528394, WO 9515309, WO 9422872, WO 0285928, WO 0272562, WO 0248122, WO 0250071, WO 0269904, WO 0228862, WO 0047595, WO 0125238, WO 0102359, WO 0253150, WO 0062778, WO 9202229, WO 9303036, WO 9219610, WO 9219609, WO 8903385, WO 9205180, WO 0015645, WO 0002839, WO 9942105, WO 9915501, WO 9856785, WO 9852933, WO 9852951, WO 9845249, WO 9832750, WO 9735575, WO 9409010, WO 9424304, WO 9507468, WO 9804279, WO 8908113, WO 9405685, WO 9102000, WO 9214476, WO 9214477, WO 9319763, WO 9747317, WO 9818468, WO 8907613, WO 8902889, WO 8805783, WO 9117748, WO 9519169, WO 0063210, WO 0048989, WO 9804521, WO 9746522, WO 9741148, WO 9739018, WO 9720811, WO 9705140, WO 9606855, WO 9602541, WO 9210295, WO 9509153,

WO 0255541, WO 0202539, WO 0063210, WO 9509153, WO 9513277, WO 9508535, WO 9501175, WO 9424133, WO 9408589, WO 9415959, WO 8906968, WO 0015604, WO 9932138, WO 9900143, WO 9852606, WO 9117748, WO 9116339, WO 9520589, WO 9211021, WO 9213874, WO 9500543, WO 9531206, WO 9520589, WO 9715561, WO 9743251, WO 9741104, WO 9743251, WO 9723453, WO 9715561, WO 9705141, WO 9640143, WO 9749399, WO 9412184, WO 9426266, WO 9507902, WO 9509626, WO 9014826, WO 9117754, WO 9119495, WO 9308802 and WO 9314771. Additionally, SMIS analogs include small molecules selected from the group consisting of cortisol, cyclophosphamide, 6-mercaptopurine, methotrexate and its polyglutamate derivatives, azathioprine metabolites, mizoribine, cyclosporin A, FK-506 (tacrolimus), rapamycin, leflunomide and its metabolites, brequinar, tacrolimus, mycophenolate mofetil, and mycophenolic acid. Further, preferred "SMIS" compound for which analogs with immunopotential capabilities exist include the Examples listed in Table 4.

[0798] Analogs of SMIS compounds are restricted to encompass substituent alterations and additions to the core scaffold. Core scaffolds of SMIS can be identified functionally by one skilled in the art as the minimal unit responsible for activity. Structurally, the core scaffold of a SMIS can be identified as the conserved region amongst several similar compounds (from the same source), typically listed adjacently. For example, the core scaffold for Examples 86-91 (Source: Aventis) is apparent by one skilled in the art as a substituted benzamide. Similarly, the core scaffold of Examples 111-15 is identified by the macrocyclic cyclosporine-like structural motif. Where a single species exists without multiple compounds to guide elucidation, e.g. Example 167, the core scaffold is confined to the central region consisting of a continuous aromatic or non-aromatic heterocyclic, polycyclic, or heteroalkyl group of at least 5 atoms (e.g. isobenzofuran-1(3H)-one for Example 167) or an ion complex, such as ruthenium. Preferred scaffolds include steroids, terpenes, macrocycles, ruthenium complexes, cannabinoids, aminoazavinyl compounds, benzazole compounds, acylpiperazine compounds, indoleione compounds, tetrahydroisoquinoline (THIQ) compounds, anthraquinone compounds, indanedione compounds, phthalimide compounds, benzocyclobutene compounds, aminobenzimidazole quinolinone (ABIQ) compounds, hydrapthalimide compounds, pyrazolopyrimidine compounds, quinazolinone compounds, quinoxaline compounds, triazine compounds, tetrahydropyrrolidinoquinoxaline compounds, pyrrole compounds, benzophenone compounds, sterol compound, and isoxazole compounds. Substituents suitable for alteration and/or addition to the core scaffold include, for example, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted carbonyloxy, substituted or unsubstituted sulfonyl, substituted or unsubstituted carbonylamino, substituted or unsubstituted aminocarbonyl, substituted or unsubstituted guanidiny, or substituted or unsubstituted alkoxy carbonyl groups.


[0799] The term "steroid SMIP" refers to a synthetic fat-soluble organic SMIP having as a basis 17 carbon atoms arranged in four rings and including the sterols and bile acids, adrenal and sex hormones, certain natural drugs such as digitalis compounds, and the precursors of certain vitamins and the derivatives thereof. Preferred steroid scaffolds for derivatization include, among others, pregnane, estrane, cholestane, gonane, and androstane.


[0800] The term "macrocycle SMIP" refers to any non-aromatic or only partially aromatic SMIP having at least 12 contiguous atoms selected from, carbon, N, O, or S bound together to in a cyclic moiety. Preferred macrocycles include cyclosporine, sirolimus, tacrolimus and their derivatives.

[0801] The term "terpene SMIP" refers to a SMIP containing at least one terpene moiety.

[0802] The term "ruthenium complex SMIP" refers to a SMIP with multiple organic compounds ionically complexed around a central ruthenium atom. Preferred organic compounds to be complexed to the ruthenium atom are nitrogen containing heteroaryl (N_{Haryl}). Preferred N_{Haryl} compounds include, for example, acridine, carbazole, β -carboline, cinno-line, imidazole, indazole, indole, indolizine, isoindole, isoquinoline, isothiazole, oxazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinoxaline, quinoline, quinolizine, quinoxaline, and thiazole.

[0803] Reference to an "expoxide" is meant to indicate a ring-shaped organic compound consisting of an oxygen atom bonded to two other atoms, preferably of carbon, that are bonded to each other.

[0804] Usage of a  symbol that crosses a covalent bond is meant to indicate the point of attachment of a substituent, as in



Similarly, usage of an asterisk also indicates the point of attachment of a substituent, as in, *-alkenyl-COOH.

[0805] Where multiple groups are combined to form a substituent, for example dialkylaminocarbonyl, the point of attachment is the last group captioned in the phrase, such as carbonyl in the aforementioned example. Although not all substituents with multiple combinations of groups described in the embodiments are explicitly defined below, for example arylsulfonylalkylloxycarbonylamino, their individual components are defined and their scope will be apparent to one skilled in the art as a summation of their individual components, such as *-NH-C(O)-O-alkyl-SO₂-aryl, in the aforementioned example.

[0806] The phrase "alkyl" refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: —CH

(CH₃)₂, —CH(CH₃)(CH₂CH₃), —CH(CH₂CH₃)₂, —C(CH₃)₃, —C(CH₂CH₃)₃, —CH₂CH(CH₃)₂, —CH₂CH(CH₃)(CH₂CH₃), —CH₂CH(CH₂CH₃)₂, —CH₂C(CH₃)₃, —CH₂C(CH₂CH₃)₃, —CH₂CH₂CH(CH₃)₂, —CH₂CH₂CH(CH₃)(CH₂CH₃), —CH₂CH₂CH(CH₂CH₃)₂, —CH₂CH₂C(CH₃)₃, —CH₂CH₂C(CH₂CH₃)₃, —CH(CH₃)CH₂CH(CH₃)₂, —CH(CH₃)CH(CH₃)CH(CH₃)₂, —CH(CH₂CH₃)CH(CH₃)CH(CH₃)(CH₂CH₃), and others. Thus, the phrase unsubstituted alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups. Unsubstituted alkyl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound. Preferred unsubstituted alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having 1 to 20 carbon atoms. More preferred such unsubstituted alkyl groups have from 1 to 10 carbon atoms while even more preferred such groups have from 1 to 5 carbon atoms. Most preferred unsubstituted alkyl groups include straight and branched chain alkyl groups having from 1 to 3 carbon atoms and include methyl, ethyl, propyl, and —CH(CH₃)₂.

[0807] The phrase “substituted alkyl” refers to an unsubstituted alkyl group as defined above in which one or more bonds to a carbon(s) or hydrogen(s) are replaced by a bond to non-hydrogen and non-carbon atoms such as, but not limited to, a halogen atom in halides such as F, Cl, Br, and I; a phosphorus atom in groups such as phosphate and dialkyl alkylphosphonate; oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles. Preferred substituted alkyl groups include, among others, alkyl groups in which one or more bonds to a carbon or hydrogen atom is/are replaced by one or more bonds to fluorine atoms. One example of a substituted alkyl group is the trifluoromethyl group and other alkyl groups that contain the trifluoromethyl group. Another example is a carbonylalkyl or -alkyl-COOH group. Other alkyl groups include those in which one or more bonds to a carbon or hydrogen atom is replaced by a bond to an oxygen atom such that the substituted alkyl group contains a hydroxyl, alkoxy, aryloxy group, or heterocycloxy group. Still other alkyl groups include alkyl groups that have an amine, alkylamine, dialkylamine, arylamine, (alkyl)(aryl)amine, diarylamine, heterocyclylamine, (alkyl)(heterocyclyl)amine, (aryl)(heterocyclyl)amine, or diheterocyclylamine group.

[0808] The term “halogen” refers to iodine, bromine, chlorine or fluorine; “halo” as used herein refers to iodo, bromo, chloro or fluoro.

[0809] The term “haloalkyl” as used herein refers to a alkyl radical, as defined above, bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl or trifluoromethyl and the like.

[0810] The term “amino” refers to —NH₂, when at the terminal position, or —NH—when conjoining 2 groups.

[0811] The term “nitro” refers to an —NO₂ substituent.

[0812] The term “cyano” refers to —CN.


[0813] The term “carboxylic acid” refers to —COOH.

[0814] The term “alkoxy” as used herein refers to RO— wherein R, for example, is alkyl such as defined above. Representative examples of alkoxy groups include methoxy, ethoxy, t-butoxy and the like.

[0815] The term “substituted alkoxy” as used herein refers to RO—, where R is, for example, an alkyl substituted, for example, with a halogen. RO is for example OCF₃, or further substituted with an aryl such as (2-chlorophenyl)methoxy.

[0816] The term “alkoxyalkyl” as used herein refers to an (alkyl)-O-(alkyl), wherein each alkyl group may be further substituted as defined below for optional substitution groups.

[0817] Reference to “malonate” is meant to indicate substituted alkoxy as shown:



[0818] The term “alkenyl” as used herein refers to a branched or straight chain groups comprising two to twenty carbon atoms which also comprises one or more carbon-carbon double bonds. Representative alkenyl groups include prenyl, 2-propenyl (i.e., allyl), 3-methyl-2-butenyl, 3,7-dimethyl-2,6-octadienyl, 4,8-dimethyl-3,7-nonadienyl, 3,7,11-trimethyl-2,6,10-dodecatrienyl and the like.

[0819] The term “substituted alkenyl” as used herein refers to alkenyl groups that are substituted, for example, *-alkenyl-carbonyl-oxy- (*-alkenyl-C(O)—O—), diethyl hex-5-enylphosphonate, and others with an alkyl or substituted alkyl group such as dialkyl phosphate or an ester such as an acetate ester.

[0820] The term “alkynyl” as used herein refers to a branched or straight chain groups comprising two to twenty carbon atoms which also comprises one or more carbon-carbon triple bonds. Representative alkynyl groups include propargyl and butynyl.

[0821] The term “substituted alkynyl” as used herein refers to alkynyl groups that are substituted, for example, propargylamine, and others with an alkyl or substituted alkyl group such as dialkyl phosphate or an ester such as an acetate ester

[0822] The term “alkylamino” as used herein refers to an amino group substituted with one alkyl groups such as C1-20 alkyl groups.

[0823] The term “substituted alkylamino” as used herein refers to an alkylamino substituted, for example, with a carboxylic acid, ester, hydroxy or alkoxy.

[0824] The term “dialkylamino” as used herein refers to an amino group substituted with two alkyl groups such as C1-20 alkyl groups.

[0825] The term “substituted dialkylamino” as used herein refers to a dialkylamino substituted, for example, with a carboxylic acid, ester, hydroxy or alkoxy.

[0826] The term “aminoalkyl” refers to an alkyl group substituted with an amino group.

[0827] The term “alkylaminoalkyl” refers to an alkyl group substituted with an aminoalkyl group, such as *-CH₂NHCH(CH₃)₂

[0828] The term “hydroxyalkylthio” as used herein refers to a thio radical to which is appended a hydroxyalkyl group, where the alkyl is for example ethyl. An example is hydroxyethylthio, $-\text{SCH}_2\text{CH}_2\text{OH}$.

[0829] The term “N-alkylsulfonamide” as used herein refers to the group $-\text{SO}_2\text{NHalkyl}$, where alkyl is, for example, octyl.

[0830] “Aminosulfonyl,” refers herein to the group $-\text{S}(\text{O})_2-\text{NH}_2$. “Substituted aminosulfonyl” refers herein to the group $-\text{S}(\text{O})_2-\text{NRR}'$ where R is alkyl and R' is hydrogen or an alkyl. The term “alkylaminosulfonyl” refers herein to the group $-\text{S}(\text{O})_2-\text{NH-alkyl}$. The term “aralkylaminosulfonyl” refers herein to the group $-\text{aryl-S}(\text{O})_2-\text{NH-aralkyl}$.

[0831] “Carbonyl” refers to the divalent group $-\text{C}(\text{O})-$.

[0832] “Carbonyloxy” refers generally to the group $-\text{C}(\text{O})-\text{O}-$. Such groups include esters, $-\text{C}(\text{O})-\text{O-R}$, where R is alkyl, cycloalkyl, aryl, or aralkyl. The term “carbonyloxycycloalkyl” refers generally herein to both an “carbonyloxycarbocycloalkyl” and an “carbonyloxyheterocycloalkyl”, i.e., where R is a carbocycloalkyl or heterocycloalkyl, respectively. The term “arylcarbonyloxy” refers herein to the group $-\text{C}(\text{O})-\text{O-aryl}$, where aryl is a mono- or polycyclic, carbocycloaryl or heterocycloaryl. The term “aralkylcarbonyloxy” refers herein to the group $-\text{C}(\text{O})-\text{O-aralkyl}$, where the aralkyl is aralkyl.

[0833] The term “sulfonyl” refers herein to the group $-\text{SO}_2-$, wherein an unsubstituted sulfonyl group is $-\text{SO}_2\text{H}$. “Alkylsulfonyl” refers to a substituted sulfonyl of the structure $^*\text{SO}_2\text{R}$ in which R is alkyl. Alkylsulfonyl groups employed in compounds of the present invention are typically alkylsulfonyl groups having from 1 to 6 carbon atoms in its backbone structure. Thus, typical alkylsulfonyl groups employed in compounds of the present invention include, for example, methylsulfonyl (i.e., where R is methyl), ethylsulfonyl (i.e., where R is ethyl), propylsulfonyl (i.e., where R is propyl), and the like. The term “arylsulfonyl” refers herein to the group $-\text{SO}_2\text{-aryl}$, or “heteroarylsulfonyl” refers herein to the group $-\text{SO}_2\text{-heteroaryl}$. The term “aralkylsulfonyl” refers herein to the group $-\text{SO}_2\text{-aralkyl}$ or layed out, $^*\text{SO}_2\text{-alkyl-aryl-}$. “Heteroaralkylsulfonyl” refers to the same as aralkylsulfonyl, except with a heteroaryl substituent in place of an aryl.


[0834] As used herein, the term “carbonylamino” refers to the divalent group $-\text{NH}-\text{C}(\text{O})-$ in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced an alkyl, aryl, or aralkyl group. Such groups include moieties such as carbamate esters ($^*\text{NH}-\text{C}(\text{O})-\text{O-R}$) and amides $^*\text{NH}-\text{C}(\text{O})-\text{O-R}$, where R is a straight or branched chain alkyl, cycloalkyl, or aryl or aralkyl. The term “alkylcarbonylamino” refers to alkylcarbonylamino where R is an alkyl having from 1 to about 6 carbon atoms in its backbone structure. The term “arylcarbonylamino” refers to group $-\text{NH}-\text{C}(\text{O})-\text{R}$ where R is an aryl. Similarly, the term “aralkylcarbonylamino” refers to carbonylamino where R is an aralkyl.

[0835] As used herein, the term “guanidino” or “guanidyl” refers to moieties derived from guanidine, $\text{H}_2\text{N}-\text{C}(=\text{NH})-\text{NH}_2$. Such moieties include those bonded at the nitrogen atom carrying the formal double bond (the “2”-position of the guanidine, e.g., diaminomethyleneamino, $(\text{H}_2\text{N})_2\text{C}=\text{NH}-^*$) and those bonded at either of the nitrogen atoms carrying a formal single bond (the “1-” and/or “3”-positions of the guanidine, e.g., $\text{H}_2\text{N}-\text{C}(=\text{NH})-\text{NH}-^*$).


The hydrogen atoms at any of the nitrogens can be replaced with a suitable substituent, such as alkyl, aryl, or aralkyl.


[0836] The term “arylthiourea” refers to $\text{aryl-NC}(\text{S})\text{N}-^*$ groups, wherein the nitrogen is the point of attachment. A preferred example of a substituted $\text{aryl-NC}(\text{S})\text{N-alkylamino}$ group is: [text missing or illegible when filed]

[0837] Representative substituted alkylcarbonylamino, alkoxycarbonylamino, aminoalkoxycarbonylamino, and arylcarbonylamino groups include, for example, those shown below. These groups can be further substituted as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.




[0838] Representative substituted aminocarbonyl groups include, for example, those shown below. These can heterocyclo groups be further substituted as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.






[0839] A preferred substituted aminocarbonylamino group (or urea) includes:



which is substituted with an anisole group.

[0840] Representative substituted alkoxy carbonyl groups include, for example, those shown below. These alkoxy carbonyl groups can be further substituted as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.



[0841] The phrase “carbocyclyl” includes cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted

with straight and branched chain alkyl groups as defined above. The phrase also includes polycyclic alkyl groups such as, but not limited to, adamantyl, norbornyl, and bicyclo[2.2.2]octyl and such rings optionally substituted as defined herein.

[0842] The phrase “aryl” refers to aryl groups that do not contain heteroatoms. Thus the phrase includes, but is not limited to, groups such as phenyl, biphenyl, anthracenyl, naphthenyl by way of example. Although the phrase “unsubstituted aryl” includes groups containing condensed rings such as naphthalene, it does not include aryl groups that have other groups such as alkyl or halo groups bonded to one of the ring members, as aryl groups such as tolyl are considered herein to be substituted aryl groups as described below. A preferred unsubstituted aryl group is phenyl. Unsubstituted aryl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound, however.

[0843] The phrase “substituted aryl group” has the same meaning with respect to aryl groups that substituted alkyl groups had with respect to alkyl groups. However, a substituted aryl group also includes aryl groups in which one of the aromatic carbons is bonded to one of the non-carbon or non-hydrogen atoms described above and also includes aryl groups in which one or more aromatic carbons of the aryl group is bonded to a substituted and/or unsubstituted alkyl, alkenyl, or alkynyl group as defined herein. This includes bonding arrangements in which two carbon atoms of an aryl group are bonded to two atoms of an alkyl, alkenyl, or alkynyl group to define a fused ring system (e.g. dihydronaphthyl or tetrahydronaphthyl). Thus, the phrase “substituted aryl” includes, but is not limited to tolyl, and hydroxyphenyl among others.

[0844] Included within the definition of aryl groups are fused and unfused arylaryl groups. The term “unfused arylaryl” refers to a group or substituent to which two aryl groups, which are not condensed to each other, are bound. Exemplary unfused arylaryl compounds include, for example, phenylbenzene, diphenyldiazene, 4-methylthio-1-phenylbenzene, phenoxybenzene, (2-phenylethynyl)benzene, diphenyl ketone, (4-phenylbuta-1,3-dienyl)benzene, phenylbenzylamine, (phenylmethoxy)benzene, and the like. Preferred substituted unfused arylaryl groups include: 2-(phenylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 1,4-diphenylbenzene, N-[4-(2-phenylethynyl)phenyl]-2-[benzylamino]acetamide, 2-amino-N-[4-(2-phenylethynyl)phenyl]propanamide, 2-amino-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(cyclopropylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(ethylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-[(2-methylpropyl)amino]-N-[4-(2-phenylethynyl)phenyl]acetamide, 5-phenyl-2H-benzo[d][1,3-dioxole], 2-chloro-1-methoxy-4-phenylbenzene, 2-[(imidazolylmethyl)amino]-N-[4-(2-phenylethynyl)phenyl]acetamide, 4-phenyl-1-phenoxybenzene, N-(2-aminoethyl)-[4-(2-phenylethynyl)phenyl]carboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-[[4-(4-methylphenyl)methyl]amino]-N-[4-(2-phenylethynyl)phenyl]acetamide, 4-phenyl-1-(trifluoromethyl)benzene, 1-butyl-4-phenylbenzene, 2-(cyclohexylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(ethylmethylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, 2-(butylamino)-N-[4-(2-phenylethynyl)phenyl]acetamide, N-[4-(2-phenylethynyl)phenyl]-2-(4-pyridylamino)acetamide, N-[4-

(2-phenylethynyl)phenyl]-2-(quinuclidin-3-ylamino)acetamide, N-[4-(2-phenylethynyl)phenyl]pyrrolidin-2-ylcarboxamide, 2-amino-3-methyl-N-[4-(2-phenylethynyl)phenyl]butanamide, 4-(4-phenylbuta-1,3-diynyl)phenylamine, 2-(dimethylamino)-N-[4-(4-phenylbuta-1,3-diynyl)phenyl]acetamide, 2-(ethylamino)-N-[4-(4-phenylbuta-1,3-diynyl)phenyl]acetamide, 4-ethyl-1-phenylbenzene, 1-[4-(2-phenylethynyl)phenyl]ethan-1-one, N-(1-carbamoyl-2-hydroxypropyl)[4-(4-phenylbuta-1,3-diynyl)phenyl]carboxamide, N-[4-(2-phenylethynyl)phenyl]propanamide, 4-methoxyphenyl phenyl ketone, phenyl-N-benzamide, (tert-butoxy)-N-[(4-phenylphenyl)methyl]carboxamide, 2-(3-phenylphenoxy)ethanehydroxamic acid, 3-phenylphenyl propanoate, 1-(4-ethoxyphenyl)-4-methoxybenzene, and [4-(2-phenylethynyl)phenyl]pyrrole. The term “fused arylaryl” as used herein refers to an aryl group as previously defined which is condensed, and fully conjugated to an aryl group. Representative fused arylaryl groups include biphenyl, 4-(1-naphthyl)phenyl, 4-(2-naphthyl)phenyl and the like.

[0845] The term “aralkyl” as used herein refers to an alkyl radical to which is appended an aryl group. Representative aralkyl groups include benzyl, phenylethyl, hydroxybenzyl, fluorobenzyl, fluorophenylethyl and the like.

[0846] The term “heteroaralkyl” as used herein refers to an alkyl radical to which is appended a heteroaryl group. Representative heteroaralkyl groups include methylpyridine, 4-sec-butylpyrimidine and the like.

[0847] The term “heterocyclalkyl” as used herein refers to an alkyl radical to which is appended a heterocycl group. Representative heterocyclalkyl groups include methylpiperazine, epichlorohydrin, sec-butylpiperidine and the like.

[0848] The term “carbocyclalkyl” as used herein refers to an alkyl radical to which is appended a carbocycl group. Representative carbocyclalkyl groups include isopropylcyclohexane, 1-ethyl-2-fluorocyclopentane and the like.

[0849] The term “arylalkenyl” as used herein refers to an alkenyl radical to which is appended an aryl group. Representative arylalkenyl groups include styrene, 1-((Z)-prop-1-enyl)benzene, and the like.

[0850] The term “heteroarylalkenyl” as used herein refers to an alkenyl radical to which is appended a heteroaryl group. Representative heteroarylalkenyl groups include 4-vinylpyrimidine, 4-((Z)-prop-1-enyl)pyridine and the like.

[0851] The term “heterocyclalkenyl” as used herein refers to an alkenyl radical to which is appended a heterocycl group. Representative heterocyclalkenyl groups include vinylpiperazine, 4-((E)-prop-1-enyl)piperidine and the like.

[0852] The term “carbocyclalkenyl” as used herein refers to an alkenyl radical to which is appended a carbocycl group. Representative carbocyclalkenyl groups include vinylcyclohexane, (prop-1-en-2-yl)cyclohexane and the like.


[0853] The term “aryloxy” as used herein refers to RO— wherein R is an aryl group. Representative aryloxy groups include benzyloxy, biphenyloxy and the like.

[0854] The term “heteroaryloxy” as used herein refers to RO— wherein R is a heteroaryl group.


[0855] The term “arylalkoxy” as used herein refers to an alkoxy radical to which is appended an aryl group. Representative arylalkoxy group include benzylmethoxy, phenylethoxy and the like.

[0856] As used herein, representative heterocycl or heterocyclo groups include, for example, those listed and shown below (where the point of attachment of the substituent

group, and the other substituent groups shown below, is through the upper left-hand bond). These heterocycl groups can be further substituted and may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein. Those heterocycl groups include, for example, pyrrolidine, piperidine, methylpyrrolidine, pyrrolidine-3-ylamine, dimethylpyrrolidin-3-ylamine, 2-aminoquinuclidine, pyrrolidin-2-one, tetrahydrofuran, 4-piperidylpiperidine, 1-benzyl-4-piperidylamine, homopiperidine, homopiperazine, homomorpholine, methylpyrrolidine,



[0857] Representative heteroaryl groups include, for example, acridine, carbazole, β -carboline, cinnoline, furan, imidazole, indazole, indole, indolizine, isoindole, isoquinoline, isothiazole, oxazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, thiazole, 4H-pyran-4-one as well as those shown below. These heteroaryl groups can be further substituted and may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein.



[0858] Included within the definition of heteroaryl groups are fused and unfused arylheteroaryl, heteroarylaryl, and heteroarylheteroaryl groups. The term “unfused heteroarylaryl” refers to a unfused arylaryl group where one of the aryl groups is a heteroaryl group. Exemplary heteroarylaryl groups include, for example, 2-phenylpyridine, phenylpyrrole, 3-(2-phenylethynyl)pyridine, phenylpyrazole, 5-(2-phenylethynyl)-1,3-dihydropyrimidine-2,4-dione, 4-phenyl-1,2,3-thiadiazole, 2-(2-phenylethynyl)pyrazine, 2-phenylthiophene, phenylimidazole, 3-(2-piperazinylphenyl)furan, 3-(2,4-dichlorophenyl)-4-methylpyrrole, and the like. Preferred substituted unfused heteroarylaryl groups include: 5-(2-phenylethynyl)pyrimidine-2-ylamine, 1-methoxy-4-(2-thienyl)benzene, 1-methoxy-3-(2-thienyl)benzene, 5-methyl-2-phenylpyridine, 5-methyl-3-phenylisoxazole, 2-[3-(trifluoromethyl)phenyl]furan, 3-fluoro-5-(2-furyl)-2-methoxy-1-prop-2-enylbenzene, (hydroxyimino)(5-phenyl(2-thienyl))methane, 5-[(4-methylpiperazinyl)methyl]-2-phenylthiophene, 2-(4-ethylphenyl)thiophene, 4-methylthio-1-(2-thienyl)benzene, 2-(3-nitrophenyl)thiophene, (tert-butoxy)-N-[(5-phenyl(3-pyridyl))methyl]carboxamide, hydroxy-N-[(5-phenyl(3-pyridyl))methyl]amide, 2-(phenylmethylthio)pyridine, and benzylimidazole.

[0859] The term “unfused heteroarylheteroaryl” refers to an unfused arylaryl group where both of the aryl groups is a heteroaryl group. Exemplary heteroarylheteroaryl groups include, for example, 3-pyridylimidazole, 2-imidazolylpyrazine, and the like. Preferred substituted unfused heteroarylheteroaryl groups include: 2-(4-piperazinyl-3-pyridyl)furan, diethyl(3-pyrazin-2-yl(4-pyridyl))amine, and dimethyl {2-[2-(5-methylpyrazin-2-yl)ethynyl](4-pyridyl)}amine.

[0860] The term “fused heteroarylaryl” as used herein refers to an aryl group as previously defined which is condensed, and fully conjugated with a heteroaryl group. Representative fused heteroarylaryl groups include quinoline, quinazoline and the like.

[0861] The term “fused heteroarylheteroaryl” as used herein refers to a heteroaryl group as previously defined which is condensed, and fully conjugated with another heteroaryl group. Representative fused heteroarylheteroaryl groups include pyrazolopyrimidine, imidazoquinoline and the like.


[0862] The term “imineheterocycl” refers to moieties having an imine substituent bound distally (w/ respect to the point attachment) to a heterocycl group. An example of an imineheterocycl is N-(piperazin-1-yl)ethanimine.

[0863] The term “fused multicycle” refers to a polycyclic group having at least three conjoined rings. Representative fused multicycle groups include anthrazine, phenanthroline, perimidine, tryptanthrin and the like.

[0864] “Substituted” refers to the definite replacement of hydrogen with one or more monovalent or divalent radicals. Suitable substitution groups include, those described herein for particular groups, as well as hydroxyl, nitro, amino, imino, cyano, halo, thio, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, alkyl, substituted alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroalkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, benzyl, pyridyl, pyrazolyl, pyrrole, thiophene, imidazolyl, and the like. “Unsubstituted” refers to the group as defined with no further substitutions except for the appropriate number H substitu-

ents, as will be apparent to one skilled in the art. For example sulfonyl refers to $\text{—SO}_2\text{—}$ and unsubstituted sulfonyl refers to $\text{—SO}_2\text{H}$.

[0865] The numbering of carbon atoms on the cyclical structures and superscripts on R-groups is to prevent degeneracy in R-group labeling. It is not meant to signify anything except a particular position on a group. For instance, 'R_b, at position 2 is ethyl' would imply:



[0866] The invention also includes isotopically-labeled SMIP compounds, that are structurally identical to those disclosed above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0867] Various compounds and methods of their synthesis are disclosed in the following US patents, US patent application publications, and PCT publications: U.S. Pat. No. 4,810,692, U.S. Pat. No. 4,617,315, U.S. Pat. No. 4,988,680, U.S. Pat. No. 5,087,619, U.S. Pat. No. 5,001,124, U.S. Pat. No. 4,987,139, U.S. Pat. No. 5,023,264, U.S. Pat. No. 5,023,263, U.S. Pat. No. 4,975,372, U.S. Pat. No. 4,981,792, U.S. Pat. No. 5,064,835, U.S. Pat. No. 5,120,842, U.S. Pat. No. 5,120,727, U.S. Pat. No. 5,120,725, U.S. Pat. No. 5,118,678, U.S. Pat. No. 5,118,677, U.S. Pat. No. 5,130,307, U.S. Pat. No. 5,100,883, U.S. Pat. No. 5,102,876, U.S. Pat. No. 5,093,338, U.S. Pat. No. 5,143,918, U.S. Pat. No. 5,091,389, U.S. Pat. No. 5,120,726, U.S. Pat. No. 5,233,036, U.S. Pat. No. 5,227,467, U.S. Pat. No. 5,221,740, U.S. Pat. No. 5,247,076, U.S. Pat. No. 5,208,241, U.S. Pat. No. 5,262,423, U.S. Pat. No. 5,260,300, U.S. Pat. No. 5,258,389, U.S. Pat. No. 5,247,119, U.S. Pat. No. 5,376,663, U.S. Pat. No. 5,373,014, U.S. Pat. No. 5,371,225, U.S. Pat. No. 5,362,735, U.S. Pat. No. 5,360,

794, U.S. Pat. No. 5,352,783, U.S. Pat. No. 5,310,903, U.S. Pat. No. 5,302,584, U.S. Pat. No. 5,444,072, U.S. Pat. No. 5,387,680, U.S. Pat. No. 5,389,639, U.S. Pat. No. 6,121,257, U.S. Pat. No. 6,071,947, U.S. Pat. No. 6,150,373, U.S. Pat. No. 6,051,590, U.S. Pat. No. 6,015,809, U.S. Pat. No. 5,252,732, U.S. Pat. No. 5,874,411, U.S. Pat. No. 5,877,184, U.S. Pat. No. 5,252,732, U.S. Pat. No. 5,247,076, U.S. Pat. No. 5,344,925, U.S. Pat. No. 5,777,105, U.S. Pat. No. 5,739,169, U.S. Pat. No. 5,696,156, U.S. Pat. No. 5,679,705, U.S. Pat. No. 5,631,282, U.S. Pat. No. 5,561,228, U.S. Pat. No. 5,563,145, U.S. Pat. No. 5,525,610, U.S. Pat. No. 5,523,408, U.S. Pat. No. 5,512,687, U.S. Pat. No. 5,463,048, U.S. Pat. No. 5,451,604, U.S. Pat. No. 5,461,054, U.S. Pat. No. 5,302,584, U.S. Pat. No. 5,162,334, U.S. Pat. No. 5,284,877, U.S. Pat. No. 5,284,840, U.S. Pat. No. 5,256,790, U.S. Pat. No. 5,252,579, U.S. Pat. No. 5,262,533, US 2002016460, US 2002061905, U.S. Pat. No. 6,440,991, U.S. Pat. No. 6,399,626, U.S. Pat. No. 6,399,773, U.S. Pat. No. 6,331,547, U.S. Pat. No. 6,110,922, U.S. Pat. No. 5,759,550, U.S. Pat. No. 5,192,773, U.S. Pat. No. 5,194,447, U.S. Pat. No. 5,189,042, U.S. Pat. No. 5,162,333, U.S. Pat. No. 5,162,334, U.S. Pat. No. 5,149,701, U.S. Pat. No. 5,147,877, U.S. Pat. No. 4,885,276, U.S. Pat. No. 4,314,061, U.S. Pat. No. 4,895,872, U.S. Pat. No. 4,847,299, U.S. Pat. No. 4,525,299, U.S. Pat. No. 5,679,640, U.S. Pat. No. 5,385,910, U.S. Pat. No. 5,385,908, U.S. Pat. No. 5,385,909, U.S. Pat. No. 5,378,836, U.S. Pat. No. 5,362,718, U.S. Pat. No. 5,470,878, U.S. Pat. No. 5,346,912, U.S. Pat. No. 5,359,073, U.S. Pat. No. 6,100,259, U.S. Pat. No. 5,550,214, U.S. Pat. No. 5,455,230, U.S. Pat. No. 6,136,817, U.S. Pat. No. 5,385,910, U.S. Pat. No. 5,730,979, U.S. Pat. No. 5,817,311, U.S. Pat. No. 5,189,039, U.S. Pat. No. 5,171,864, U.S. Pat. No. 5,169,963, U.S. Pat. No. 5,183,906, U.S. Pat. No. 5,006,520, U.S. Pat. No. 5,091,381, U.S. Pat. No. 5,905,090, U.S. Pat. No. 5,665,772, U.S. Pat. No. 5,260,323, U.S. Pat. No. 5,091,381, U.S. Pat. No. 4,675,382, U.S. Pat. No. 5,321,009, U.S. Pat. No. 5,776,943, U.S. Pat. No. 5,286,730, U.S. Pat. No. 5,387,589, U.S. Pat. No. 5,496,832, U.S. Pat. No. 4,829,061, U.S. Pat. No. 4,963,557, U.S. Pat. No. 4,648,996, U.S. Pat. No. 4,351,841, U.S. Pat. No. 4,284,786, U.S. Pat. No. 4,965,276, U.S. Pat. No. 5,268,382, U.S. Pat. No. 5,459,163, U.S. Pat. No. 5,504,084, U.S. Pat. No. 5,494,911, U.S. Pat. No. 5,532,259, U.S. Pat. No. 5,700,823, U.S. Pat. No. 5,700,822, U.S. Pat. No. 5,610,173, U.S. Pat. No. 4,968,702, U.S. Pat. No. 5,639,455, U.S. Pat. No. 5,466,697, U.S. Pat. No. 5,366,986, U.S. Pat. No. 5,173,499, U.S. Pat. No. 5,391,730, U.S. Pat. No. 4,968,702, U.S. Pat. No. 4,910,211, U.S. Pat. No. 4,968,702, U.S. Pat. No. 4,603,137, U.S. Pat. No. 4,347,315, U.S. Pat. No. 5,051,441, U.S. Pat. No. 4,894,374, U.S. Pat. No. 5,470,831, U.S. Pat. No. 6,034,096, U.S. Pat. No. 5,356,897, U.S. Pat. No. 5,478,827, U.S. Pat. No. 5,624,931, U.S. Pat. No. 5,219,864, U.S. Pat. No. 4,894,374, U.S. Pat. No. 5,530,101, U.S. Pat. No. 4,753,935, U.S. Pat. No. 4,786,637, U.S. Pat. No. 4,894,366, U.S. Pat. No. 4,929,611, U.S. Pat. No. 4,956,352, U.S. Pat. No. 5,110,811, U.S. Pat. No. 5,254,562, U.S. Pat. No. 5,266,692, U.S. Pat. No. 4,916,138, U.S. Pat. No. 4,940,797, U.S. Pat. No. 5,087,703, U.S. Pat. No. 5,011,943, U.S. Pat. No. 5,194,378, U.S. Pat. No. 5,196,437, WO 8707276, WO 8805784, WO 8809183, WO 8908658, WO 9110650, WO 9102736, WO 9101982, WO 9200314, WO 9014359, WO 9200313, WO 9113899, WO 9113889, WO 9211275, WO 9205189, WO 9205179, WO 9118901, WO 9203441, WO 9200980, WO 9200314, WO 9316083, WO 9311130, WO 9312125, WO 9310122, WO 9310796, WO 9305059, WO 9305058,

WO 9318050, WO 9318049, WO 9318048, WO 9318042, WO 9501355, WO 9429295, WO 9322286, WO 9425468, WO 9424095, WO 9420488, WO 9418208, WO 9418206, WO 9409010, WO 9522537, WO 9522536, WO 9408943, WO 9516691, WO 9515328, WO 9517381, WO 9514023, WO 9408943, WO 9506045, WO 9509857, WO 9504060, WO 9504738, WO 0058318, WO 0053190, WO 0058314, WO 0039129, WO 0034228, WO 0034248, WO 0032604, WO 9840380, WO 0024744, WO 0012514, WO 0009510, WO 0002879, WO 9955689, WO 9965909, WO 9965908, WO 9965450, WO 9947707, WO 9938829, WO 9940069, WO 9941239, WO 9509857, WO 9305058, WO 9931087, WO 9931060, WO 9929695, WO 9931066, WO 9931063, WO 9931064, WO 9925703, WO 9912890, WO 9920267, WO 9920274, WO 9915530, WO 9305058, WO 9305059, WO 9708182, WO 9828301, WO 9818780, WO 9816532, WO 9816531, WO 9816518, WO 9806719, WO 9809972, WO 9739999, WO 9748696, WO 9748695, WO 9744351, WO 9744052, WO 9317699, WO 9740028, WO 9606068, WO 9720814, WO 9716438, WO 9716437, WO 9716182, WO 9716068, WO 9714410, WO 9712888, WO 9712887, WO 9711080, WO 9711092, WO 9709298, WO 9640688, WO 9641807, WO 9631529, WO 9304679, WO 9630381, WO 9625936, WO 9624579, WO 9617845, WO 9615131, WO 9611200, WO 9613510, WO 9535299, WO 9535120, WO 9534568, WO 9534565, WO 9522538, WO 9515947, WO 9522534, WO 9522537, WO 9220688, WO 9402485, WO 9402137, WO 9402136, WO 9404540, WO 0270472, WO 0253543, WO 0257216, WO 0257237, WO 0251397, WO 0125238, WO 0119829, WO 0230938, WO 0228867, WO 0228866, WO 0218395, WO 0206268, WO 0025780, WO 0200661, WO 0190110, WO 0034296, WO 0033887, WO 0059880, WO 0039081, WO 0107401, WO 0105768, WO 0105750, WO 0076953, WO 9426265, WO 9305058, WO 9222294, WO 9307871, WO 9221313, WO 9305046, WO 9220688, WO 9218496, WO 9010631, WO 9007523, WO 9007520, WO 9002727, WO 9824762, WO 9809946, WO 9743434, WO 9809970, WO 9804521, WO 9732847, WO 9741148, WO 9739018, WO 9723453, WO 9709325, WO 9702285, WO 9702820, WO 9709315, WO 9428910, WO 9422863, WO 9412500, WO 0062778, WO 0056331, WO 9831227, WO 0040562, WO 0025786, WO 9615105, WO 9617874, WO 9616967, WO 9611199, WO 9611198, WO 9603419, WO 9531463, WO 9531463, WO 9528394, WO 9515309, WO 9422872, WO 0285928, WO 0272562, WO 0248122, WO 0250071, WO 0269904, WO 0228862, WO 0047595, WO 0125238, WO 0102359, WO 0253150, WO 0062778, WO 9202229, WO 9303036, WO 9219610, WO 9219609, WO 8903385, WO 9205180, WO 0015645, WO 0002839, WO 9942105, WO 9915501, WO 9856785, WO 9852933, WO 9852951, WO 9845249, WO 9832750, WO 9735575, WO 9409010, WO 9424304, WO 9507468, WO 9804279, WO 8908113, WO 9405685, WO 9102000, WO 9214476, WO 9214477, WO 9319763, WO 9747317, WO 9818468, WO 8907613, WO 8902889, WO 8805783, WO 9117748, WO 9519169, WO 0063210, WO 0048989, WO 9804521, WO 9746522, WO 9741148, WO 9739018, WO 9720811, WO 9705140, WO 9606855, WO 9602541, WO 9210295, WO 9509153, WO 0255541, WO 0202539, WO 0063210, WO 9509153, WO 9513277, WO 9508535, WO 9501175, WO 9424133, WO 9408589, WO 9415959, WO 8906968, WO 0015604, WO 9932138, WO 9900143, WO 9852606, WO 9117748, WO 9116339, WO 9520589, WO 9211021, WO 9213874, WO 9500543, WO 9531206,

WO 9520589, WO 9715561, WO 9743251, WO 9741104, WO 9743251, WO 9723453, WO 9715561, WO 9705141, WO 9640143, WO 9749399, WO 9412184, WO 9426266, WO 9507902, WO 9509626, WO 9014826, WO 9117754, WO 9119495, WO 9308802 and WO 9314771, which have been found within context of this invention to be useful for immune potentiation. The entire disclosure of these U.S. and international publications is incorporated herein by this reference. Other compounds or intermediates of interest in the present invention were purchased from commercially available sources using the following method: the chemical structure of interest was drawn into the ACD-SC database (from MDL Information Systems). A search of the following companies/institutions, among others, retrieved the identified compound's supplier and purchasing information: ASDI, ASINEX, BIONET, CHEMBRIDGE, CHEMDIV, CHEMEX, CHEMSTAR, COMGENEX, CSC, INTERBIO-SCREEN, LABOTEST, MAYBRIDGE, MICROSOURCE/GENESIS, OLIVIA, ORION, PEAKDALE, RYAN SCIENTIFIC, SPECS, TIMTEC, U OF FLORIDA, and ZELINSKY.

[0868] Compositions of the invention may be administered in conjunction with one or more antigens for use in therapeutic, prophylactic, or diagnostic methods of the present invention. Preferred antigens include those listed below. Additionally, the compositions of the present invention may be used to treat or prevent infections caused by any of the below-listed microbes.

[0869] In addition to combination with the antigens described below, the compositions of the invention may also be combined with an adjuvant as described herein. Antigens for use with the invention include, but are not limited to, one or more of the following antigens set forth below, or antigens derived from one or more of the pathogens set forth below:

[0870] A. Bacterial Antigens

[0871] Bacterial antigens suitable for use in the invention include proteins, polysaccharides, lipopolysaccharides, and outer membrane vesicles which may be isolated, purified or derived from a bacteria. In addition, bacterial antigens may include bacterial lysates and inactivated bacteria formulations. Bacteria antigens may be produced by recombinant expression. Bacterial antigens preferably include epitopes which are exposed on the surface of the bacteria during at least one stage of its life cycle. Bacterial antigens are preferably conserved across multiple serotypes. Bacterial antigens include antigens derived from one or more of the bacteria set forth below as well as the specific antigens examples identified below.

[0872] *Neisseria meningitidis*: *Meningitidis* antigens may include proteins (such as those identified in References 1-7), saccharides (including a polysaccharide, oligosaccharide or lipopolysaccharide), or outer-membrane vesicles (References 8, 9, 10, 11) purified or derived from *N. meningitidis* serogroup A, C, W135, Y, and/or B. *Meningitidis* protein antigens may be selected from adhesions, autotransporters, toxins, Fe acquisition proteins, and membrane associated proteins (preferably integral outer membrane protein).

[0873] *Streptococcus pneumoniae*: *Streptococcus pneumoniae* antigens may include a saccharide (including a polysaccharide or an oligosaccharide) or protein from *Streptococcus pneumoniae*. Saccharide antigens may be selected from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Protein antigens may be selected from a protein identified in WO 98/18931, WO 98/18930, U.S. Pat. No. 6,699,703, U.S. Pat. No. 6,800,

744, WO 97/43303, and WO 97/37026. *Streptococcus pneumoniae* proteins may be selected from the Poly Histidine Triad family (PhtX), the Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 or Sp133.

[0874] *Streptococcus pyogenes* (Group A *Streptococcus*): Group A *Streptococcus* antigens may include a protein identified in WO 02/34771 or WO 2005/032582 (including GAS 40), fusions of fragments of GAS M proteins (including those described in WO 02/094851, and Dale, Vaccine (1999) 17:193-200, and Dale, Vaccine 14(10): 944-948), fibronectin binding protein (Sfb1), Streptococcal heme-associated protein (Shp), and Streptolysin S (SagA).

[0875] *Moraxella catarrhalis*: *Moraxella* antigens include antigens identified in WO 02/18595 and WO 99/58562, outer membrane protein antigens (HMW-OMP), C-antigen, and/or LPS.

[0876] *Bordetella pertussis*: Pertussis antigens include pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B. pertussis*, optionally also combination with pertactin and/or agglutinogens 2 and 3 antigen.

[0877] *Staphylococcus aureus*: *Staph aureus* antigens include *S. aureus* type 5 and 8 capsular polysaccharides optionally conjugated to nontoxic recombinant *Pseudomonas aeruginosa* exotoxin A, such as StaphVAX™, or antigens derived from surface proteins, invasins (leukocidin, kinases, hyaluronidase), surface factors that inhibit phagocytic engulfment (capsule, Protein A), carotenoids, catalase production, Protein A, coagulase, clotting factor, and/or membrane-damaging toxins (optionally detoxified) that lyse eukaryotic cell membranes (hemolysins, leukotoxin, leukocidin).

[0878] *Staphylococcus epidermidis*: *S. epidermidis* antigens include slime—associated antigen (SAA).

[0879] Tetanus: Tetanus antigens include tetanus toxoid (TT), preferably used as a carrier protein in conjunction/conjugated with the compositions of the present invention.

[0880] *Diphtheria*: *Diphtheria* antigens include diphtheria toxin, preferably detoxified, such as CRM₁₉₇, additionally antigens capable of modulating, inhibiting or associated with ADP ribosylation are contemplated for combination/co-administration/conjugation with the compositions of the present invention, the diphtheria toxoids are preferably used as carrier proteins.

[0881] *Haemophilus influenzae* B (Hib): Hib antigens include a Hib saccharide antigen.

[0882] *Pseudomonas aeruginosa*: *Pseudomonas* antigens include endotoxin A, Wzz protein, *P. aeruginosa* LPS, more particularly LPS isolated from PAO 1 O5 serotype), and/or Outer Membrane Proteins, including Outer Membrane Proteins F (OprF) (*Infect Immun.* 2001 May; 69(5): 3510-3515).

[0883] *Legionella pneumophila* (Legionnaires' Disease): *L. pneumophila* antigens may optionally derived from cell lines with disrupted *asd* genes (*Infect Immun.* 1998 May; 66(5): 1898).

[0884] *Streptococcus agalactiae* (Group B *Streptococcus*): Group B *Streptococcus* antigens include a protein or saccharide antigen identified in WO 02/34771, WO 03/093306, WO 04/041157, or WO 2005/002619 (including proteins GBS 80, GBS 104, GBS 276 and GBS 322, and including saccharide antigens derived from serotypes 1a, 1b, 1a/c, II, III, N, V, VI, VII and VIII).

[0885] *Neisseria gonorrhoeae*: Gonorrhoeae antigens include For (or porin) protein, such as PorB (see Zhu et al., Vaccine (2004) 22:660-669), a transferring binding protein, such as TbpA and TbpB (See Price et al., Infection and Immunity (2004) 71(1):277-283), a opacity protein (such as Opa), a reduction-modifiable protein (Rmp), and outer membrane vesicle (OMV) preparations (see Plante et al., J Infectious Disease (2000) 182:848-855), also see e.g. WO99/24578, WO99/36544, WO99/57280, WO02/079243).

[0886] *Chlamydia trachomatis*: *Chlamydia trachomatis* antigens include antigens derived from serotypes A, B, Ba and C are (agents of trachoma, a cause of blindness), serotypes L₁, L₂ & L₃ (associated with Lymphogranuloma venereum), and serotypes, D-K. *Chlamydia trachomatis* antigens may also include an antigen identified in WO 00/37494, WO 03/049762, WO 03/068811, or WO 05/002619.

[0887] *Treponema pallidum* (Syphilis): Syphilis antigens include TmpA antigen.

[0888] *Haemophilus ducreyi* (causing chancroid): Ducreyi antigens include outer membrane protein (DsrA).

[0889] *Enterococcus faecalis* or *Enterococcus faecium*: Antigens include a trisaccharide repeat or other *Enterococcus* derived antigens provided in U.S. Pat. No. 6,756,361.

[0890] *Helicobacter pylori*: *H. pylori* antigens include Cag, Vac, Nap, HopX, HopY and/or urease antigen.

[0891] *Staphylococcus saprophyticus*: Antigens include the 160 kDa hemagglutinin of *S. saprophyticus* antigen.

[0892] *Yersinia enterocolitica* Antigens include LPS (*Infect Immun.* 2002 August; 70(8): 4414).

[0893] *E. coli*: *E. coli* antigens may be derived from enterotoxigenic *E. coli* (ETEC), enteroaggregative *E. coli* (EAggEC), diffusely adhering *E. coli* (DAEC), enteropathogenic *E. coli* (EPEC), and/or enterohemorrhagic *E. coli* (EHEC).

[0894] *Bacillus anthracis* (anthrax): *B. anthracis* antigens are optionally detoxified and may be selected from A-components (lethal factor (LF) and edema factor (EF)), both of which can share a common B-component known as protective antigen (PA).

[0895] *Yersinia pestis* (plague): Plague antigens include F1 capsular antigen (*Infect Immun.* 2003 January; 71(1): 374-383, LPS (*Infect Immun.* 1999 October; 67(10): 5395), *Yersinia pestis* V antigen (*Infect Immun.* 1997 November; 65(11): 4476-4482).

[0896] *Mycobacterium tuberculosis*: Tuberculosis antigens include lipoproteins, LPS, BCG antigens, a fusion protein of antigen 85B (Ag85B) and/or ESAT-6 optionally formulated in cationic lipid vesicles (*Infect Immun.* 2004 October; 72(10): 6148), *Mycobacterium tuberculosis* (Mtb) isocitrate dehydrogenase associated antigens (*Proc. Natl Acad Sci USA.* 2004 Aug. 24; 101(34): 12652), and/or MPT51 antigens (*Infect Immun.* 2004 July; 72(7): 3829).

[0897] *Rickettsia*: Antigens include outer membrane proteins, including the outer membrane protein A and/or B (OmpB) (*Biochim Biophys Acta.* 2004 November 1; 1702(2): 145), LPS, and surface protein antigen (SPA) (*J Autoimmun.* 1989 June; 2 Suppl:81).

[0898] *Listeria monocytogenes*: Antigens derived from *L. monocytogenes* are preferably used as carriers/vectors for intracytoplasmic delivery of conjugates/associated compositions of the present invention.

[0899] *Chlamydia pneumoniae*: Antigens include those identified in WO 02/02606.

[0900] *Vibrio cholerae*: Antigens include proteinase antigens, LPS, particularly lipopolysaccharides of *Vibrio cholerae* II, O1 Inaba O-specific polysaccharides, *V. cholera* 0139, antigens of IEM108 vaccine (*Infect Immun.* 2003 October; 71(10):5498-504), and/or Zonula occludens toxin (Zot).

[0901] *Salmonella typhi* (typhoid fever): Antigens include capsular polysaccharides preferably conjugates (Vi, i.e. vax-TyVi).

[0902] *Borrelia burgdorferi* (Lyme disease): Antigens include lipoproteins (such as OspA, OspB, Osp C and Osp D), other surface proteins such as OspE-related proteins (Erps), decorin-binding proteins (such as DbpA), and antigenically variable VI proteins, such as antigens associated with P39 and P13 (an integral membrane protein, *Infect Immun.* 2001 May; 69(5): 3323-3334), VlsE Antigenic Variation Protein (*J. Clin Microbiol.* 1999 December; 37(12): 3997).

[0903] *Porphyromonas gingivalis*: Antigens include *P. gingivalis* outer membrane protein (OMP).

[0904] *Klebsiella*: Antigens include an OMP, including OMP A, or a polysaccharide optionally conjugated to tetanus toxoid.

[0905] Where not specifically referenced, further bacterial antigens of the invention may be capsular antigens, polysaccharide antigens or protein antigens of any of the above. Further bacterial antigens may also include an outer membrane vesicle (OMV) preparation. Additionally, antigens include live, attenuated, split, and/or purified versions of any of the aforementioned bacteria. The bacterial or microbial derived antigens of the present invention may be gram-negative or gram-positive and aerobic or anaerobic.

[0906] Additionally, any of the above bacterial-derived saccharides (polysaccharides, LPS, LOS or oligosaccharides) can be conjugated to another agent or antigen, such as a carrier protein (for example CRM₁₉₇). Such conjugation may be direct conjugation effected by reductive amination of carbonyl moieties on the saccharide to amino groups on the protein, as provided in U.S. Pat. No. 5,360,897 and *Can J Biochem Cell Biol.* 1984 May; 62(5):270-5. Alternatively, the saccharides can be conjugated through a linker, such as, with succinamide or other linkages provided in *Bioconjugate Techniques*, 1996 and CRC, *Chemistry of Protein Conjugation and Cross-Linking*, 1993.

[0907] B. Viral Antigens

[0908] Viral antigens suitable for use in the invention include inactivated (or killed) virus, attenuated virus, split virus formulations, purified subunit formulations, viral proteins which may be isolated, purified or derived from a virus, and Virus Like Particles (VLPs). Viral antigens may be derived from viruses propagated on cell culture or expressed recombinantly. Viral antigens preferably include epitopes which are exposed on the surface of the virus during at least one stage of its life cycle. Viral antigens are preferably conserved across multiple serotypes. Viral antigens include antigens derived from one or more of the viruses set forth below as well as the specific antigens examples identified below.

[0909] Orthomyxovirus: Viral antigens may be derived from an Orthomyxovirus, such as Influenza A, B and C. Orthomyxovirus antigens may be selected from one or more of the viral proteins, including hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix protein (M1), membrane protein (M2), one or more of the transcriptase components (PB1, PB2 and PA). Preferred antigens include HA and NA.

[0910] Influenza antigens may be derived from interpanemic (annual) flu strains. Alternatively influenza antigens may be derived from strains with the potential to cause pandemic a pandemic outbreak (i.e., influenza strains with new haemagglutinin compared to the haemagglutinin in currently circulating strains, or influenza strains which are pathogenic in avian subjects and have the potential to be transmitted horizontally in the human population, or influenza strains which are pathogenic to humans).

[0911] Paramyxoviridae viruses: Viral antigens may be derived from Paramyxoviridae viruses, such as Pneumoviruses (RSV), Paramyxoviruses (PN) and Morbilliviruses (Measles).

[0912] Pneumovirus: Viral antigens may be derived from a Pneumovirus, such as Respiratory syncytial virus (RSV), Bovine respiratory syncytial virus, Pneumonia virus of mice, and Turkey rhinotracheitis virus. Preferably, the Pneumovirus is RSV. Pneumovirus antigens may be selected from one or more of the following proteins, including surface proteins Fusion (F), Glycoprotein (G) and Small Hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P and L and nonstructural proteins NS1 and NS2. Preferred Pneumovirus antigens include F, G and M. See e.g., *J Gen Virol.* 2004 November; 85(Pt 11):3229. Pneumovirus antigens may also be formulated in or derived from chimeric viruses. For example, chimeric RSV/PIV viruses may comprise components of both RSV and PIV.

[0913] Paramyxovirus: Viral antigens may be derived from a Paramyxovirus, such as Parainfluenza virus types 1-4 (PIV), Mumps, Sendai viruses, Simian virus 5, Bovine parainfluenza virus and Newcastle disease virus. Preferably, the Paramyxovirus is PIV or Mumps. Paramyxovirus antigens may be selected from one or more of the following proteins: Hemagglutinin—Neuraminidase (HN), Fusion proteins F1 and F2, Nucleoprotein (NP), Phosphoprotein (P), Large protein (L), and Matrix protein (M). Preferred Paramyxovirus proteins include HN, F1 and F2. Paramyxovirus antigens may also be formulated in or derived from chimeric viruses. For example, chimeric RSV/PIV viruses may comprise components of both RSV and PIV. Commercially available mumps vaccines include live attenuated mumps virus, in either a monovalent form or in combination with measles and rubella vaccines (MMR).

[0914] Morbillivirus: Viral antigens may be derived from a Morbillivirus, such as Measles. Morbillivirus antigens may be selected from one or more of the following proteins: hemagglutinin (H), Glycoprotein (G), Fusion factor (F), Large protein (L), Nucleoprotein (NP), Polymerase phosphoprotein (P), and Matrix (M). Commercially available measles vaccines include live attenuated measles virus, typically in combination with mumps and rubella (MMR).

[0915] Picornavirus: Viral antigens may be derived from Picornaviruses, such as Enteroviruses, Rhinoviruses, Heparnavirus, Cardioviruses and Aphthoviruses. Antigens derived from Enteroviruses, such as Poliovirus are preferred.

[0916] Enterovirus: Viral antigens may be derived from an Enterovirus, such as Poliovirus types 1, 2 or 3, Coxsackie A virus types 1 to 22 and 24, Coxsackie B virus types 1 to 6, Echovirus (ECHO) virus) types 1 to 9, 11 to 27 and 29 to 34 and Enterovirus 68 to 71. Preferably, the Enterovirus is poliovirus. Enterovirus antigens are preferably selected from one or more of the following Capsid proteins VP1, VP2, VP3 and

VP4. Commercially available polio vaccines include Inactivated Polio Vaccine (IPV) and Oral poliovirus vaccine (OPV).

[0917] Heparnavirus: Viral antigens may be derived from an Heparnavirus, such as Hepatitis A virus (HAV). Commercially available HAV vaccines include inactivated HAV vaccine.

[0918] Togavirus: Viral antigens may be derived from a Togavirus, such as a Rubivirus, an Alphavirus, or an Arterivirus. Antigens derived from Rubivirus, such as Rubella virus, are preferred. Togavirus antigens may be selected from EL, E2, E3, C, NSP-1, NSPO-2, NSP-3 or NSP-4. Togavirus antigens are preferably selected from E1, E2 or E3. Commercially available Rubella vaccines include a live cold-adapted virus, typically in combination with mumps and measles vaccines (MMR).

[0919] Flavivirus: Viral antigens may be derived from a Flavivirus, such as Tick-borne encephalitis (TBE), Dengue (types 1, 2, 3 or 4), Yellow Fever, Japanese encephalitis, West Nile encephalitis, St. Louis encephalitis, Russian spring-summer encephalitis, Powassan encephalitis. Flavivirus antigens may be selected from PrM, M, C, E, NS-1, NS-2a, NS2b, NS3, NS4a, NS4b, and NS5. Flavivirus antigens are preferably selected from PrM, M and E. Commercially available TBE vaccine include inactivated virus vaccines.

[0920] Pestivirus: Viral antigens may be derived from a Pestivirus, such as Bovine viral diarrhea (BVDV), Classical swine fever (CSFV) or Border disease (BDV).

[0921] Hepadnavirus: Viral antigens may be derived from a Hepadnavirus, such as Hepatitis B virus. Hepadnavirus antigens may be selected from surface antigens (L, M and S), core antigens (HBc, HBe). Commercially available HBV vaccines include subunit vaccines comprising the surface antigen S protein.

[0922] Hepatitis C virus: Viral antigens may be derived from a Hepatitis C virus (HCV). HCV antigens may be selected from one or more of E1, E2, E1/E2, NS345 polypeptide, NS 345-core polypeptide, core, and/or peptides from the nonstructural regions (Houghton et al., *Hepatology* (1991) 14:381).

[0923] Rhabdovirus: Viral antigens may be derived from a Rhabdovirus, such as a Lyssavirus (Rabies virus) and Vesiculovirus (VSV). Rhabdovirus antigens may be selected from glycoprotein (G), nucleoprotein (N), large protein (L), non-structural proteins (NS). Commercially available Rabies virus vaccine comprise killed virus grown on human diploid cells or fetal rhesus lung cells.

[0924] Caliciviridae: Viral antigens may be derived from Caliciviridae, such as Norwalk virus.

[0925] Coronavirus: Viral antigens may be derived from a Coronavirus, SARS, Human respiratory coronavirus, Avian infectious bronchitis (IBV), Molise hepatitis virus (MHV), and Porcine transmissible gastroenteritis virus (TGEV). Coronavirus antigens may be selected from spike (S), envelope (E), matrix (M), nucleocapsid (N), and Hemagglutinin-esterase glycoprotein (HE). Preferably, the Coronavirus antigen is derived from a SARS virus. SARS viral antigens are described in WO 04/92360;

[0926] Retrovirus: Viral antigens may be derived from a Retrovirus, such as an Oncovirus, a Lentivirus or a Spumavirus. Oncovirus antigens may be derived from HTLV-1, HTLV-2 or HTLV-5. Lentivirus antigens may be derived from HIV-1 or HIV-2. Retrovirus antigens may be selected from gag, pol, env, tax, tat, rex, rev, nef, vif, vpr, HIV

antigens may be selected from gag (p24gag and p55gag), env (gp160 and gp41), pol, tat, nef, rev vpr, miniproteins, (preferably p55 gag and gp140v delete). HIV antigens may be derived from one or more of the following strains: HIV_{IIIb}, HIV_{SF2}, HIV_{LAV}, HIV_{LAI}, HIV_{MN}, HIV-1_{CM235}, HIV-1_{US4}.

[0927] Reovirus: Viral antigens may be derived from a Reovirus, such as an *Orthoreovirus*, a Rotavirus, an Orbivirus, or a Coltivirus. Reovirus antigens may be selected from structural proteins $\lambda 1$, $\lambda 2$, $\lambda 3$, $\mu 1$, $\mu 2$, $\sigma 1$, $\sigma 2$, or $\sigma 3$, or nonstructural proteins σNS , μNS , or $\sigma 1s$. Preferred Reovirus antigens may be derived from a Rotavirus. Rotavirus antigens may be selected from VP1, VP2, VP3, VP4 (or the cleaved product VP5 and VP8), NSP 1, VP6, NSP3, NSP2, VP7, NSP4, or NSP5. Preferred Rotavirus antigens include VP4 (or the cleaved product VP5 and VP8), and VP7.

[0928] Parvovirus: Viral antigens may be derived from a Parvovirus, such as Parvovirus B19. Parvovirus antigens may be selected from VP-1, VP-3, NS-1 and NS-2. Preferably, the Parvovirus antigen is capsid protein VP-2.

[0929] Delta hepatitis virus (HDV): Viral antigens may be derived HDV, particularly δ -antigen from HDV (see, e.g., U.S. Pat. No. 5,378,814).

[0930] Hepatitis E virus (HEV): Viral antigens may be derived from HMV.

[0931] Hepatitis G virus (HGV): Viral antigens may be derived from HMV.

[0932] Human Herpesvirus: Viral antigens may be derived from a Human Herpesvirus, such as Herpes Simplex Viruses (HSV), Varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Human Herpesvirus 6 (HHV6), Human Herpesvirus 7 (HHV7), and Human Herpesvirus 8 (HHV8). Human Herpesvirus antigens may be selected from immediate early proteins (α), early proteins (β), and late proteins (γ). HSV antigens may be derived from HSV-1 or HSV-2 strains. HSV antigens may be selected from glycoproteins gB, gC, gD and gH, fusion protein (gB), or immune escape proteins (gC, gE, or gI). VZV antigens may be selected from core, nucleocapsid, tegument, or envelope proteins. A live attenuated VZV vaccine is commercially available. EBV antigens may be selected from early antigen (EA) proteins, viral capsid antigen (VCA), and glycoproteins of the membrane antigen (MA). CMV antigens may be selected from capsid proteins, envelope glycoproteins (such as gB and gH), and tegument proteins

[0933] Papovaviruses: Antigens may be derived from Papovaviruses, such as Papillomaviruses and Polyomaviruses. Papillomaviruses include HPV serotypes 1, 2, 4, 5, 6, 8, 11, 13, 16, 18, 31, 33, 35, 39, 41, 42, 47, 51, 57, 58, 63 and 65. Preferably, HPV antigens are derived from serotypes 6, 11, 16 or 18. HPV antigens may be selected from capsid proteins (L1) and (L2), or E1-E7, or fusions thereof. HPV antigens are preferably formulated into virus-like particles (VLPs). Polyomavirus viruses include BK virus and JK virus. Polyomavirus antigens may be selected from VP1, VP2 or VP3.

[0934] Further provided are antigens, compositions, methods, and microbes included in Vaccines, 4th Edition (Plotkin and Orenstein ed. 2004); *Medical Microbiology* 4th Edition (Murray et al. ed. 2002); *Virology*, 3rd Edition (W. K. Joklik ed. 1988); *Fundamental Virology*, 2nd Edition (B. N. Fields and D. M. Knipe, eds. 1991), which are contemplated in conjunction with the compositions of the present invention.

[0935] Fungal Antigens

[0936] In some embodiments compositions of the present invention are combined with fungal antigens for use in meth-

ods of the present invention, including treatment or prevention of mycoses. Fungal antigens for use herein, associated with vaccines include those described in: U.S. Pat. Nos. 4,229,434 and 4,368,191 for prophylaxis and treatment of trichophytosis caused by *Trichophyton mentagrophytes*; U.S. Pat. Nos. 5,277,904 and 5,284,652 for a broad spectrum dermatophyte vaccine for the prophylaxis of dermatophyte infection in animals, such as guinea pigs, cats, rabbits, horses and lambs, these antigens comprises a suspension of killed *T. equineum*, *T. mentagrophytes* (var. *granulare*), *M. canis* and/or *M. gypseum* in an effective amount optionally combined with an adjuvant; U.S. Pat. Nos. 5,453,273 and 6,132,733 for a ringworm vaccine comprising an effective amount of a homogenized, formaldehyde-killed fungi, i.e., *Microsporum canis* culture in a carrier; U.S. Pat. No. 5,948,413 involving extracellular and intracellular proteins for pythiosis. Additional antigens identified within antifungal vaccines include Ringvac bovis LTF-130 and Bioveta.

[0937] Further, fungal antigens for use herein may be derived from Dermatophytes, including: *Epidermophyton floccosum*, *Microsporum audouini*, *Microsporum canis*, *Microsporum distortum*, *Microsporum equinum*, *Microsporum gypseum*, *Microsporum nanum*, *Trichophyton concentricum*, *Trichophyton equinum*, *Trichophyton gallinae*, *Trichophyton gypseum*, *Trichophyton megnini*, *Trichophyton mentagrophytes*, *Trichophyton quinckeanum*, *Trichophyton rubrum*, *Trichophyton schoenleinii*, *Trichophyton tonsurans*, *Trichophyton verrucosum*, *T. verrucosum* var. *album*, var. *discoides*, var. *ochraceum*, *Trichophyton violaceum*, and/or *Trichophyton favifoprine*.

[0938] Fungal pathogens for use as antigens or in derivation of antigens in conjunction with the compositions of the present invention comprise *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus niger*, *Aspergillus nidulans*, *Aspergillus terreus*, *Aspergillus sydowii*, *Aspergillus flavus*, *Aspergillus glaucus*, *Blastoschizomyces capitatus*, *Candida albicans*, *Candida enolase*, *Candida tropicalis*, *Candida glabrata*, *Candida krusei*, *Candida parapsilosis*, *Candida stellatoidea*, *Candida kusei*, *Candida parakwsei*, *Candida lusitanae*, *Candida pseudotropicalis*, *Candida guillienndi*, *Cladosporium carrionii*, *Coccidioides immitis*, *Blastomyces dermatidis*, *Cryptococcus neoformans*, *Geotrichum clavatum*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Paracoccidioides brasiliensis*, *Pneumocystis carinii*, *Pythilann insidiosum*, *Pityrosporum ovale*, *Sacharomyces cerevisiae*, *Sacharomyces boulardii*, *Sacharomyces pombe*, *Scedosporium apiospermum*, *Sporothrix schenckii*, *Trichosporon beigelii*, *Toxoplasma gondii*, *Penicillium marneffei*, *Malassezia* spp., *Fonsecaea* spp., *Wangiella* spp., *Sporothrix* spp., *Basidiobolus* spp., *Conidiobolus* spp., *Rhizopus* spp., *Mucor* spp., *Absidia* spp., *Mortierella* spp., *Cunninghamella* spp., and *Saksenaia* spp.

[0939] Other fungi from which antigens are derived include *Alternaria* spp., *Curvularia* spp., *Helminthosporium* spp., *Fusarium* spp., *Aspergillus* spp., *Penicillium* spp., *Monolinia* spp., *Rhizoctonia* spp., *Paecilomyces* spp., *Pithomyces* spp., and *Cladosporium* spp.

[0940] Processes for producing a fungal antigens are well known in the art (see U.S. Pat. No. 6,333,164). In a preferred method a solubilized fraction extracted and separated from an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed, characterized in that the process comprises the steps of: obtaining living fungal cells; obtaining fungal cells

of which cell wall has been substantially removed or at least partially removed; bursting the fungal cells of which cell wall has been substantially removed or at least partially removed; obtaining an insoluble fraction; and extracting and separating a solubilized fraction from the insoluble fraction.

STD Antigens

[0941] Embodiments of the invention include compositions and methods related to a prophylactic and therapeutic treatments for microbes that can be neutralized prior to infection of a cell. In particular embodiments, microbes (bacteria, viruses and/or fungi) against which the present compositions and methods can be implement include those that cause sexually transmitted diseases (STDs) and/or those that display on their surface an antigen that can be the target or antigen composition of the invention. In a preferred embodiment of the invention, compositions are combined with antigens derived from a viral or bacterial STD. Antigens derived from bacteria or viruses can be administered in conjunction with the compositions of the present invention to provide protection against at least one of the following STDs, among others: chlamydia, genital herpes, hepatitis (particularly HCV), genital warts, gonorrhoea, syphilis and/or chancroid (See, WO00/15255).

[0942] In another embodiment the compositions of the present invention are co-administered with an antigen for the prevention or treatment of an STD.

[0943] Antigens derived from the following viruses associated with STDs, which are described in greater detail above, are preferred for co-administration with the compositions of the present invention: hepatitis (particularly HCV), HPV, HIV, or HSV.

[0944] Additionally, antigens derived from the following bacteria associated with STDs, which are described in greater detail above, are preferred for co-administration with the compositions of the present invention: *Neisseria gonorrhoeae*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Treponema pallidum*, or *Haemophilus ducreyi*.

Respiratory Antigens

[0945] The invention provides methods of preventing and/or treating infection by a respiratory pathogen, including a virus, bacteria, or fungi such as respiratory syncytial virus (RSV), PIV, SARS virus, influenza, *Bacillus anthracis*, particularly by reducing or preventing infection and/or one or more symptoms of respiratory virus infection. A composition comprising an antigen described herein, such as one derived from a respiratory virus, bacteria or fungus is administered in conjunction with the compositions of the present invention to an individual which is at risk of being exposed to that particular respiratory microbe, has been exposed to a respiratory microbe or is infected with a respiratory virus, bacteria or fungus. The composition(s) of the present invention is/are preferably co-administered at the same time or in the same formulation with an antigen of the respiratory pathogen. Administration of the composition results in reduced incidence and/or severity of one or more symptoms of respiratory infection.

Tumor Antigens

[0946] One embodiment of the present involves a tumor antigen or cancer antigen in conjunction with the compositions of the present invention. Tumor antigens can be, for

example, peptide-containing tumor antigens, such as a polypeptide tumor antigen or glycoprotein tumor antigens. A tumor antigen can also be, for example, a saccharide-containing tumor antigen, such as a glycolipid tumor antigen or a ganglioside tumor antigen. The tumor antigen can further be, for example, a polynucleotide-containing tumor antigen that expresses a polypeptide-containing tumor antigen, for instance, an RNA vector construct or a DNA vector construct, such as plasmid DNA.

[0947] Tumor antigens appropriate for the practice of the present invention encompass a wide variety of molecules, such as (a) polypeptide-containing tumor antigens, including polypeptides (which can range, for example, from 8-20 amino acids in length, although lengths outside this range are also common), lipopolypeptides and glycoproteins, (b) saccharide-containing tumor antigens, including poly-saccharides, mucins, gangliosides, glycolipids and glycoproteins, and (c) polynucleotides that express antigenic polypeptides.

[0948] The tumor antigens can be, for example, (a) full length molecules associated with cancer cells, (b) homologs and modified forms of the same, including molecules with deleted, added and/or substituted portions, and (c) fragments of the same. Tumor antigens can be provided in recombinant form. Tumor antigens include, for example, class I-restricted antigens recognized by CD8⁺ lymphocytes or class II-restricted antigens recognized by CD4⁺ lymphocytes.

[0949] Numerous tumor antigens are known in the art, including: (a) cancer-testis antigens such as NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to address melanoma, lung, head and neck, NSCLC, breast, gastrointestinal, and bladder tumors), (b) mutated antigens, for example, p53 (associated with various solid tumors, e.g., colorectal, lung, head and neck cancer), p21/Ras (associated with, e.g., melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, e.g., melanoma), MUM1 (associated with, e.g., melanoma), caspase-8 (associated with, e.g., head and neck cancer), CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701, beta catenin (associated with, e.g., melanoma), TCR (associated with, e.g., T-cell non-Hodgkins lymphoma), BCR-abl (associated with, e.g., chronic myelogenous leukemia), triosephosphate isomerase, KIA 0205, CDC-27, and LDLR-FUT, (c) over-expressed antigens, for example, Galectin 4 (associated with, e.g., colorectal cancer), Galectin 9 (associated with, e.g., Hodgkin's disease), proteinase 3 (associated with, e.g., chronic myelogenous leukemia); WT 1 (associated with, e.g., various leukemias), carbonic anhydrase (associated with, e.g., renal cancer), aldolase A (associated with, e.g., lung cancer), PRAME (associated with, e.g., melanoma), HER-2/neu (associated with, e.g., breast, colon, lung and ovarian cancer), alpha-fetoprotein (associated with, e.g., hepatoma), KSA (associated with, e.g., colorectal cancer), gastrin (associated with, e.g., pancreatic and gastric cancer), telomerase catalytic protein, MUC-1 (associated with, e.g., breast and ovarian cancer), G-250 (associated with, e.g., renal cell carcinoma), p53 (associated with, e.g., breast, colon cancer), and carcinoembryonic antigen (associated with, e.g., breast cancer, lung cancer, and cancers of the gastrointestinal tract such as colorectal cancer), (d) shared antigens, for example, melanoma-melanocyte differentiation antigens such as MART-1/Melan A, gp100, MC¹R, melanocyte-stimulating hormone receptor, tyrosinase, tyro-

sinase related protein-1/TRP1 and tyrosinase related protein-2/TRP2 (associated with, e.g., melanoma), (e) prostate associated antigens such as PAP, PSA, PSMA, PSH-P1, PSM-P1, PSM-P2, associated with e.g., prostate cancer, (f) immunoglobulin idiotypes (associated with myeloma and B cell lymphomas, for example), and (g) other tumor antigens, such as polypeptide- and saccharide-containing antigens including (i) glycoproteins such as sialyl Tn and sialyl Le^x (associated with, e.g., breast and colorectal cancer) as well as various mucins; glycoproteins may be coupled to a carrier protein (e.g., MUC-1 may be coupled to KLH); (ii) lipopolypeptides (e.g., MUC-1 linked to a lipid moiety); (iii) polysaccharide s (e.g., Globo H synthetic hexasaccharide), which may be coupled to a carrier proteins (e.g., to KLH), (iv) gangliosides such as GM2, GM12, GD2, GD3 (associated with, e.g., brain, lung cancer, melanoma), which also may be coupled to carrier proteins (e.g., KLH). Additional tumor antigens which are known in the art include p15, Hom/MeI-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein Barr virus antigens, EBNA, human papillomavirus (HPV) antigens, including E6 and E7, hepatitis B and C virus antigens, human T-cell lymphotropic virus antigens, TSP-180, p185erbB2, p180erbB-3, c-met, mn-23H1, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, p16, TAGE, PSCA, CT7, 43-9F, 5T4, 791 Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA 195, CA 2-42, CA-50, CAM43, CD68/KP1, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175, M344-, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 (Mac-2 binding protein/cyclophilin C-associated protein), TAAL6, TAG72, TLP, TPS, and the like. These as well as other cellular components are described for example in United States Patent Application 20020007173 and references cited therein.

[0950] Polynucleotide-containing antigens in accordance with the present invention typically comprise polynucleotides that encode polypeptide cancer antigens such as those listed above. Preferred polynucleotide-containing antigens include DNA or RNA vector constructs, such as plasmid vectors (e.g., pCMV), which are capable of expressing polypeptide cancer antigens in vivo.

[0951] Tumor antigens may be derived, for example, from mutated or altered cellular components. After alteration, the cellular components no longer perform their regulatory functions, and hence the cell may experience uncontrolled growth. Representative examples of altered cellular components include ras, p53, Rb, altered protein encoded by the Wilms' tumor gene, ubiquitin, mucin, protein encoded by the DCC, APC, and MCC genes, as well as receptors or receptor-like structures such as neu, thyroid hormone receptor, platelet derived growth factor (PDGF) receptor, insulin receptor, epidermal growth factor (EGF) receptor, and the colony stimulating factor (CSF) receptor. These as well as other cellular components are described for example in U.S. Pat. No. 5,693, 522 and references cited therein.

[0952] Additionally, bacterial and viral antigens, may be used in conjunction with the compositions of the present invention for the treatment of cancer. In particular, carrier proteins, such as CRM₁₉₇, tetanus toxoid, or *Salmonella typhimurium* antigen can be used in conjunction/conjugation with compounds of the present invention for treatment of cancer. The cancer antigen combination therapies will show increased efficacy and bioavailability as compared with existing therapies.

[0953] Additional information on cancer or tumor antigens can be found, for example, in

Moingeon P, "Cancer vaccines," *Vaccine*, 2001, 19:1305-1326; Rosenberg SA, "Progress in human tumor immunology and immunotherapy," *Nature*, 2001, 411:380-384; Dermine, S. et al, "Cancer Vaccines and Immunotherapy," *British Medical Bulletin*, 2002, 62, 149-162; Espinoza-Delgado I., "Cancer Vaccines," *The Oncologist*, 2002, 7(suppl3):20-33; Davis, I. D. et al., "Rational approaches to human cancer immunotherapy," *Journal of Leukocyte Biology*, 2003, 23: 3-29; Van den Eynde B, et al., "New tumor antigens recognized by T cells," *Curr. Opin. Immunol.*, 1995, 7:674-81; Rosenberg SA, "Cancer vaccines based on the identification of genes encoding cancer regression antigens," *Immunol. Today*, 1997, 18:175-82; Offringa R et al., "Design and evaluation of antigen-specific vaccination strategies against cancer," *Current Opin. Immunol.*, 2000, 2:576-582; Rosenberg SA, "A new era for cancer immunotherapy based on the genes that encode cancer antigens," *Immunity*, 1999, 10:281-7; Sahin U et al., "Serological identification of human tumor antigens," *Curr. Opin. Immunol.*, 1997, 9:709-16; Old L J et al., "New paths in human cancer serology," *J. Exp. Med.*, 1998, 187:1163-7; Chaux P, et al., "Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes," *J. Exp. Med.*, 1999, 189:767-78; Gold P, et al., "Specific carcinoembryonic antigens of the human digestive system," *J. Exp. Med.*, 1965, 122:467-8; Livingston P C, et al., Carbohydrate vaccines that induce antibodies against cancer: Rationale," *Cancer Immunol. Immunother.*, 1997, 45:1-6; Livingston P0, et al., Carbohydrate vaccines that induce antibodies against cancer: Previous experience and future plans," *Cancer Immunol. Immunother.*, 1997, 45:10-9; Taylor-Papadimitriou J, "Biology, biochemistry and immunology of carcinoma-associated mucins," *Immunol. Today*, 1997, 18:105-7; Zhao X-J et al., "GD2 oligosaccharide: target for cytotoxic T lymphocytes," *J. Exp. Med.*, 1995, 182:67-74; Theobald M, et al., "Targeting p53 as a general tumor antigen," *Proc. Natl. Acad. Sci. USA*, 1995, 92:11993-7; Gaudemack G, "T cell responses against mutant ras: a basis for novel cancer vaccines," *Immunotechnology*, 1996, 2:3-9; WO 91/02062; U.S. Pat. No. 6,015,567; WO 01/08636; WO 96/30514; U.S. Pat. No. 5,846,538; and U.S. Pat. No. 5,869,445.

Pediatric/Geriatric Antigens.

[0954] In one embodiment the compositions of the present invention are used in conjunction with an antigen for treatment of a pediatric population, as in a pediatric antigen. In a more particular embodiment the pediatric population is less than about 3 years old, or less than about 2 years, or less than about 1 years old. In another embodiment the pediatric antigen (in conjunction with the composition of the present invention) is administered multiple times over at least 1, 2, or 3 years.

[0955] In another embodiment the compositions of the present invention are used in conjunction with an antigen for treatment of a geriatric population, as in a geriatric antigen.

Other Antigens

[0956] Other antigens for use in conjunction with the compositions of the present include hospital acquired (nosocomial) associated antigens.

[0957] In another embodiment, parasitic antigens are contemplated in conjunction with the compositions of the present invention. Examples of parasitic antigens include those derived from organisms causing malaria and/or Lyme disease.

[0958] In another embodiment, the antigens in conjunction with the compositions of the present invention are associated with or effective against a mosquito born illness.

[0959] In another embodiment, the antigens in conjunction with the compositions of the present invention are associated with or effective against encephalitis. In another embodiment the antigens in conjunction with the compositions of the present invention are associated with or effective against an infection of the nervous system.

[0960] In another embodiment, the antigens in conjunction with the compositions of the present invention are antigens transmissible through blood or body fluids.

Antigen Formulations

[0961] In other aspects of the invention, methods of producing microparticles having adsorbed antigens are provided. The methods comprise: (a) providing an emulsion by dispersing a mixture comprising (i) water, (ii) a detergent, (iii) an organic solvent, and (iv) a biodegradable polymer selected from the group consisting of a poly(α -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate. The polymer is typically present in the mixture at a concentration of about 1% to about 30% relative to the organic solvent, while the detergent is typically present in the mixture at a weight-to-weight detergent-to-polymer ratio of from about 0.00001:1 to about 0.1:1 (more typically about 0.0001:1 to about 0.1:1, about 0.001:1 to about 0.1:1, or about 0.005:1 to about 0.1:1); (b) removing the organic solvent from the emulsion; and (c) adsorbing an antigen on the surface of the microparticles. In certain embodiments, the biodegradable polymer is present at a concentration of about 3% to about 10% relative to the organic solvent.

[0962] Microparticles for use herein will be formed from materials that are sterilizable, non-toxic and biodegradable. Such materials include, without limitation, poly(α -hydroxy acid), polyhydroxybutyric acid, polycaprolactone, polyorthoester, polyanhydride, PACA, and polycyanoacrylate. Preferably, microparticles for use with the present invention are derived from a poly(α -hydroxy acid), in particular, from a polylactide ("PLA") or a copolymer of D,L-lactide and glycolide or glycolic acid, such as a poly(D,L-lactide-co-glycolide) ("PLG" or "PLGA"), or a copolymer of D,L-lactide and caprolactone. The microparticles may be derived from any of various polymeric starting materials which have a variety of molecular weights and, in the case of the copolymers such as PLG, a variety of lactide:glycolide ratios, the selection of which will be largely a matter of choice, depending in part on the coadministered macromolecule. These parameters are discussed more fully below.

[0963] Further antigens may also include an outer membrane vesicle (OMV) preparation.

[0964] Additional formulation methods and antigens (especially tumor antigens) are provided in U.S. patent Ser. No. 09/581,772.

ANTIGEN REFERENCES

[0965] The following references include antigens useful in conjunction with the compositions and methods of the present invention:

- [0966] 1 International patent application WO99/24578
- [0967] 2 International patent application WO99/36544.
- [0968] 3 International patent application WO99/57280.
- [0969] 4 International patent application WO00/22430.
- [0970] 5 Tettelin et al. (2000) Science 287:1809-1815.
- [0971] 6 International patent application WO96/29412.
- [0972] 7 Pizza et al. (2000) Science 287:1816-1820.
- [0973] 8 PCT WO 01/52885.
- [0974] 9 Bjune et al. (1991) Lancet 338(8775).
- [0975] 10 Fuskasawa et al. (1999) Vaccine 17:2951-2958.
- [0976] 11 Rosenqist et al. (1998) Dev. Biol. Strand 92:323-333.
- [0977] 12 Constantino et al. (1992) Vaccine 10:691-698.
- [0978] 13 Constantino et al. (1999) Vaccine 17:1251-1263.
- [0979] 14 Watson (2000) Pediatr Infect Dis J 19:331-332.
- [0980] 15 Rubin (20000) Pediatr Clin North Am 47:269-285.v.
- [0981] 16 Jedrzejewski (2001) Microbiol Mol Biol Rev 65:187-207.
- [0982] 17 International patent application filed on 3rd Jul. 2001 claiming priority from GB-0016363 4; WO 02/02606; PCT IB/01/00166.
- [0983] 18 Kalman et al. (1999) Nature Genetics 21:385-389.
- [0984] 19 Read et al. (2000) Nucleic Acids Res 28:1397-406.
- [0985] 20 Shirai et al. (2000) J. Infect. Dis 181(Suppl 3):S524-S527.
- [0986] 21 International patent application WO99/27105.
- [0987] 22 International patent application WO00/27994.
- [0988] 23 International patent application WO00/37494.
- [0989] 24 International patent application WO99/28475.
- [0990] 25 Bell (2000) Pediatr Infect Dis J 19:1187-1188.
- [0991] 26 Iwarson (1995) APMIS 103:321-326.
- [0992] 27 Gerlich et al. (1990) Vaccine 8 Suppl:S63-68 & 79-80.
- [0993] 28 Hsu et al. (1999) Clin Liver Dis 3:901-915.
- [0994] 29 Gastofsson et al. (1996) N. Engl. J. Med. 334:349-355.
- [0995] 30 Rappuoli et al. (1991) TIBTECH 9:232-238.
- [0996] 31 Vaccines (1988) eds. Plotkin. & Mortimer. ISBN 0-7216-1946-0.
- [0997] 32 Del Guidice et al. (1998) Molecular Aspects of Medicine 19:1-70.
- [0998] 33 International patent application WO93/018150.
- [0999] 34 International patent application WO99/53310.
- [1000] 35 International patent application WO98/04702.
- [1001] 36 Ross et al. (2001) Vaccine 19:135-142.
- [1002] 37 Sutter et al. (2000) Pediatr Clin North Am 47:287-308.
- [1003] 38 Zimmerman & Spann (1999) Am Fam Physician 59:113-118, 125-126.
- [1004] 39 Dreensen (1997) Vaccine 15 Suppl:S2-6.
- [1005] 40 MMWR Morb Mortal Wkly rep 1998 Jan 16:47 (1):12, 9.
- [1006] 41 McMichael (2000) Vaccine 19 Suppl 1:S101-107.
- [1007] 42 Schuchat (1999) Lancet 353 (9146):51-6.
- [1008] 43 GB patent applications 0026333.5, 0028727.6 & 0105640.7.
- [1009] 44 Dale (1999) Infect Disclin North Am 13:227-43, viii.
- [1010] 45 Ferretti et al. (2001) PNAS USA 98: 4658-4663.
- [1011] 46 Kuroda et al. (2001) Lancet 357(9264):1225-1240; see also pages 1218-1219.
- [1012] 47 Ramsay et al. (2001) Lancet 357(9251):195-196.
- [1013] 48 Lindberg (1999) Vaccine 17 Suppl 2:S28-36.

- [1014] 49 Buttery & Moxon (2000) J R Coil Physicians Long 34:163-168.
- [1015] 50 Ahmad & Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii.
- [1016] 51 Goldblatt (1998) J. Med. Microbiol. 47:663-567.
- [1017] 52 European patent 0 477 508.
- [1018] 53 U.S. Pat. No. 5,306,492.
- [1019] 54 International patent application WO98/42721.
- [1020] 55 Conjugate Vaccines (eds. Cruse et al.) ISBN 3805549326, particularly vol. 10:48-114.
- [1021] 56 Hermanson (1996) bioconjugate Techniques ISBN: 012323368 & 012342335X.
- [1022] 57 European patent application 0372501.
- [1023] 58 European patent application. 0378881.
- [1024] 59 European patent application. 0427347.
- [1025] 60 International patent application WO93/17712.
- [1026] 61 International patent application WO98/58668.
- [1027] 62 European patent application 0471177.
- [1028] 63 International patent application WO00/56360.
- [1029] 64 International patent application WO00/67161.
- [1030] The contents of all of the above cited patents, patent applications and journal articles are incorporated by reference as if set forth fully herein.
- [1031] Nomenclature for the Example compounds was provided using ACD Name version 5.07 software (Nov. 14, 2001) available from Advanced Chemistry Development, Inc. Some of the compounds and starting materials were named using standard IUPAC nomenclature.
- [1032] The foregoing may be better understood by reference to the following Examples, Methods, and Schemes that are presented for illustration and not to limit the scope of the inventive concepts. Those groups of compounds that do not have experimental procedures relating to their synthesis are either commercially available, described by procedures incorporated herein by reference, or are easily synthesized by one skilled in the art from easily recognizable, commercially available starting materials.
- [1033] All patents, patent applications and publications referred to herein are incorporated by reference in their entirety.

EXAMPLES


I. Synthetic

[1034] Unless otherwise specified, the numbering of the R groups in the Examples section is not meant to correspond to the numbering used throughout the rest of the specification. Reference to a particular reaction by name will be apparent to one skilled in the art and/or described in: Name Reactions and Reagents in Organic Synthesis, Mundy et al. 1988, which is incorporated by reference. Additionally, particular reagents may be added, or reactions modified as will be apparent to one skilled in the art and/or as described in: March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Edition.


Synthesis of Example 83

[1035] Synthesis of analogs of 5'-modified derivatives of bredinin, the 5'-phosphate 2, the 5'-deoxy derivative 3, and the 5'-O-(3-aminopropyl)carbamate 4 (FIG. 1) were attempted.

Fig. 1




-continued





2

-continued





8

3





6

4




7

Scheme 1




5




[1036] A phosphoramidite method with o-xylene N,N-diethylphosphoramidite (XEPA) is effective in this system (Scheme 2). Treatment of 17 with (EPA and tetrazole in CH_2Cl_2 , followed by oxidation with aq. I_2 , gives the corresponding 5'-phosphotriester 19 in 70% yield. The isopropylidene and Boc groups of 19 are removed simultaneously with 90% aq. TEA, and the resulting product, without purification, is heated with $(\text{EtO})_3\text{CH}$ in DMF at 90°C . to give the bredinin 5'-phosphate derivative 20 in 47% yield from 19. Hydrogenation of 20 with Pd-carbon in MeOH furnished bredinin 5'-phosphate 2, which is isolated as a disodium salt in 89% yield, after successive treatment with Dowex 50 (H^+) and Diaion WK-20 (Na^+) resins.

Scheme 2




-continued




Synthesis of Example 102

[1037]

Scheme 3



Scheme 4



Synthesis of Cyclosporin Examples (111-115)

[1038] Most naturally occurring cyclosporins studied, include most of N-desMe analogues, and can be produced by the common strain of *Tolypocladium inflatum* Gams (NRRL

modified and specific aspects of the structure-activity relationships examined one after the other.

[1040] For the synthesis of the undecapeptide, a fragment-condensation technique introducing the amino acid MeBmt at




FIG. 1. a Schematic representation of the structure and conformation of the cyclosporin in the solid state. b Schematic representation of the structure and conformation of the cyclosporin in the apolar solvents. The two peptide conformations are very similar: the main difference lies in the orientation of the carbon chain of the MeBmt amino acid and a minor variation is the presence of a three-center hydrogen bond in solution.

8044), but several other fungi could provide either limited panels of cyclosporin analogues, such as *Cylindrotrichum oligospermum* (SDZ 214-103 and all of its [Thr², D-Hiv⁸, Leu¹⁰]-CsA congeners), or unique cyclosporins such as *Acremonium luzulae* (Fuckel) W. Gams ([Thr², Leu⁵, Ala¹⁰], *Tolypocladium terricola* ([Leu⁴]-CsA), a mutant strain of *Tolypocladium inflatum* NRRL 8044 ([Thr², Leu¹⁰]-CsA), and a *Leptostroma* anamorph of *Hypoderma eucalyptii* Cooke and Harkn ([Thr², Ile⁵]-CsA). Most other analogues are obtained by precursor-directed biosynthesis, and other analogues can be obtained by chemical modification. For the synthesis of cyclosporin, the peptide bond between the L-alanine in position 7 and the D-alanine in position 8 is chosen for the cyclization step for two main reasons. The intrachain H-bonds between amide groups of the linear peptide may operate so as to stabilize the open chain in folded conformations approximating the cyclic structure of cyclosporin and thus assist cyclization. The strategy is at so specifically chosen to preclude an N-methylamino acid at the N- and C-terminus of the undecapeptide, since bond formation between N-methylated amino acid residues presents more difficulties than for non-N-methylated derivatives. Therefore, bond formation between the only consecutive pair of non-Nmethylated amino acids in cyclosporin is the logical choice for the cyclization step.

[1039] Using the synthetic approach potentially any amino acid of the peptide chain of cyclosporin (FIG. 1a) can be

the end of the synthesis is used. In this way, the number of steps after the introduction of this amino acid is minimized. The peptide fragments are built up in the direction shown by the arrows in FIG. 3 using the step sequence which is indicated numerically. The amino groups of the amino acids and peptides being reacted are protected with a tert-butoxycarbonyl group (Boc) and the carboxy groups with a benzyloxy group (benzylester; OBzl). The carboxy groups are generally activated using a variation of the mixed pivalic anhydride method reported by Zaoral [14] and adapted by us for N-methyl-amino-acid derivatives [15] allowing slow anhydride formation in CHCl₃ at -20 C with pivaloylchloride (=trimethylacetyl chloride) in presence of 2 equivalents of a tertiary base such as N-methylmorpholine before adding the amino acid or peptide esters to be coupled as free bases. The Boc-protecting groups of the peptide intermediates are removed with CF₃COOH at -20 C, the acids neutralized with NaHCO₃ and the peptide bases isolated. The benzyloxy protecting groups of the peptide intermediates are removed with H₂ and Pd on C in ethanol. The tetrapeptide Boc-D-Ala-MeLeu-MeLeu-vIeVal-OBzl was made from the left to the right by forming bonds 1, 2 and 3 (FIG. 3). Bond 4 is made and the dipeptide Boc-Abu-Sar-OBzl synthesized. The tetrapeptide Boc-MeLeu-Val-MeLeu-Ala-OBzl is synthesized from the left to the right by forming bonds 5, 6 and 7 in that order. Then,

by forming the bond 8, the hexapeptide Boc-Abu-Sar-Me-Leu-Val-MeLeu-ALa-OBzl is prepared. To prepare the protected heptapeptide from the protected MeBmt amino acid and the hexapeptide, the dicyclohexylcarbodiimide (DCCI) coupling method is used in presence of N-hydroxybenztriazol (BtOH). The final amide linkage 10 is made to produce the undecapeptide Boc-D-Ala-MeLeu-MeLeu-MeVal-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-Obzl by coupling Boc-D-Ala-MeLeta-MeLeu-MeVal-OH with the heptapeptide by using the reagent (1H-benzo[d][1, 2, 3]triazol-1-yloxy)-tris-(dimethylamino) phosphonium hexafluorophosphate, developed by Castro et al., in presence of N-methylmorpholine in CH_2Cl_2 at room temperature. The ester group of the undecapeptide is removed by hydrolysis with NaOH at 0 C and the Boc group with CF_3COOH at -20°C , then, the unprotected H-D-Ala-MeLeu-MeLeu-MeVal-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-OH is cyclized in CH_2Cl_2 (0.0002 M) using 4 equivalents of propane phosphonic acid anhydride ($\text{CH}_3\text{CH}_2\text{CH}_2\text{POVn}$ in presence of 5 equivalents of 4-dimethylaminopyridine (1 day at room temperature) to give crystalline cyclosporin, isolated in 65% yield. Using this fragment-condensation technique, it is now possible to synthesize very efficiently cyclosporin in 30% yield with respect to the amino acid MeBmt. Thus, due to the molecular weight increase during this synthesis, 1.7 g of cyclosporin can be produced starting from 1 g of the amino acid MeBmt.






FIG. 2. Synthesis of the amino acid (4R)-4-[(E)-2-butenyl]-4,N-dimethyl-L-threonine (MeBmt.). (1) First operation: formation of the asymmetric centers C-3 and C-4 of the MeBmt amino acid. (a) $\text{C}_2\text{H}_5\text{OH}/\text{HCl}$ (esterification); (b) $\text{C}_6\text{H}_5\text{CHO}/\text{HC}(\text{OC}_2\text{H}_5)_3/\text{TsOH}\cdot\text{H}_2\text{O}$ (OH-protection); (c) LiAlH_4 (ester reduction); (d) $\text{C}_6\text{H}_5\text{CH}_2\text{Br}/\text{KOH}$ (OH-Benzylation); (e) N-bromosuccinimide; (f) $\text{KOH}/\text{C}_2\text{H}_5\text{OH}$ (e + f. epoxidation); (g) $2\text{CH}_3\text{Li}/\text{CuI}$ (methylation); (h) Pd/H_2 (debenzylation). (2) Second operation: introduction of the carbon chain containing a trans double bond. (i) $(\text{CH}_3)_2\text{C}(\text{OCH}_3)_2/\text{TsOH}\cdot\text{H}_2\text{O}$ (protection of the vicinal OH-groups); (k) TsCl/Py (tosylate formation); (l) KCN/DMSO (nitrile formation); (m) DIBAH (reduction of aldehyde); (n) $(\text{C}_6\text{H}_5)_3\text{P}^+ \text{---} \text{C}_2\text{H}_5\text{Br}^-/\text{BuLi}$ (Wittig reaction); (o) 1.1 eq. 0.1 N HCl in $\text{THF}/\text{H}_2\text{O}$ (deprotection of the OH-groups). (3) Third operation: introduction of the methylamino and carboxy groups. (p) $\text{DCCI}/\text{DMSO}/\text{C}_6\text{H}_6/\text{Py}/\text{TFA}$ (Moffatt-oxidation); (q) $\text{KCN}/\text{CH}_3\text{NH}_2 \text{---} \text{HCl}/\text{CH}_3\text{OH} \text{---} \text{H}_2\text{O}$ (cyanamine formation); (r) 1,1'-carbonyldiimidazole/ CH_2Cl_2 (oxazolidine-2-one formation); (s) $\text{K}_2\text{CO}_3/\text{C}_2\text{H}_5\text{OH}$ (conversion to an ethylcarboximate); (t) 1 N HCl in $\text{C}_2\text{H}_5\text{OH}$ (hydrolysis to a N,O-carbonyl-MeBmt $\text{---} \text{OC}_2\text{H}_5$); (u) 2 N $\text{KOH}/\text{H}_2\text{O}/80^\circ\text{C}$. then HCl (deprotection and isolation of the H-MeBmt $\text{---} \text{OH}$ amino acid).


Ⓢ indicates text missing or illegible when filed


FIG. 4. Synthetic analogues of cyclosporin (strategy for their synthesis).



-continued

	8	9	10	11	1	2	3	4	5	6			
Boc	OH	H	OBzl										
Boc			OBzl								80		
Boc		OH	H	OBzl							97		
Boc			OBzl								80		
Boc			OH	H	OBzl						92		
Boc				OBzl							88		
Boc				OH							81		
					Boc	OH	H	OBzl					
					Boc			OBzl			87		
					Boc			OH			98		
									Boc	OH	H	OBzl	89
									Boc			OBzl	91
									Boc	OH	H		88
												OBzl	97
									Boc			OBzl	97
									Boc	OH	H		98
									Boc			OBzl	88
									Boc	OH	H		83
									Boc			OBzl	90
									Boc			OBzl	95
												OBzl	80
Boc												OH	67
Boc												OH	87
Boc													
H													






Ⓢ indicates text missing or illegible when filed

Synthesis of Example 129

[1041]





[1042] Reagents are added together in MeOH (or CH₂Cl₂ or THF) and stirred for at least 0.5 h at RT. To facilitate the reaction, the solution may be heated. Progress is monitored by TLC and HPLC. Work-up involves quenching with aqueous solution and extracting product in CH₂Cl₂.

Synthesis of Example 130

[1043] The syntheses of the compounds (4a, 5a-d) are outlined in Scheme 7. 5-Substituted 2-mercapto-1H-benzimidazoles (2a, b) are synthesized from corresponding acetanilide derivatives (1a, b). [10] 4-Substituted 2-(chloromethyl)pyridines (3a-c) are purchased or derived from corresponding


picoline-1-oxides via Pummerer-like rearrangement and chlorination with thionyl chloride in chloroform. Coupling reactions of 3a-c with 2a or 2b are performed in aqueous basic conditions to obtain the sulfenyl derivatives (4a-d), and continuous selective oxidation of the benzimidazolyl sulfur atom using m-chloroperbenzoic acid are subjected to obtain sulfoxides 5a-d.





Synthesis of Example 133


[1044] The synthesis of (alkylimino)-1,4-dihydroquinolines is illustrated in Scheme 8. The key synthetic precursors, 4-chloroquinolines **12**, are prepared from commercially available anilines according to the well-established route of Price and Roberts. Conversion into the hexyl ether analog **13** is accomplished by treatment of 4-chloroquinoline with hexanol in the presence of base and phase transfer catalyst tris [2-(2-methoxyethoxy)-ethyl]amine, TDA-1. The alkylamine group is installed using a modified procedure of the Surrey method, whereby the 4-chloroquinoline derivative **12** is heated with an excess of alkylamine to furnish 4-(alkylamino)quinoline **14**. Alkylation on the quinoline nitrogen was performed by treatment of the 4-substituted quinolines **13** and **14** with the appropriate alkyl halide or benzylic halide to afford target molecules.




^aReagents: (a) hexanol, TDA-1, KOH, K₂CO₃; (b) alkylamine, Δ; (c) BnBr, Δ; (d) R'X.

Synthesis of Example 145

[1045]





(a) LiOH, 3:1 MeOH/H₂O, 60° C., 86%; (b) oxalyl chloride/benzene, 0° C. → 23° C., 2 h, 100%;
 (c) (S)-(+)-2-phenylglycinol/CH₂Cl₂, 0° C. → 23° C., 0.75 h, 75-87%; (d) 3M HCl (aq),
 1,4-dioxane, reflux, 2.5 h, 62%; (e) fluoroethylamine, 0° C. → 23° C., 0.75 h, 85%.

[1046] Example 145 (+)-2-methylarachidonyl-2'-fluoroethylamide (4) (Scheme 9), is synthesized from methyl arachidonate by o-alkylation with methyl iodide to give ester (+)-1, which is hydrolyzed to afford acid (+)-3. It is converted to its acid chloride and treated with excess fluoroethylamine to give the final product.

[1047] The current objective is accomplished by performing a resolution of the acid precursor and then converting it to the enantiomeric products. To resolve acid (+)-3, it is converted to its acid chloride and then treated with (S)-(+)-2-phenylglycinol to give amide 2 as a diastereomeric mixture which is easily separated by flash chromatography to give diastereomers 2a (87%; R_f 0.37 (50% ethyl acetate/hexanes); [α]_D²⁵ +54° (c 0.14, MeOH)) and 2b (75%; R_f 0.19 (50% ethyl acetate/hexanes); [α]_D²⁵ +28° (c 0.15, MeOH)). Each amide is hydrolyzed to give the corresponding enantiomeric acids 3a (62%) and 3b (77%). To check the enantiomeric purity of acids 3a and 3b (i.e., to verify that no racemization occurred during the amide hydrolysis), they are again converted to their respective diastereomeric amides 2 and analyzed by HPLC eluting with 55% ethyl acetate/hexanes. Regenerated diastereomer 2a shows a single peak eluting at R_t 7.69 min, which indicated >98% ee. The optical purity of 3b is determined similarly—HPLC analysis of regenerated 2b (R_t 15.82 min) indicating 98% ee (i.e., 1% of diastereomer 2a is detected).


[1048] The enantiomeric acids 3a and 3b are then converted to the target fluoroethylamides (+)-4a and (-)-4b as described above for the racemic compound. Enantiomer (+)-4a is obtained in 82% yield; [α]_D²⁵ +19.9° (c 0.99, MeOH); MS m/z 364 (M+1). Similarly enantiomer (-)-4b is obtained in 89% yield; [α]_D²⁵ -17.1° (c 0.98, MeOH); MS m/z 364 (M+1). Finally, assuming there is no further racemization during the conversion of acids 3a/3b to fluoroethylamides 4a/4b, (a reasonable assumption considering that the same reaction procedures are used when regenerating amides 2a/2b), assuming that amide 4a is >98% ee and that amide 4b was 98% ee, corresponding to the ee's of the regenerated amides 2a/2b, which is consistent with the optical rotations of 4a and 4b within experimental error.


Synthesis of Examples 134-136

[1049] The approach described in Scheme 10 is chosen primarily because it permits the use of either (-) or (+) a-pinene as the starting point. The optically active pinenes are then be converted into the verbenols 8a and 8b which leads to the optically active 9-ketocannabinoids (6a and 6b). Likewise, the choice of the (f)-a-pinene as the starting material gives a desired racemate. Fixing the 6a, 10a ring juncture

trans early in the synthesis avoids the separation of isomers that can be a drawback. The appropriate verbenol 8a or 8b is converted into the AS isomers 9a or 9b by reaction with the resorcinol (1) in a manner similar to that reported for the synthesis of A8-THC. Acetylation to 10a or 10b followed by photolysis gives the isomers 11a or 11b. During the photolysis, the 1-acetate group is removed so that it is necessary to reacetylate the isomers to give 12a or 12b which are subsequently ozonized to yield the keto acetates 13a or 13b. Hydrolysis of the 1-acetate affords the desired optically active ketones 6a or 6b. From (-)-a-pinene is obtained the isomer 6a; from (+)-a-pinene, the isomer 6b. The assignment of absolute stereochemistry rests upon the fact that (-)-verbenol has been converted into (-)-A9-THC whose absolute stereochemistry has been shown to be 6aR, 10aR.

Scheme 10





^a The a and b refer to (-) and (+) optical isomers, respectively.



Synthesis of Example 143

[1050] A microorganism (e.g. IT-121 strain), belonging to the genus *Myrothecium* and having the ability to produce TAN-1140 is cultured in a potato/glucose agar culture medium at 20-30 deg.C and pH4-10 for 2 weeks to provide the compound of Example 143, which in turn may be further derivatized.

Synthesis of Example 152


[1051]


Scheme 11



(a) $Me_3SiCH_2CH_2SO_2NSO$ (SESNSO)/ $BF_3 \cdot Et_2O$, $ClCH_2CH_2Cl$, $42^\circ C$.; (b) $NaCNBH_3$, tert-amyl alcohol; (c) mCPBA, CH_2Cl_2 ; (d) $HCOOH$; $MeOH/Et_3N$; (e) $Me_2AlNMe(OMe)$, THF; (f) $Me_2C(OMe)_2/p-TsOH$, DMF; (g) TBSOTf/2,6-lutidine, DMF, $-15^\circ C$.; (h) $MeMgBr$, THF; (i) $n-Bu_4NF$, THF, room temperature.

Scheme 12














(j) $\text{Cl}_2\text{CHLi}/\text{CeCl}_3$, Et_2O , -100°C ; (k) CrO_3/pyr , CH_2Cl_2 ; (l) MeOCOCI , Et_3N , 4-pyrrolidinopyridine; (m) NaOMe , MeOH ; (n) $n\text{-Bu}_4\text{NF}$, THF , 52°C ; MeOH/HCl ; (o) $\text{Cbz-L-alanine}/\text{DCC}/\text{Et}_3\text{N}$, DMF ; (p) $\text{H}_2/\text{Pd}-\text{C}$, MeOH/HOAc , 0.5N HCl .

Analog Synthesis of Example 161

[1052]

Scheme 13





[1053] Structurally, ovalicin (1) is very similar to the antibiotic fumagillin (2), which has been synthesized and well described. We report herein a short, stereo controlled synthesis of ovalicin. Phenol 3 is prepared from 2,4-dihydroxybenzoic acid by (1) reaction with 2.5 equiv of methyl iodide and 2 equiv of potassium carbonate in acetone at reflux for 16 h to give after extractive isolation and chromatography on silica gel (sg) methyl 2-hydroxy-4-methoxybenzoate (83%) and (2) subsequent reduction with 1.8 equiv of sodium bis(2-methoxyethoxy)aluminum di-hydride in ether at reflux for 30 min (97% yield). Reaction of 3 with aqueous sodium periodate solution 4 (0.3 M) in tetra-hydrofuran (THF) at 23° C. for 1.5 h affords after extractive isolation and filtration through neutral alumina (1:1 hexane:ethyl acetate) dienone epoxide 4 in 61% yield. Reduction of the double bond of 4 by catalytic hydrogenation under a wide variety of conditions results in formation of the phenol 3. However, reduction using diimides generates, by addition of acetic acid solution (1 M in dimethoxyethane (DME) 12 equiv) over a 24 h period to a stirred mixture of 4 and potassium azodicarboxylate (18 equiv) at 45° C. in DME given after filtration and chromatography on neutral alumina (1:1 hexane-ethyl acetate), the desired epoxy enone 5 (77%).




[1054] Vinylolithium reagent 6a is prepared stereospecifically from vinyl iodide 6b which is synthesized by a method in 90% overall yield from acetone (2,4,6-triisopropylbenzyl) sulfonyl-hydrazone as follows. To a solution of this hydrazone in DME at -78° C. was added n-butyllithium (2.15

equiv). The mixture is warmed to -66° C. over 20 min and recooled to -78° C. after which 1-bromo-3-methyl-2-butene (1.2 equiv) is added. The solution is warmed to -66° C. over 20 min, stirred for 1 h at -66° C. and recooled to -78° C. Following addition of N,N, -N',N'-tetramethylethylenediamine (3.3 equiv) and n-butyllithium (1.1 equiv), the reaction mixture is warmed to -3° C. over 2 h, recooled to -78° C. and treated with tri-n-butyltin chloride (1.25 equiv) at -78° C. for 35 min, at -35° C. for 1 h, and finally at room temperature for 45 min. Extractive isolation and chromatography on triethylamine deactivated sg (hexane eluent) gives 6c as a single isomer with a small amount of tetra-n-butyltin side product (>90% purity by ¹H NMR analysis). Vinyltin 6c is treated with iodine (1.2 equiv) at room temperature in methylene chloride for 1 h to afford, after extractive workup and chromatography on sg (pentane eluent), 6b.

[1055] A solution of 6b in ether at -78° C. is stirred with tert-butyllithium (1.6 equiv) for 3.25 h and then epoxy enone 5 (0.8 equiv) in toluene is added to the resulting vinylolithium reagent 6a. After stirring at -78° C. for 1.25 h and extractive workup a 17:1 mixture (by ¹H NMR analysis) of diastereoisomers 7 and 8 (sg TLC R_f values 0.58 and 0.72, respectively, with 1:1 hexane-ethyl acetate) is isolated. Separation of the mixture is achieved on triethylamine deactivated sg (4: 1 hexane-ethyl acetate containing 1% triethylamine cosolvent) to give pure 7 in 83% yield. Reaction of 7 with N-bromosuccinimide (1.12 equiv) in methanol at 0° C. cleanly provides a 3:1 mixture (by ¹H NMR analysis) of bromo ketal 9 and the corresponding α-bromo α'-enol ether (sg TLC R_f values 0.33 and 0.44, respectively, with 4:1 hexane-ethyl acetate) in quantitative yield. The mixture is stirred at room temperature in acetone-water (1.5:1) with a catalytic amount of p-toluene-sulfonic acid for 24 h to afford, after extractive workup, bromo ketone 10 (94%) which is of good purity by ¹H NMR analysis. Chromatography on sg at 4° C. (4:1 hexane-ethyl acetate) gives pure 10 (55% overall from 7). Reaction of bromo ketone 10 with hydroxylamine hydrochloride (3.56 equiv) in acetic acid buffered to pH 6 with potassium acetate (1:1 equiv) at room temperature for 1 h gives, after extractive workup, bromo oxime 11 (quantitative). Treatment of 11 in methanol with triethylamine (5 equiv) for 2 h at room temperature and 24 h at 48° C. yielded, after extractive isolation, the α-methoxy oxime 12 (quantitative recovery, >90% purity by ¹H NMR analysis). Hydrolysis of the oxime is carried out with aqueous titanium trichloride solution (4 equiv) in methanol buffered with aqueous ammonium acetate solution (pH 6; 18 equiv) for 2.5 h at room temperature to provide, after extractive isolation, a 1:1 mixture of diastereoisomers 13 and 14. Treatment of the mixture with potassium carbonate (2 equiv) in methanol at 0° C. for 2 h results in complete isomerization of 14 to 13, which is isolated in pure condition (63% from 12) by chromatography on triethylamine-deactivated sg (3:1 hexane-ethyl acetate). The conversion of 13 to ovalicin (1) is carried out as follows. A solution of 13 in benzene is treated with vanadyl acetylacetonate (0.14 equiv) followed by a solution of dry tert-butyl hydroperoxide in toluene (2 equiv) for 2 h at room temperature to give stereospecifically (by TLC and ¹H NMR analyses) (*)-ovalicin (1), which is isolated by chromatography on triethylamine-deactivated sg (3:1 hexane-ethyl acetate) in 89% yield. Synthetic (*)-1 is indistinguishable from an authentic sample by ¹H NMR, IR, mass spectra, ¹³C NMR analyses as well as chromatographic mobility on sg in several solvent systems. Further derivatization may occur by reaction and opening of the epoxide.

Synthesis of Example 162


[1056]



II. Mechanistic

[1057]

Method 1: Derivatization of a SMIS imidazoquinoline to a create SMIP imidazoquinoline.



-continued




TABLE 1

In vitro inhibitory activity of TNF- α production for 1H-imidazoquinolines

Compd	R ¹	R ³	Inhibition of TNF- α production IC ₅₀ (nM)
2	Benzyl	NH ₂	4810
9	H	Cl	205

-continued

12	H	OPh	3660
14	H	NH ₂	1380
15	H	H	3680
16	n-Butyl	Cl	8020
17	Benzyl	Cl	2670
18	Acetyl	Cl	>10,000
22	Acetyl	NH ₂	>10,000
1			>10,000

Method 2: Derivatization of a SMIS fused tetracyclopymidinone to a create SMIP fused tetracyclopymidinone.




TABLE 2

NOVEL SMIP COMPOUNDS AND THEIR SMIS ANALOGS

SMIP Ex-ample	SMIP Hit	SMIS Source	Immunosuppressor	Mechanism
16		Astra-zeneca		chemokine receptor (WO 0177087)

TABLE 2-continued











NOVEL SMIP COMPOUNDS AND THEIR SMIS ANALOGS				
SMIP Ex- am- ple	SMIP Hit	SMIS Source	Immunosuppressor	Mechan- ism
51		Univer- sidad de Sala- manca		Cell pro- liferation (EP711765); J. Med. Chem, 39, 2865
21		Smith- Kline Beecham		Caspases 3 & 7 (WO 0122966)
26		Sterling Win- throp Pharma- ceuticals Re- search Division		tyrosine kinase, BBRC 287: 829; Biochem 34: 12404
2		Applied Research Systems ARS Holding N.V.; ADIR et cie		JNK (WO 01/47920), IKK (WO 200100610, 2001030774)
47		Celegene		phospho- diesterase III, IV (WO 9712859)

TABLE 2-continued

NOVEL SMIP COMPOUNDS AND THEIR SMIS ANALOGS				
SMIP Ex- am- ple	SMIP Hit	SMIS Source	Immunosuppressor	Mechan- ism
32		Shire, Mary; Celegene		inhibitor for TNF α production (WO 9712859, 9620926)
39		Cheil Jedang; Tularic		phospho- diesterase IV (WO 0073280); IKK (WO 02/41843)

[1058] Nomenclature for the Example compounds was provided using ACD Name version 5.07 software (Nov. 14, 2001) available from Advanced Chemistry Development, Inc. Some of the compounds and starting materials were named using standard IUPAC nomenclature.

[1059] Examples 2-67 of Table 3 were synthesized following the synthetic methodology described above in the Examples and Schemes, and screened following the methods that directly follow the table. The precursors are readily recognizable by one skilled in the art and are commercially available from Aldrich (Milwaukee, Wis.) or Acros Organics (Pittsburgh, Pa.), among others.

TABLE 3

Example	Structure	Name	MH+
2		N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide	402.5
3		N-methyl-4-[(1-methyl-2-((3-(trimethylsilyl)ethynyl)phenyl)amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide	470.6

TABLE 3-continued

Example	Structure	Name	MH+
4		N-methyl-4-[(1-methyl-2-[(2-(phenylcarbonyl)phenyl]amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide	478.5
5		4-(methoxy)-N-[6-(methoxy)-1,3-benzothiazol-2-yl]-3-nitrobenzamide	360.4
6		4-[(2-[(4-butylphenyl)amino]-1,3-benzothiazol-5-yl]oxy)-N-methylpyridine-2-carboxamide	433.5
7		N-methyl-4-[(1-methyl-2-[(6-pyrrolidin-1-ylpyridin-3-yl)amino]-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide	444.5
8		4-[(2-[[1,1'-bi(cyclohexyl)-2-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-methylpyridine-2-carboxamide	462.6
9		4-[(2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy)-N-1,3-thiazol-2-yl]pyridine-2-carboxamide	477.9

TABLE 3-continued





Example	Structure	Name	MH+
10		4-[(1-methyl-2-{{2-(methyloxy)phenyl}amino}-1H-benzimidazol-5-yl)oxy]-N-[3-(methyloxy)propyl]pyridine-2-carboxamide	462.5
11		4-{{2-[(4-ethylphenyl)amino]-1,3-benzoxazol-5-yl}oxy}-N-methylpyridine-2-carboxamide	389.4
12		1-[(3-fluorophenyl)carbonyl]-4-{{4-(trifluoromethyl)phenyl}methyl}piperazine	367.4
13		1-[2-(ethoxy)phenyl]-4-{{3,4,5-tris(methyloxy)phenyl}carbonyl}piperazine	401.5

TABLE 3-continued

Example	Structure	Name	MH+
14		1-(3-chlorophenyl)-4-([2-(ethoxy)phenyl]carbonyl)-piperazine	345.8
15		3-({4-[(2E)-3-phenylprop-2-enyl]piperazin-1-yl}carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid	371.4
16		1-[2-(methoxy)phenyl]-4-{[3,4,5-tris(methoxy)phenyl]carbonyl}piperazine	387.4
17		3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid	332.4
18		3-pentyl-7-[(4-phenylpiperazin-1-yl)carbonyl]-2-thioxo-2,3-dihydroquinazolin-4(1H)-one	437.6

TABLE 3-continued






Example	Structure	Name	MH+
19		1-[(E)-({4-[(2,4-dimethylphenyl)methyl]piperazin-1-yl}imino)methyl]naphthalen-2-ol	374.5
20		5-chloro-1--{[3-(trifluoromethyl)phenyl]methyl}-1H-indole-2,3-dione	340.7
21		1-[(4-methylphenyl)methyl]-5-nitro-1H-indole-2,3-dione	297.3
22		1-methyl-6,7-bis(methoxy)-2-{[3-(methoxy)phenyl]carbonyl}-1,2,3,4-tetrahydroisoquinoline	342.4
23		1-methyl-6,7-bis(methoxy)-2-(naphthalen-2-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	362.4

TABLE 3-continued






Example	Structure	Name	MH+
24		[2-(trifluoromethyl)phenyl]methyl 3-[4-(aminocarbonyl)phenyl]-2-cycloheptyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate	565.6
25		anthra[1,2-c][1,2,5]thiadiazole-6,11-dione	267.2
26		benzo[b]oxanthrene-6,11-dione	265.2
27		ethyl 6,11-dioxo-6,11-dihydrobenzo[b]phenazine-2-carboxylate	333.3
28		N,N-dimethyl-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide	316.3

TABLE 3-continued






Example	Structure	Name	MH+
29	 <p>Ⓢ indicates text missing or illegible when filed</p>	2-(trifluoromethyl)-3-({[3,4,5-tris(methoxy)phenyl]carbonyl}naphtho[2,3-b]furan-4,9-dione	461.4
30		2-(2-oxopropyl)-2-phenyl-1H-indene-1,3(2H)-dione	279.3
31		ethyl 4-{5-[(3-nitrophenyl)carbonyl]-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl}benzoate	445.4
32		5,6-dichloro-2-[2-chloro-5-(trifluoromethyl)phenyl]-1H-isoindole-1,3(2H)-dione	395.6
33		3-bromo-4-({[(2-fluorophenyl)methyl]oxy}-5-(methoxy)benzaldehyde thiosemicarbazone	413.3

TABLE 3-continued







Example	Structure	Name	MH+
34		2-[4-(3-chlorophenyl)piperazin-1-yl]-5-nitrobenzaldehyde thiosemicarbazone	419.9
35		4-{{[2-(3-chlorophenyl)ethyl]amino}-3-nitrobenzaldehyde thiosemicarbazone	378.9
36		(1E)-6,9-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-1-one thiosemicarbazone	287.4
37		(2E)-1,1'-bi(cyclohexan)-1-en-2-one thiosemicarbazone	252.4
38		4-{{[2-(4-chlorophenyl)ethyl]amino}-3-nitrobenzaldehyde thiosemicarbazone	378.9
39		4-(diethylamino)-2-[[[4-(4-fluorophenyl)methyl]oxy]benzaldehyde N-(2-piperidin-1-ylethyl)thiosemicarbazone	486.7

TABLE 3-continued

Example	Structure	Name	MH+
40		3,4-bis(methoxy)benzaldehyde (1,1-dioxido-1,2-benzisothiazol-3-yl)(methyl)hydrazone	360.4
41		(2E)-2-[(4-chlorophenyl)(5-chlorothiophen-2-yl)methylidene]hydrazinecarboximidamide	314.2
42		2-(4-amino-2-oxo-1-propyl-1,2-dihydroquinolin-3-yl)-1H-benzimidazole-6-carbonitrile	344.4
43		4-amino-6-fluoro-7-({[4-(methoxyphenyl)methyl]amino}-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one	528.6

TABLE 3-continued







Example	Structure	Name	MH+
44		6-chloro-3-(5-chloro-1H-benzimidazol-2-yl)-4-([2-(dimethylamino)ethyl]amino)quinolin-2(1H)-one	417.3
45		4-amino-5-(1H-benzimidazol-2-yl)-1-methyl-1,7-dihydro-6H-pyrazolo[3,4-b]pyridin-6-one	281.3
46	 (?) indicates text missing or illegible when filed	5,5-dimethyl-4-methylidene-3-(2,4,6-trinitrophenyl)-1,3-oxazolidin-2-one	339.2
47		5-methyl-2-[4-(methoxy)phenyl]hexahydro-1H-isoindole-1,3(2H)-dione	274.3
48		5-methyl-2-(4-methylphenyl)hexahydro-1H-isoindole-1,3(2H)-dione	258.3
49		N-2-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine	252.7

TABLE 3-continued

Example	Structure	Name	MH+
50		(7Z)-7-(furan-2-ylmethylidene)-3-phenyl-3,4-dihydro-2H-[1,3]thiazolo[3,2-a][1,3,5]triazin-6(7H)-one	312.4
51		(3aR,9R,9aR)-6,7-dihydroxy-9-[3,4,5-tris(methoxy)phenyl]-3a,4,9,9a-tetrahydronaphtho[2,3-c]furan-1(3H)-one	387.4
52		6-chloro-2-(ethyloxy)-4-methyl-3-(4-nitrophenyl)-3a,4,9,9a-tetrahydro-3H-pyrrolo[2,3-b]quinoxaline	387.8
53		ethyl 2-(ethyloxy)-4-methyl-3a,4,9,9a-tetrahydro-3H-pyrrolo[2,3-b]quinoxaline-3-carboxylate	304.4
54		ethyl 4-({[2,5-bis(methoxy)phenyl]amino}methyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate	333.4

TABLE 3-continued

Example	Structure	Name	MH+
55		Chiral 1-{3-[(6-amino-5-nitropyridin-2-yl)amino]propyl}-4-(2-chlorophenyl)-N-[(2S)-2-hydroxypropyl]-1H-pyrrole-3-carboxamide	473.9
56		(4-methylphenyl)(5-nitro-2-piperidin-1-ylphenyl)methanone	325.4
57		Chiral (2S,5R)-N~1~-(4-methylphenyl)-5-phenyl-N~2~-(2-pyridin-2-ylethyl)pyrrolidine-1,2-dicarboxamide	429.5
58		Chiral 2-[(3S)-3-(acetylamino)-2-oxopyrrolidin-1-yl]-N-[2-(4-fluorophenyl)ethyl]acetamide	322.4
59		Chiral N-[2-(2,4-dichlorophenyl)ethyl]-4-({(Z)-[(4,4-difluorocyclohexyl)imino]}[(3S)-3-methylpiperazin-1-yl]methyl)amino)benzamide	553.5

TABLE 3-continued





Example	Structure	Name	MH+
60		4-[4-(methoxy)phenyl]-5-phenylisoxazole	252.3
61		methyl 4-{{[4-(1-methylethyl)-2,3-dioxo-7-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl]methyl}benzoate	421.4
62		Chiral (3beta, 16beta)-3,14,16-trihydroxybufa-20,22-dienolide	403.5
63		2-(aminomethyl)-1-(2-pyridin-2-ylethyl)quinazolin-4(1H)-one	281.3

TABLE 3-continued


Example	Structure	Name	MH+
64		ethyl 4-({[5-[3,4-bis(methoxy)phenyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]carbonyl}piperazine-1-carboxylate	508.5
65		5-[3,4-bis(methoxy)phenyl]-3-(piperidin-1-ylcarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine	435.4
66		5-[3,4-bis(methoxy)phenyl]-N-methyl-N-(2-pyridin-2-ylethyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide	486.5
67		5-propyl-2-thien-2-ylpyrazolo[1,5-a]pyrimidin-7-ol	260.3

TABLE 4

Example	Structure	Drug
68		Chiral A-85917


TABLE 4-continued

69




ascrolimus

70



L-683742

71




L-685487

TABLE 4-continued

72


L-732531



73

Chiral

everolimus



74

Chiral

sirolimus






TABLE 4-continued

75




MLR-52

76




laquinimod

77




brequinar

78



VUF-K-8788


79



TAK-603

TABLE 4-continued


80




Chiral

WY-50295-
tromethamine

81


apoptosis
stimulators,
Hughes Institute

82



KF-20444


83



Chiral

mizoribine


84



MDL-28842

TABLE 4-continued


85a



Chiral


amiprilose

85b




GW-92527

86




FK-778

87




HMR-1279

88



leflunomide


89



teriflunomide


TABLE 4-continued

90




HR-325


91

NF-kB/AP-1
inhibitor, Tanabe

92


MAP/ERK
kinase (MEK)-1
inhibitors, Pfizer

93




actarit

94



HSR-6071


95



Chiral

RU-24858


96



tipredane


TABLE 4-continued

97




IPL-576092

98




CBP-1011


99

prasterone,
Genelabs/Watson

100

halobetasol
propionate

101




Org-4094

TABLE 4-continued


102

Chiral

rimexolone




103

celastrol
(cancer),
Schering-Plough

104


BX-471



105

Chiral

CGP-47969A



106

peldesine




TABLE 4-continued







107		CT-2576
108		CC-1088
109		IMPDH inhibitors (immunosuppressants), BMS
110		Chiral SMP-114
111		FR-901459


TABLE 4-continued

112



ISAtx-247


113



Chiral

ciclosporin
(topical; HILT),
SkyePharma


114



Chiral

DE-076


115



oxciclosporin


TABLE 4-continued

116




reblastatin


117

radicicol
derivatives,
Kyowa

118


oligomycin-F,
Boehringer
Mannheim

119




tresperimus

120



Chiral anisperimus

121

gusperimus
trihydrochloride

H-Cl H-Cl H-Cl

TABLE 4-continued










122		WF-10917
123		ISP-1/myriocin analogs, Yoshitomi
124		Chiral Mycestericin E
125		FTY-720 H—Cl
128		JWH-015
129		TJU-103
130		TU-572

TABLE 4-continued

131


dipeptidyl
peptidase IV
inhibitors,
Tanabe

132




RP-54745

133




Win-17317-3

134



JWH-051

135



L-759633

TABLE 4-continued







136		Chiral	L-759656
137		Chiral	lexacalcitol
138		Chiral	MC-1288
139		Chiral	Ro-63-2023

TABLE 4-continued


140		Chiral	Ro-26-2198
-----	--	--------	------------




141			SKF-105685
-----	--	--	------------




142			SKF-106610
-----	--	--	------------



143			Tan-1140
-----	--	--	----------



144			enisoprost
-----	--	--	------------



145			O-689
-----	--	--	-------






TABLE 4-continued

146




LY-178002

147




SM-8849

148




FR-115092

149




FR-901483

150



MT-2221

151



iguratimod

TABLE 4-continued







152	 Chiral	bactobolamine
153	 Chiral	SNF-4435
154		NK-10958P
155	 Chiral	PA-48153C
156		terpenin derivatives, Shionogi
157	 Chiral	neurophilins (neurological disease), Vertex/Schering

TABLE 4-continued








158	 Chiral	carbohydrate-based therapeutics, Pharmaxis/Australian Nat Univ
159	 Na Na	TRK-530
160	 Cl- Cl- Ru ²⁺	ruthenium complexes, Procept
161		PF-1131
162		NIP-520
163		OR-1384


TABLE 4-continued

164




PNU-156804

165




fenclofenac

166




etarotene

167


mycophenolate
mofetil

168








SR-31747

169



NPC-16570

TABLE 4-continued

170		SY-640
171		TA-383
172		HS-378
173		YM-13650
174		Ridaura Ridauran SK&F-39162

Example	Company	Action	Indication	Reference
68	Abbott Laboratories	Immunosuppressant	Immune disorder;	WO 9113889
69	Abbott Laboratories	Immunosuppressant	Autoimmune disease	WO 9113889
70	Merck & Co Inc	Immunosuppressant	Atopic dermatitis; Psoriasis;	WO 9113889
71	Merck & Co Inc	Immunosuppressant	Dermatitis	U.S. Pat. No. 4,975,372
72	Merck & Co Inc	Immunosuppressant	Transplant rejection	U.S. Pat. No. 05,310,903;
				EP532088-19930317;
				JP94116274-19940426;
				U.S. Pat. No. 5252732-
				19931012; WO9305058-
				19930318

TABLE 4-continued

73	Novartis AG	Anticancer; IL-2 synthesis inhibitor; Immunosuppressant	Inflammatory bowel disease; Rheumatoid arthritis; Transplant rejection; Solid tumor	WO-09409010-19940428; WO9735575-19971002; EP663916-19950726; U.S. Pat. No. 5,665,772-19,970,909; WO9424304-19941027; WO9507468-19950316; WO9804279-19980205; WO9214476-19920903; WO9214477-1920903; U.S. Pat. No. 5,321,009-19,940,614; U.S. Pat. No. 5,776,943-19,980,707; U.S. Pat. No. 5,286,730-19,940,215; WO9319763-19931014; U.S. Pat. No. 5,387,589-19,950,207; U.S. Pat. No. 5,496,832-19,960,305; WO9747317-19971218; WO9818468-19980507; WO 0230941; WO 9707081
74	Wyeth Pharmaceuticals	Protein synthesis inhibitor; Immunosuppressant	Transplant rejection	
75	Abbott Laboratories	Anti-inflammatory; Protein kinase C inhibitor; Immunosuppressant	Inflammation	
76	Active Biotech AB	Immunomodulator; Immunosuppressant	Multiple sclerosis	EP 1073639-20010207; JP 2002511008-20020508; uS 6077851-20000620; WO 9955678-19991104; EP 1224172-20020724; JP 2003512454-20030402; U.S. Pat. No. 6395750-20020528; WO 0130758-20010503; U.S. Pat. No. 55,393,891; U.S. Pat. No. 5,707,844
77	Bristol-Myers Squibb Pharma Co	Anticancer; Immunosuppressant; Dehydrogenase inhibitor	Immune disorder; Psoriasis; Transplant rejection; Carcinoma; Cancer	
78	Gifu Pharmaceutical University	Histamine antagonist; Immunosuppressant	Asthma	EP957100-19991117; WO9902520-19990121
79	Takeda Chemical Industries Ltd	Immunosuppressant; Bone resorption inhibitor; Cytokine synthesis inhibitor	Inflammation; Arthritis; Psoriasis; Rheumatoid arthritis; Bone disease; Graft versus host disease; Crohns disease	EP608870-940803; JP95118266-950509; U.S. Pat. No. 5,436,247-950,725; EP634169-950118; JP95096890-950314; U.S. Pat. No. 5,173,488; U.S. Pat. No. 6,177,477; AU8819209-19890202; EP301813-19890201; GB2207428-19890201; WO 2004013091; WO 2003101380; WO 2003065971; WO 2003149045; U.S. Pat. No. 5,480,883; U.S. Pat. No. 5,371,225-19,941,208; WO9322286-19951111
80	Wyeth-Ayerst Pharmaceutical Inc	LT antagonist; 5-Lipoxygenase inhibitor; Anti-inflammatory; Immunosuppressant	Inflammation; Arthritis; Psoriasis; Asthma	See above
81	Hughes Institute	Anticancer; Apoptosis stimulator; Jak3 tyrosine kinase inhibitor; Immunosuppressant	Allergy; Acute lymphoblastic leukemia; Leukemia; Motor neurone disease; Transplant rejection; Cancer; Insulin dependent diabetes	
82	Kyowa Hakko Kogyo Co Ltd	Anticancer; Immunosuppressant; Dehydrogenase inhibitor	Rheumatoid arthritis; Autoimmune disease; Transplant rejection; Cancer	
83	Asahi Kasei Pharma Corp	Anticancer; Immunosuppressant; IMP dehydrogenase inhibitor	Renal disease; Viral infection; Transplant rejection; Cancer	
84	Hoechst Marion Roussel Inc	Anticancer; Anti-inflammatory; Immunosuppressant; Adenosylhomocysteinase inhibitor	Inflammation; Cancer	EP304889-19890301; U.S. Pat. No. 4,997,925-19,910,305; AU9163842-19910418; EP422638-19910417; JP91133992-19910607; U.S. Pat. No. 4,997,924-19,910,305
85a	Greenwich Pharmaceuticals Inc	Immunosuppressant	Rheumatoid arthritis	U.S. Pat. No. 4,017,608
85b	Boston Life Sciences	Immunosuppressant	Arthritis, rheumatoid	

TABLE 4-continued

86	Aventis Pharma AG	Anticancer; antimetabolite; Immunosuppressant; DNA modulator; Antiviral	Multiple sclerosis; Autoimmune disease; Transplant rejection; Dermatological disease	EP 551230-930714 U.S. Pat. No. 5,308,865
87	Aventis Pharma AG	Immunosuppressant; DNA modulator	Multiple sclerosis; Autoimmune disease; Transplant rejection; Dermatological disease	EP 484223-920506; JP 92288048-921013 U.S. Pat. No. 5240960
88	Aventis Pharma AG	Anti-inflammatory; Immunosuppressant	Multiple sclerosis; Rheumatoid arthritis; Transplant rejection	U.S. Pat. No. 4,351,841-19,820,928; U.S. Pat. No. 4,284,786-19,810,818; U.S. Pat. No. 4,965,276-19,901,023; U.S. Pat. No. 5,268,382-19,931,207; U.S. Pat. No. 5,459,163-19,951,017; U.S. Pat. No. 5,504,084-19,960,402; U.S. Pat. No. 5,494,911-19,960,227; U.S. Pat. No. 5,532,259-19,960,702; WO 9117748-19911128; U.S. Pat. No. 5,700,823-19,971,223; WO 9519169-19950720; U.S. Pat. No. 5,700,822-19,971,223; U.S. Pat. No. 5,610,173-19,970,311 WO 9117748-911128
89	Aventis Pharma AG	Dihydroorotate dehydrogenase inhibitor; Protein tyrosine kinase inhibitor; Immunosuppressant	Multiple sclerosis	
90	Hoechst Marion Roussel Inc	Anticancer; Immunosuppressant	Rheumatoid arthritis; Cancer	EP484223-920506; JP92288048-921013
91	Signal Research Division	Nuclear factor kappa B inhibitor; Anti-inflammatory; Protein synthesis inhibitor; Immunosuppressant; Jun N terminal kinase-1a modulator	Inflammation; Osteoarthritis; Psoriasis; Rheumatoid arthritis; Transplant rejection;	WO9709315-970313
92	Pfizer Inc	Anticancer; Immunosuppressant; MEK-1 protein kinase inhibitor	Non-small-cell lung cancer; Pancreas tumor, Breast tumor; Transplant rejection; Cancer; Colon tumor	WO 9901426, 19990114, 9837881, 19980903; U.S. Pat. No. 19,970,701, 19,970,228
93	Nippon Shinyaku Co Ltd	Immunosuppressant	Immune disorder; Rheumatoid arthritis	DE3317107-831124; U.S. Pat. No. 4,720,506-880,119
94	Hokuriku Seiyaku KK	Immunosuppressant	Allergy; Asthma	EP227026-19870701; JP87153284-19870708; JP88112578-19880517; U.S. Pat. No. 4,792,547-19,881,220 WO 9739018-19971023
95	Aventis Pharma AG	Steroidal anti-inflammatory; Glucocorticoid agonist; Receptor modulator; Immunosuppressant	Immune disorder; Inflammation; Asthma	
96	Bristol-Myers Squibb Co	LT antagonist; Anti-inflammatory; Immunosuppressant; Arachidonic acid antagonist	Allergy; Inflammation; Ocular disease; Asthma	U.S. Pat. No. 04,361,559
97	Inflazyme Pharmaceuticals Ltd	Anti-inflammatory; Immunosuppressant	Inflammation; Ocular disease; Asthma; Dermatitis	WO-09414451
98	inKine Pharmaceutical Co Inc	Anti-inflammatory; Corticosteroid agonist; Immunosuppressant	Thrombocytopenic purpura; Inflammatory bowel disease; Asthma; Systemic lupus erythematosus; Ulcerative colitis; Autoimmune disease; Crohns disease	U.S. Pat. No. 3,280,155 WO 9832718

TABLE 4-continued

99	Leland Stanford Junior University	Nootropic agent; Immunosuppressant; Androgen agonist; NO modulator	Systemic lupus erythematosus	WO-09408589-940428
100	Novartis AG	Corticosteroid agonist; Immunosuppressant	Psoriasis	WO 2003047329 WO 9832718
101	NV Organon	Immunosuppressant	Autoimmune disease	U.S. Pat. No. 5,512,556
102	NV Organon	Steroidal anti-inflammatory; PAF antagonist; Corticosteroid agonist; Immunosuppressant	Rheumatoid arthritis; Uveitis; Cataract; Ocular inflammation	See above for synthesis
103	Schering-Plough Research Institute	Topoisomerase I inhibitor; Anticancer; Protein tyrosine kinase inhibitor; Immunosuppressant	Cancer	U.S. Pat. No. 5,580,562
104	Berlex Biosciences	Anti-inflammatory; CCR1 chemokine antagonist; Immunosuppressant; Imaging agent	Atopic dermatitis; Alzheimers disease; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Autoimmune disease; Transplant rejection	WO-09856771-19981217; U.S. Pat. No. 6,207,665-20,010,327
105	Novartis AG	IL-1 release inhibitor; IL synthesis inhibitor; Anti-inflammatory; Immunosuppressant	Rheumatoid arthritis; Autoimmune disease	U.S. Pat. No. 5,888,969; U.S. Pat. No. 5,888,978; U.S. Pat. No. 6,664,256; U.S. Pat. No. 6,680,316; EP524146-930120; JP93202014-930810; U.S. Pat. No. 5,286,728-940,215
106	BioCyst Pharmaceuticals Inc	Anticancer; Purine nucleoside phosphorylase inhibitor; Immunosuppressant; Antiviral	HIV infection; Multiple sclerosis; Ocular disease; Psoriasis; Rheumatoid arthritis; Non-Hodgkin lymphoma; Transplant rejection; Dermatitis	U.S. Pat. No. 04,985,433-910,115; U.S. Pat. No. 5,008,270-910,416; WO9106548-910516
107	Cell Therapeutics Inc	Immunosuppressant	Acquired Immune Deficiency Syndrome; Transplant rejection; Cancer	U.S. Pat. No. 5,859,222; U.S. Pat. No. 6,274,363; U.S. Pat. No. 5,470,878-951,128; WO9422863-941013 WO-09723457-970703
108	Celgene Corp	Cytokine release inhibitor; Anti-inhibitor; inflammatory; PDE 4 inhibitor; TNF alpha synthesis inhibitor; Immunosuppressant	Myelodysplastic syndrome; Inflammation; Crohns disease	
109	Bristol-Myers Squibb Pharmaceutical Research Institute	Immunosuppressant; IMP dehydrogenase inhibitor	Arthritis	WO03099206A2; WO03099206A3; U.S. Pat. No. 20,030,232,866A1; U.S. Pat. No. 20,040,077,878A1; WO04032875A2; EP1126843-20010829; U.S. Pat. No. 6,399,773-20,020,604; WO0025780-20000511 EP0979226-20000216; JP1S99240873-19990907; U.S. Pat. No. 6,100,260-20,000,808; WO9847880-19981029 WO 2002032447
110	Sumitomo Pharmaceuticals Co Ltd	Anti-inflammatory; Immunosuppressant	Rheumatoid arthritis	
111	Fujisawa Pharmaceutical Co Ltd	Anti-inflammatory; Immunosuppressant	Inflammation	
112	Isotechnika Inc	Immunosuppressant; Calcineurin inhibitor	Psoriasis; Rheumatoid arthritis; Autoimmune disease; Transplant rejection; Insulin dependent diabetes	WO-09918120
113	Hyal Pharmaceutical Corp	Immunosuppressant; Calcineurin modulator; Cytokine synthesis inhibitor	Psoriasis	WO9813044A2
114	Santen Pharmaceutical Co Ltd	Anti-inflammatory; Immunosuppressant; Calcineurin inhibitor	Keratoconjunctivitis	J Pharm Pharmacol. 49:835

TABLE 4-continued

115	Novartis AG	Immunosuppressant	Psoriasis; Asthma; Transplant rejection	AU9059727-19910124; EP414632-19910227; JP93218396-19910925 JP97286779-19971104 WO 2003013430
116	Glaxo Wellcome plc	Immunosuppressant	Rheumatoid arthritis	WO 9314215 EP0889042-19990107; WO9818780-19980507
117	Kyowa Hakko Kogyo Co Ltd	Anticancer; Apoptosis stimulator; Immunosuppressant	Allergy; Autoimmune disease; Transplant rejection; Cancer	U.S. Pat. No. 6,395,711
118	Roche Holding AG	Immunosuppressant	Transplant rejection	EP-00600762-940608; FR2698628-940603; U.S. Pat. No. 5,476,870 EP669316-950830; FR2716451-950825; FR2716452-950825; JP96Q41007-960213; U.S. Pat. No. 5,637,613 BE-00894651; U.S. Pat. No. 4,518,532
119	Fournier Pharma	Immunosuppressant	Autoimmune disease; Transplant rejection	WO9709298-970313
120	Fournier Pharma	Immunosuppressant	Autoimmune disease	EP-00436020; JP89104087-19890421; WO9002727-19900322 U.S. Pat. No. 6,720,391
121	Nippon Kayaku Co Ltd	Immunosuppressant	Granulomatosis; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection	U.S. Pat. No. 6,121,329; EP627406- 941207; JP94509845- 941102; WO9408943- 940428
122	Fujisawa Pharmaceutical Co Ltd	Immunosuppressant	Psoriasis; Rheumatoid arthritis; Autoimmune disease; Transplant rejection; Graft versus host disease	WO 2003049727; WO 2001028588
123	Mitsubishi Pharma Corp	Immunosuppressant	Autoimmune disease; Graft versus host disease	See above for synthesis
124	Taito Co Ltd	Immunosuppressant	Immune disorder	Int Arch Allergy Immunol 126:318; See above for synthesis WO9818763-19980507
125	Welfide Corp	Anticancer; Apoptosis stimulator; Immunosuppressant	Inflammatory bowel disease; Multiple sclerosis; Myocarditis; Autoimmune disease; Transplant rejection; Cancer; Insulin dependent diabetes	U.S. Pat. No. 4,576,954- 19,860,318
128	Clemson University	Cannabinoid CB2 agonist; Immunosuppressant	Transplant rejection	
129	Jefferson Medical College	Immunosuppressant	Craft versus host disease	
130	Taisho Pharmaceutical Co Ltd	Protein tyrosine phosphatase inhibitor; Immunosuppressant	Immune disorder	
131	Tanabe Seiyaku Co Ltd	Immunosuppressant; Dipeptidyl peptidase IV inhibitor	Rheumatoid arthritis; Autoimmune disease; Diabetes mellitus	
132	Rhone-Poulenc SA	Immunosuppressant	Rheumatoid arthritis	
133	Sanofi Winthrop Inc	Potassium channel blocker; Immunosuppressant	Autoimmune disease; Transplant rejection	
134	Clemson University	Immunosuppressant; Cannabinoid agonist	Transplant rejection	Eur J Pharmacol 339:53
135	Merck & Co Inc	Immunosuppressant; Cannabinoid agonist	Autoimmune disease	Br J Pharmacol 126:665
136	Merck & Co Inc	Immunosuppressant; Cannabinoid agonist	Autoimmune disease	Br J Pharmacol 126:665
137	LEO Pharma A/S	Anticancer; Immunosuppressant; Vitamin D3 agonist	Sarcoidosis; Psoriasis; Breast tumor; Skin tumor; Insulin dependent diabetes	WO9414453-19940707
138	LEO Pharma A/S	Immunosuppressant; Vitamin D3 agonist	Sarcoidosis; Multiple sclerosis; Transplant rejection; Cancer	U.S. Pat. No. 6,071,897
139	F Hoffmann-La Roche Ltd	Immunosuppressant	Multiple sclerosis	WO9100855-19910124
140	Roche SpA	Cytokine release inhibitor; Immunosuppressant	Insulin dependent diabetes	U.S. Pat. No. 5,428,029- 19,950,627
141	SmithKline Beecham plc	Immunosuppressant	HIV-1 infection; Rheumatoid arthritis; Autoimmune disease; Transplant rejection	WO 92/02229
142	SmithKline Beecham plc	Immunosuppressant	Rheumatoid arthritis; Autoimmune disease; Insulin dependent diabetes	WO9202229-920920
143	Takeda Chemical Industries Ltd	Immunosuppressant	Immune disorder	JP90193940-19900731; See above procedure

TABLE 4-continued

144	GD Searle & Co	Prostanoid receptor agonist;	Peptic ulcer; Transplant rejection	U.S. Pat. No. 6,255,518; U.S. Pat. No. 5,807,895; U.S. Pat. No. 5,218,139
145	Organix Inc	Immunosuppressant; Cannabinoid. agonist	Transplant rejection	Eur J Pharmacol. 355:113 See above synthesis
146	Eli Lilly & Co	Anti-inflammatory; Immunosuppressant; Antioxidant agent	Inflammation; Neurodegenerative disease	EP-00211670-19870225; JP87042977-19870224; AU8660872-19870212; U.S. Pat. No. 5,356,917
147	Sumitomo Pharmaceuticals Co Ltd	Immunosuppressant; Bone resorption inhibitor	Rheumatoid arthritis	EP248399-19871209; JP88152368-19880624; U.S. Pat. No. 4,914,112
148	Fujisawa Pharmaceutical Co Ltd	Immunosuppressant	Thrombocytopenic purpura; Systemic lupus erythematosus; Thrombocytopenia; Autoimmune disease	EP-00412404-19910213; JP91068567-19910325; JP9604862B-19960220; U.S. Pat. No. 5,256,675
149	Fujisawa Pharmaceutical Co Ltd	Immunosuppressant	Transplant rejection; Graft versus host disease	WO9312125-930624
150	Ishihara Sangyo KK	Immunosuppressant	Rheumatoid arthritis	CA2087805-930807; EP560055-930915; JP94183965-940705; U.S. Pat. No. 5,380,834
151	Toyama Chemical Co Ltd	Immunosuppressant	Rheumatoid arthritis	FR2621585-19890414; GB22210879-19890621; JP90268178-19901101; U.S. Pat. No. 4,954,518
152	Meiji Seika Kaisha Ltd	Immunosuppressant	Autoimmune disease	Transplant Proc 28:1049 See above synthesis
153	Snow Brand Milk Products Co Ltd	Antibacterial; Immunomodulator; Immunosuppressant	Allergy; Autoimmune disease; Infection	WO9743434-19971120
154	Nippon Kayaku Co Ltd	Antibacterial; Immunosuppressant	Transplant rejection	EP 560389,930915; JP 93310726. 931122; U.S. Pat. No. 5,314,911
155	Shionogi & Co Ltd	Fungicide; Immunosuppressant	Fungal infection; Immune disorder; Arthritis; Autoimmune disease	EP560389-930915; JP93310726-931122; U.S. Pat. No. 5,314,911
156	Shionogi & Co Ltd	Immunosuppressant	Allergy	WO9739999-19971030
157	Vertex Pharmaceuticals Inc	Antiparkinsonian; Immunosuppressant	Alzheimers disease; Multiple sclerosis; Parkinsons disease; Arthritis; Psoriasis; Autoimmune disease; Neurological disease; Diabetes mellitus	WO9929858A1
158	The Australian National University	Anti-inflammatory; Immunosuppressant	Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Arthritis; Rheumatoid arthritis; Asthma; Cystic fibrosis; Diabetes mellitus	WO-09001938
159	Toray Industries Inc	Non-steroidal anti-inflammatory; Immunosuppressant; Bone resorption inhibitor	Rheumatoid arthritis	U.S. Pat. No. 6,670,343; EP594857-19940504; WO9305052-19930318; WO9419359-19940901
160	Paligent Inc	Immunosuppressant	Multiple sclerosis; Systemic lupus erythematosus; Autoimmune disease; Graft versus host disease	WO9613510A1; U.S. Pat. No. 5,512,687-960,430; U.S. Pat. No. 5,708,022; U.S. Pat. No. 5,512,687-960430
161	Meiji Seika Kaisha Ltd	Immunosuppressant	Asthma	JP95017957-950120
162	Nissan Chemical Industries Ltd	Immunosuppressant	Asthma	Jpn J Pharmacol 68:47
163	Orion Corp	Immunosuppressant	Inflammatory bowel disease; Asthma	U.S. Pat. No. 6,201,027; U.S. Pat. No. 5,185,370-930,209
164	Pharmacia & Upjohn Inc .	Immunosuppressant	Multiple sclerosis; Rheumatoid arthritis; Autoimmune disease	WO9517381-950629

TABLE 4-continued

165	Reckitt & Colman plc	Anti-inflammatory; Immunosuppressant	Inflammation; Arthritis	U.S. Pat. No. 4,468,469; WO9827972A2; WO9827972A3; U.S. Pat. No. 4,845,083; U.S. Pat. No. 4,912,136 EP058370-19820825; U.S. Pat. No. 4,396,553 JS4753935-19880628; JS4786637-19881122; WO9412184-199406G9; WV09426266-19941124; WO9507902-19950323; WVO9509626-19950413
166	Roche Holding AG	Immunosuppressant	Neoplasm; Psoriasis; Dermatitis	
167	Roche Holding AG	Vasoprotectant; Anti-inflammatory; Immunosuppressant; IMP dehydrogenase inhibitor	Inflammatory bowel disease; Respiratory syncytial virus infection; Rheumatoid arthritis; Systemic lupus erythematosus; Thrombocytopenia; Restenosis; Autoimmune disease; Transplant rejection; Crohns disease	
168	Sanofi-Synthelabo	Anticancer; IL-1 antagonist; Sigma opioid agonist; Immunosuppressant; IFN beta antagonist; IL-6 antagonist	Immune disorder; Prostate tumor, Psoriasis; Rheumatoid arthritis; Autoimmune disease; Breast tumor; Cancer	EP376850-19900704; FR2641276-19900706; U.S. Pat. No. 5,354,781
169	Scios Inc	Immunosuppressant	Allergy; Allergic encephalitis	WO 96/15105 U.S. Pat. No. 5,519,043 WO 93/11764 U.S. Pat. No. 6,723,743
170	Taisho Pharmaceutical Co Ltd	Immunosuppressant; Protectant	Hepatitis; Liver disease	
171	Tanabe Seiyaku Co Ltd	IL-1 antagonist; Immunosuppressant; IFN beta antagonist; IL-6 antagonist	Rheumatoid arthritis	U.S. Pat. No. 5,051,441
172	University of Innsbruck	Opioid receptor modulator; Anti-inflammatory; Immunosuppressant	Arthritis; Transplant rejection	WO9531463
173	Yamanouchi Pharmaceutical Co Ltd	Immunosuppressant	Allergy; Transplant rejection	EP082712-19830629; U.S. Pat. No. 4,464,384
174	GlaxoSmithKline	Immunosuppressant Prostaglandin synthase inhibitor	Arthritis, rheumatoid	3708579

[1060] Preferred analogs of compounds of Table 4 include those encompassed by formulas I, II, III, IV, V, VI, VII, VIII, IX, XII, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, XL, XLI, XLII, XLIII, XLIV, XLV, XLVI, XLVII, XLVIII, XLIX, L, and LI.

BIOLOGICAL EXAMPLES

Example 174

[1061] Candidate small molecule immuno-potentiators can be identified in vitro. Compounds are screened in vitro for their ability to activate immune cells. One marker of such activation is the induction of cytokine production, for example TNF- α production. Apoptosis inducing small molecules may be identified having this activity. These small molecule immuno-potentiators have potential utility as adjuvants and immuno-therapeutics.

[1062] In an assay procedure (High Throughput Screening (HTS)) for small molecule immune potentiators (SMIPs), human peripheral blood mononuclear cells (PBMC), 500,000 per mL in RPMI 1640 medium with 10% FCS, were distributed in 96 well plates (100,000 per well) already containing 5 μ M of compound in DMSO. The PBMCs were incubated for 18 h at 37° C. in 5% CO₂. Their ability to produce cytokines

in response to the small molecule compounds is determined using a modified sandwich ELISA. Alternatively, Luminex Technology may be used.

[1063] Briefly supernatants from the PBMC cultures were assayed for secreted TNF using a primary plate bound antibody for capture followed by a secondary biotinylated anti-TNF antibody forming a sandwich. The biotinylated second antibody was then detected using streptavidin-Europium and the amount of bound europium was determined by time resolved fluorescence. SMIP compounds were confirmed by their TNF inducing activity that was measured in the assay as increased Europium counts over cells incubated in RPMI medium alone. "Hits" were selected based on their TNF-inducing activity relative to an optimal dose or lipopolysaccharide LPS (1 μ g/ml), a strong TNF inducer. The robustness of the assay and low backgrounds allowed for the routine selection of hits with ~10% of LPS activity that was normally between 5-10 \times background (cells alone). Selected hits are then subjected to confirmation for their ability to induce cytokines from multiple donors at decreasing concentrations. Those compounds with consistent activity at or below 5 μ M are considered confirmed for the purposes of this assay. The assay is readily modified for screening for compounds effective at higher or lower concentrations.

Example 175

[1064] Each of Examples 2-67 elicited TNF- α production in human peripheral blood mononuclear cells. Many of the

compounds showed activity at less than 20 μM with respect to production of TNF- α . Many of these compounds showed activity at less than 5 μM with respect to production of TNF- α . Many of these compounds showed activity in the production of TNF- α at less than 1.5 μM .

[1065] For this reason, each of the R groups of any of the compounds listed in Table 3 are preferred. Additionally, because of the excellent activity of each of the compounds, and the mechanistic correlations, each of these compounds of Tables 3 and 4 are individually preferred and is preferred as a member of a group that includes any or all of the other compounds and each compound is preferred in methods of modulating immunopotential and in methods of treating biological conditions associated therewith, for example to be used as a vaccine adjuvant. Each of the compounds is also preferred for use in preparation of medicaments for vaccines, immunopotential, reducing tumor growth and in treating biological conditions mediated therefrom.

[1066] In addition to the procedure described above, methods of measuring other cytokines (e.g. IL-1-beta, IL-12, IL-6, IFN-gamma, IL-10 etc.) are well known in the art and can be used to find active SMIP compounds of the present invention.

[1067] Compounds may be useful that cause production of TNF- α at higher concentrations, such as 100 μM , 200 μM or 300 μM in the assays described herein. For example Loxoribine causes useful production of TNF- α at 300 μM (see Pope et al Immunostimulatory Compound 7-Allyl-8-Oxoguanosine (Loxoribine) Induces a Distinct Subset of Murine Cytokines Cellular Immunology 162: 333-339 (1995)).

Example 176

[1068] A combinatorial library is constructed (e.g., using a conventional mix/split synthesis on suitable resin bead supports) which comprises a number of sublibrary mixtures, each generally containing about 2 to 500, and preferably about 20 to 100 compounds each. It is preferable that the bead supports be high-loading beads (which provide >1 nmole of compound per bead). It is also preferable that the bead supports have a substantially uniform diameter. The use of a substantially uniform population of bead supports in the methods of the invention provide the added benefit that final reaction volumes of compounds cleaved from the bead supports will have substantially uniform compound concentrations. Thus, the bead supports preferably have a diameter variance of about 40%, preferably about 30%, more preferably about 20%, and most preferably about 5-10% or less. The actual number of individual compounds in each sublibrary is not important or limiting in the present invention, and the method can be practiced with any size sublibrary selected according to user preferences. Prior to cleavage of the compounds from the resin bead supports, each sublibrary is split into archive and screening samples, wherein the screening sample is generally comprised of roughly 10 to 30 percent of the entire sublibrary volume.

[1069] A small aliquot of the archive sample can be used in a statistical post-synthesis analysis, wherein the method and device of the present invention are used to deposit single beads in a suitable reaction vessel (preferably a multi-well plate or a fixed array of reaction vials) so that each bead can be chemically analyzed or screened separately. This statistical analysis can be used to determine the amount of, and/or identify different compounds present in the archive sample. The remainder of the archive sample is retained in bound form (uncleaved), but is treated to remove solvents, suitably

dried, and then stored either as an intact archive sample, or in a plurality of replica samples which can contain individual beads, small collections of beads, or the entire sublibrary pool of beads. Storing the archive sample in a dried, uncleaved form allows for indefinite archiving of the library with a reduced incidence of compound loss and/or decomposition.

[1070] The screening sample is distributed into reaction vessels (e.g., a multi-well plate or an array of reaction vials) to establish screening aliquots. The screening aliquots are then treated in a suitable cleavage step to remove and separate the bead supports from the cleaved compounds, and the cleaved compounds are screened in a typical primary screen for desired activity. For example, the cleaved compounds can be subjected to evaporation to remove solvents, lyophilized, labeled (if desired), and subjected to dissolution. Sublibraries which contain active components are then subjected to the following nonsynthetic deconvolution methodology.

[1071] The dried archive sample, which corresponds to a sublibrary identified as having activity in the above-described primary screen of the analysis sample, is then retrieved. The sample is reconstituted in a suitable solvent, preferably a solvent with a density of at least about 1.1 g/ml, and a suitable bead-sorting apparatus is used to distribute one bead per well in a multi-well reaction plate or reaction vessel array in multiple redundancy such that there is a greater than 95% probability that every compound in the sublibrary is represented (e.g., at a 5 \times redundancy). If desired, the bead-sorting apparatus is used to distribute any number of beads per well, such as where combinations of compounds are to be assessed for activity in the screening method.

After the desired number of beads have been distributed, the nonsynthetic deconvolution method of the invention is then carried out. As discussed above, each sublibrary generally contains about 20-100 compounds each, thus about 100-500 discrete beads can be distributed from the archive sample to provide a screening array with adequate compound representation. The compounds are cleaved from the bead supports using a suitable cleavage reagent, and the compounds reconstituted in a suitable reaction solvent (e.g., DMSO). Portions of the cleaved compounds are delivered into a further array which replicates the screening array. This replica array is then contacted with the cells, such as HPMCs, and immunologically active compounds are identified using the high throughput assay of the instant invention. A sampling of the reserved portion of the screening array (e.g., about 10%) is then removed for conventional chemical analytics (e.g., liquid chromatography such as HPLC, mass spectrometry (MS) and/or nitrogen (N_2) analyses) in order to provide for direct chemical identification and characterization of active compounds. As can be seen, the above nonsynthetic deconvolution obviates the iterative deconvolution by resynthesis normally needed to identify single compounds responsible for biological and/or chemical activity in a mixture of compounds that were synthesized by a mix-and-split method. If desired, the individual compounds can be suitably labeled with a chemical tag (e.g., mass tags, enzymatic labels, or the like) to facilitate sample identification, however such labeling only provides marginal advantage in the present nonsynthetic deconvolution method, since MS data can easily be used as a "tag" to identify active sublibrary component.

TABLE 5

Chemokine Species Chemokine nomenclature ^a (tab001cbb)		
Systematic name	Original ligand name	Receptors
CXC chemokines		
CXCL1	GRO α	CXCR2, CXCR
CXCL2	GRO β	CXCR2
CXCL3	GRO γ	CXCR2
CXCL4	PF4	Unknown
CXCL5	ENA-78	CXCR2
CXCL6	GCP-2	CXCR1, CXCR2
CXCL7	NAP-2	CXCR2
CXCL8	IL-8	CXCR1, CXCR2
CXCL9	Mig	CXCR3
CXCL10	IP-10	CXCR3
CXCL11	I-TAC	CXCR3
CXCL12	SDF-1 α/β	CXCR4
CXCL13	BCA-1	CXCR5
CXCL14	BRAK	Unknown
CXCL15	Unknown	Unknown
CXCL16	—	CXCR6
C chemokines		
XCL1	Lymphotactin/SCM-1 α	XCR1
XCL2	SCM-1 β	XCR1
CX₃C chemokines		
CX ₃ CL1	Fractalkine	CX ₃ CR1
CC chemokines		
CCL1	I-309	CCR8
CCL2	MCP-1	CCR2
CCL3	MIP-1 α	CCR1, CCR5
CCL3L1	LD78 β	CCR1, CCR5
CCL4	MIP-1 β	CCR5
CCL5	RANTES	CCR1, CCR3, CCR5
CCL6	Unknown	Unknown
CCL7	MCP3	CCR1, CCR2, CCR3

TABLE 5-continued

Chemokine Species Chemokine nomenclature ^a (tab001cbb)		
Systematic name	Original ligand name	Receptors
CCL8	MCP-2	CCR3, CCR5
CCL9/CCL10	Unknown	CCR1
CCL11	Eotaxin	CCR3
CCL12	Unknown	CCR2
CCL13	MCP-4	CCR2, CCR3
CCL14	HCC-1	CCR1, CCR5
CCL15	HCC-2/Lkn-1/MIP-18	CCR1, CCR
CCL16	HCC-4/LEC/LCC-1	CCR1, CCR2
CCL17	TARC	CCR4
CCL18	DC-CK1	Unknown
CCL19	MIP-3 β /ELC	CCR7
CCL20	MIP-3 α /LARC	CCR6
CCL21	6Ckine/SLC	CCR7
CCL22	MDC	CCR4
CCL23	MPIF-1/CKb8	CCR1
CCL24	Eotaxin-2	CCR3
CCL25	TECK	CCR9
CCL26	Eotaxin-3	CCR3
CCL27	CTACK	CCR10
CCL28	MEC	CCR3/CCR10

^aThe new nomenclature for human cytokines is detailed. Adapted from Ref. 95.

Abbreviations for Table 5 (tab001cbb)

BCA-1, B-cell-attracting chemokine 1; CTACK, cutaneous T-cell-attracting chemokine; DC-CK1, dendritic-cell-derived CC chemokine 1; ELC, EBL-1-ligand chemokine; ENA-78, epithelial-cell-derived neutrophil attractant 78; GCP, granulocyte chemotactic protein; GRO, growth-related oncogene; HCC, haemofiltrate CC chemokine; IL, interleukin; IP-10, interferon-inducible protein 10; I-TAC, interferon-inducible T-cell alpha chemoattractant; LARC, liver- and activation-regulated chemokine; LEC, liver-expressed chemokine; LCC-1, liver-specific CC chemokine-1; Lkn-1, leukotactin; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MEC, mammary-enriched chemokine; Mig, monokine induced by interferon- γ ; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP, neutrophil-activating peptide; PF4, platelet factor 4; RANTES, "regulated on activation, normally T-cell-expressed and -secreted"; SCM-1 α/β , single C motif-1 α/β ; SDF, stromal-cell-derived factor; SLC, secondary lymphoid tissue chemokine; TARC, thymus- and activation-regulated chemokine; TECK, thymus-expressed chemokine.

TABLE 6

Interleukin Species (IL 1-30)							
Symbol	Name	Aliases	Previous Symbol	Location	LocusLink	PMID1	Accession ID
IL1A	interleukin 1, alpha	IL1F1	IL1	2q12-q21	3552		M28983
IL1B	interleukin 1, beta	IL1F2		2q13-q21	3553		M15330
IL1F5	interleukin 1 family, member 5 (delta)	FIL1, IL1HY1, IL-1RP3, IL1L1		2q14	26525	10625660	AF201830
IL1F6	interleukin 1 family, member 6 (epsilon)	FIL1		2q14	27179	10625660	AF201831
IL1F7	interleukin 1 family, member 7 (zeta)	FIL1, IL-1H4, IL-1RP1		2q14	27178	10625660	AF201832
IL1F8	interleukin 1 family, member 8 (eta)	FIL1, IL-1H2		2q14	27177	10625660	AF201833
IL1F9	interleukin 1 family, member 9	IL-1H1, IL-1RP2		2q12-q21	56300	10860666	AF200492
IL1F10	interleukin 1 family, member 10 (theta)	FKSG75, FIL1-theta, IL-1HY2		2q13-14.1	84639	11747621	AY026753
IL1R1	interleukin 1 receptor, type I	D2S1473	IL1R, IL1RA	2q12	3554	1833184	M27492
IL1R2	interleukin 1 receptor, type II		IL1RB	2q12	7850	10191101	X59770

TABLE 6-continued

Interleukin Species (IL 1-30)							
Symbol	Name	Aliases	Previous Symbol	Location	LocusLink	PMID1	Accession ID
IL1RAP	interleukin 1 receptor accessory protein	IL-1RAcP, IL1R3		3q28	3556	9479509	AB006537
IL1RAPL1	interleukin 1 receptor accessory protein-like 1	OPHN4, TIGIRR-2	IL1RAPL	Xp22.1-p21.3	11141	10471494	AJ243874
IL1RAPL2	interleukin 1 receptor accessory protein-like 2	IL-1R9, TIGIRR-1, IL1RAPL-2, IL1R9		Xq22	26280	10757639	AF181285
IL1RL1	interleukin 1 receptor-like 1	ST2, FIT-1, ST2L, ST2V		2q12	9173	1482686	D12764
IL1RL2	interleukin 1 receptor-like 2	IL1R- η 2		2q12	8808	8898719	U49065
IL1RN	interleukin 1 receptor antagonist	IL1RA, ICIL-1RA, IL1F3		2q14.2	3557	1386337	M55646
IL2	interleukin 2			4q26-q27	3558	3260003	U25676
IL2RA	interleukin 2 receptor, alpha		IL2R	10p15-p14	3559	3925551	X01057
IL2RB	interleukin 2 receptor, beta			22q13	3560		M26062
IL2RG	interleukin 2 receptor, gamma (severe combined immunodeficiency)		SCIDX1, IMD4	Xq13	3561	1631559	D11086
IL3	interleukin 3 (colony-stimulating factor, multiple)			5q23-q31	3562		M14743
IL3RA	interleukin 3 receptor, alpha (low affinity)			Xp22.3; Yp13.3	3563	1833064	M74782
IL4	interleukin 4			5q23-q31	3565		M23442
IL4R	interleukin 4 receptor			16p11.2-12.1	3566	1679753	X52425
IL5	interleukin 5 (colony-stimulating factor, eosinophil)			5q23-q31	3567		X04688
IL5RA	interleukin 5 receptor, alpha		IL5R	3p26-p24	3568	1732409	M96652
IL6	interleukin 6 (interferon, beta 2)		IFNB2	7p21-p15	3569	3294161	M18403
IL6R	interleukin 6 receptor			1	3570		X12830
IL6RL1	interleukin 6 receptor-like 1			9	3571	1889804	
IL6ST	interleukin 6 signal transducer (gp130, oncostatin M receptor)	GP130		5q11	3572	2261637	M57230
IL6ST2	interleukin 6 signal transducer-2	dJ738P15.3		20p11.2-11.22			AL035252
IL6STP	interleukin 6 signal transducer (gp130, oncostatin M receptor) pseudogene			17p11	3573		
IL7	interleukin 7			8q12-q13	3574		J04156
IL7R	interleukin 7 receptor			5p13	3575	2317865	M29696
IL8	interleukin 8	SCYB8, LUCT, LECT, MDNCF, TSG-1		4q13-q21	3576		Y00787
IL8RA	interleukin 8 receptor, alpha	CXCR1, C-C	CMKAR1	2q35	3577	1303245	U11870
IL8RB	interleukin 8 receptor, beta	CKR-1, CXCR2, CMKAR2		2q35	3579	1427896	U11869
IL8RBP	interleukin 8 receptor, beta pseudogene			2q35	3580	1427896	

TABLE 6-continued

Interleukin Species (IL 1-30)							
Symbol	Name	Aliases	Previous Symbol	Location	LocusLink	PMID1	Accession ID
IL9	interleukin 9			5q31-q35	3578		S63356
IL9R	interleukin 9 receptor			Xq28 or Yq12	3581	1376929	M84747
IL9RP1	interleukin 9 receptor pseudogene 1			9q34	3582	8666384	
IL9RP2	interleukin 9 receptor pseudogene 2			10p15	3583	8666384	
IL9RP3	interleukin 9 receptor pseudogene 3			16p13.3	3584	8666384	L39062
IL9RP4	interleukin 9 receptor pseudogene 4			18p11.3	3585	8666384	
IL10	interleukin 10	CSIF, TGIF, IL10A		1q31-q32	3586	9162098	U16720
IL10RA	interleukin 10 receptor, alpha	HIL-10R	IL10R	11q23	3587	8120391	U00672
IL10RB	interleukin 10 receptor, beta	CRF2-4	CRFB4, D21S58, D21366	21q22.1-q22.2	3588	8314576	U08988
IL11	interleukin 11			19q13.3-q13.4	3589	1386338	X58377
IL11RA	interleukin 11 receptor, alpha			9p13	3590	7670098	Z38102
IL11RB	interleukin 11 receptor, beta			reserved	3591		
IL12A	interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35)	CLMF	NKSF1	3p12-q13.2	3592	1673147	M65271
IL12B	interleukin 12B natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)	CLMF	NKSF2	5q31.1-q33.1	3593	1673147	M65290
IL12RB1	interleukin 12 receptor, beta 1		IL12RB	19p13.1	3594	9284929	U03187
IL12RB2	interleukin 12 receptor, beta 2			1p31.3-p31.2	3595	9284929	U64198
IL13	interleukin 13	P600		5q31	3596		U31120
IL13RA1	interleukin 13 receptor, alpha 1	IL-13Ra, NR4		Xq24	3597	8910586	U62858
IL13RA2	interleukin 13 receptor, alpha 2	IL-13R, IL13BP		Xq13.1-q28	3598	8663118	X95302
IL14	interleukin 14	HMW-BCGF		1p34.3	3599		L15344
IL15	interleukin 15			4q31	3600	8178155	U14407
IL15RA	interleukin 15 receptor, alpha			10p15-10p14	3601	8530383	U31628
IL15RB	interleukin 15 receptor, beta			reserved	3602		
IL16	interleukin 16 (lymphocyte chemoattractant factor)	LCF		15q26.3	3603	9144227	U82972
IL17	interleukin 17 (cytotoxic T- lymphocyte- associated serine esterase 8)	IL-17A	CTLA8	2q31	3605	8390535	U32659
IL17B	interleukin 17B	IL-17B, ZCYTO7, IL- 20		5q32-34	27190	10639155	AF184969
IL17C	interleukin 17C	IL-17C, CX2, IL-21		16q24	27189	10639155	AF152099
IL17D	interleukin 17D	IL-22, IL-27		13q11	53342		AY078238
IL17E	interleukin 17E	IL25, IL-25		14q11.2	64806	11058597	AF305200

TABLE 6-continued

Interleukin Species (IL 1-30)							
Symbol	Name	Aliases	Previous Symbol	Location	LocusLink	PMID1	Accession ID
IL17F	interleukin 17F	IL-17F, ML-1, ML1, IL-24, IL-26		6p12	112744		AF384857
IL17R	interleukin 17 receptor	hIL-17R		22	23765	9367539	U58917
IL17RB	interleukin 17 receptor B	IL17RH1, EVI27, CRL4	IL17BR	3p21.1	55540	10749887	AF212365
IL17RC	interleukin 17 receptor C	IL17-RL		3p			BC006411
IL17RD	interleukin 17 receptor D	SEF, IL17RLM, FLJ35755, IL-17RD		3p			AF494208
IL17RE	interleukin 17 receptor E	FLJ23658		3p			AF458069
IL18	interleukin 18 (interferon-gamma-inducing factor)	IGIF, IL1F4, IL-1g		11q22.2-q22.3	3606	7477296	U90434
IL18BP	interleukin 18 binding protein			11q13	10068	10023777	AF110798
IL18R1	interleukin 18 receptor 1	IL1RRP, IL-1Rrp		2q12	8809	8626725	U43672
IL18RAP	interleukin 18 receptor accessory protein	AcPL		2p24.3-p24.1	8807	9792649	AF077346
IL19	interleukin 19	IL-19, MDA1, ZMDA1, IL-10C		1q32.2	29949		AF192498
IL20	interleukin 20	ZCYTO10, IL10D		1q32	50604		AF224266
IL20RA	interleukin 20 receptor, alpha	ZCYTOR7		6q23	53832	10875937	AF184971
IL20RB	interleukin 20 receptor beta						
IL21	interleukin 21	Za11		4q26-q27	59067	11081504	AF254069
IL21R	interleukin 21 receptor			16p11	50615	11081504	AF254067
IL22	interleukin 22	LTIF, IL-21, zcyto18, IL-TIF, IL-D110, TIFa, TIFIL-23		12q15	50616	10954742	AF279437
IL22RA1	interleukin 22 receptor alpha 1	CRF2-9	IL22R	1p36.11	58985	10875937	AF286095
IL22RA2	interleukin 22 receptor alpha 2	CRF2-S1, IL-22BP		6q24.1-q24.2			
IL23A	interleukin 23, alpha subunit p19	SGRF, IL23P19, IL-23		12	51561	11114383	AB030000
IL24	interleukin 24	mda-7, IL10B, Mob-5, C49A, FISP	ST16	1q32	11009	8545104	U16261
IL25	This symbol will not be used						
IL26	interleukin 26	AK155		12q15	55801	10729163	AJ251549
IL27	This symbol will not be used						
IL28A	interleukin 28A (interferon, lambda 2)	IL-28A, IFNL2		19q13.13			AY129148
IL28B	interleukin 28B (interferon, lambda 3)	IL-28B, IFNL3		19q13.13			AY129149
IL28RA	interleukin 28 receptor, alpha (interferon, lambda receptor)	CRF2/12, IFNLR		1p36.11			AY129153

TABLE 6-continued

Interleukin Species (IL 1-30)							
Symbol	Name	Aliases	Previous Symbol	Location	LocusLink	PMID1	Accession ID
IL29	interleukin 29 (interferon, lambda 1)	IL-29, IFNL1		19q13.13			AY129150
IL30	interleukin 30	IL-27, p28		16p11	246778	12121660	AY099296


[1072] While the invention has been described with respect to specific example including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention.

[1073] Each of the following U.S. Provisional Applications is incorporated herein by reference in their entirety: 60/599,717, filed Aug. 5, 2004; 60/599,592, filed Aug. 5, 2004; 60/600,850, filed Aug. 11, 2004; 60/603,001, filed Aug. 19, 2004; 60/603,867, filed Aug. 23, 2004; 60/612,070, filed Sep. 21, 2004; 60/582,654, filed Jun. 24, 2004; 60/614,963, filed Sep. 21, 2004; and 60/590,459, filed Jul. 22, 2004.

INCORPORATION BY REFERENCE

[1074] The contents of all of the patents, patent applications and journal articles cited throughout this document are incorporated by reference as if set forth fully herein.

1. A method of eliciting an immune response in a patient comprising administering a SMIP of formula (IV):



IV

wherein,

R_{11} is selected from the group consisting of hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted hydroxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl;

R_{12} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and


R_{13} is selected from the group consisting of H, hydroxyl, alkoxy, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl; or

R_{12} and R_{13} are bound together to form a substituted or unsubstituted heterocyclyl group; and

R_b is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbocyclyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroaralkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroaralkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl.

2. The method according to claim 1 wherein R_{12} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl; R_{13} is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl; and

R₁₁ is further defined as structure of formula (R_{11a}):



wherein,

R₁₄ and R₁₅ are independently selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroalkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or

R₁₄ and R₁₅ are taken together to form a substituted or unsubstituted heteroaryl group.

3. The method according to claim 2 wherein R₁₄ and R₁₅ are taken together to form a substituted heteroaryl group such that R_{11a} is a DNA base.

4. The method according to claim 3 wherein said DNA base is adenine.

5. The method according to claim 2 wherein R₁₄ is aminocarbonyl.

6. The method according to claim 2 wherein R₁₄ is hydroxy.

7. The method according to claim 1 wherein R₁₂ and R₁₃ are bound together to form a heterocyclyl group as shown in Figure (IV_a):



wherein,

R_{12a} is selected from the group consisting of H, halogen, hydroxy, amino, nitro, cyano, carboxylic acid, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted alkylamino, substituted and unsubstituted carbonyloxy, substituted and unsubstituted alkoxy, substituted and unsubstituted aminocarbonyl, substituted and unsubstituted carbonylamino, substituted and unsubstituted sulfonyl, substituted and unsubstituted alkoxy, substituted and unsubstituted alkoxyalkyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted aralkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heterocyclylalkyl, substituted and unsubstituted carbocyclylalkyl, substituted and unsubstituted aralkenyl, substituted and unsubstituted heteroalkenyl, substituted and unsubstituted heterocyclylalkenyl, and substituted and unsubstituted carbocyclylalkenyl; or

tuted and unsubstituted alkoxy, and substituted and unsubstituted alkoxyalkyl; and

R_{13a} is selected from the group consisting of H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclyl and substituted and unsubstituted heteroaryl.

8. The method as in any of claims 1-7, wherein said SMIP is administered in a dose capable of increasing TNF- α levels.

9. The method as in any of claims 1-7, wherein said SMIP modulates activity of at least one target selected from the group consisting of glucocorticoid receptors, DNA alkylation, calcineurin, JNK, p38 kinase, cyclin kinase cascade, PDE IV, IMPDH, DHOD, lck, and thymidylate synthase.

10. The method as in any of claims 1-7, wherein said immune response involves production of cytokines.

11. The method as in any of claims 1-7, wherein said immune response involves increased production of TNF- α .

12. The method as in any of claims 1-7, wherein the patient is suffering from a viral infection.

13. The method according to claim 12 wherein said viral infection is HCV.

14. The method as in any of claims 1-7, wherein said patient is suffering from increased cellular proliferation or cancer.

15. The method as in any of claims 1-7, wherein said patient is suffering from allergic diseases.

16. The method as in any of claims 1-7, wherein said patient is suffering from asthma.

17. The method according to claim 12 wherein said SMIP is co-administered with another agent.

18. The method as in claim 17 wherein the other agent is a vaccine.

19. The method according to claim 13 wherein said SMIP is co-administered with another agent.

20. The method as in claim 19 wherein the other agent is a vaccine.

21. The method according to claim 14 wherein said SMIP is co-administered with another agent.

22. The method according to claim 15 wherein said SMIP is co-administered with another agent.

23. The method according to claim 16 wherein said SMIP is co-administered with another agent.

24. The method as in any of claims 1-7, wherein said SMIP is co-administered with another agent.

25. The method as in claim 16 wherein the other agent is a vaccine.

26. The method as in any of claims 1-7, wherein said SMIP, present at a concentration less than 20 μ M, induces production of TNF- α .

27. A high throughput assay for identifying small molecule immunomodulators, said assay comprising:

- contacting a plurality of test compounds with cells to form one or more test solution (s);
- incubating said test solution for at least 30 minutes;
- measuring for an increased level of one or more immunological markers in said test solution;

wherein immunomodulation by one or more test compounds present in said plurality of test compounds causes an increase in the amount of said immunological markers in said test solution.

28. The high throughput assay of claim 27 wherein said small molecule immuno-modulators are SMIPs and said immunomodulation is immunopotential.

29. The high throughput assay of claim **28**, further comprising the step of comparing said amount of immunological markers in said test solution with an unstimulated solution, devoid of any test compounds.

30. The high throughput assay of claim **29**, wherein said unstimulated solution is run in parallel with said test solution.

31. The high throughput assay of claim **28** further comprising the step of comparing said amount of immunological markers in said test solution with a stimulated solution containing a known immunopotentiating agent.

32. The high throughput assay of claim **31**, wherein said stimulated solution is run in parallel with said test solution.

33. The high throughput assay of claim **31**, wherein said immunopotentiating agent is selected from the group consisting of LPS, CpG, resiquimod, Poly I:C (dsRNA), Pam3-Cys, MPL, and anti-CD3.

34. The high throughput assay of claim **28**, wherein said immunological markers are cytokines.

35. The high throughput assay of claim **28**, wherein said immunological markers are chemokines.

36. The high throughput assay of claim **28**, wherein said immunological markers are growth factors.

37. The high throughput assay of claim **28**, wherein said immunological markers are both cytokines and chemokines.

38. The high throughput assay of claim **28**, wherein said immunological markers are both cytokines and growth factors.

39. The high throughput assay of claim **28**, wherein said immunological markers are both chemokines and growth factors.

40. The high throughput assay of claim **28**, wherein said immunological markers are cytokines, chemokines and growth factors.

41. The high throughput assay of claim **26** wherein said immunological marker is TGF-beta, said small molecule immunomodulators are SMIS, and said immunomodulation is immunosuppression.

* * * * *